Avon Products (AVP) 10-K 10 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Jan. 30, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-4881
Entity Registrant Name	AVON PRODUCTS, INC.
Entity Incorporation, State or Country Code	NY
Entity Tax Identification Number	13-0544597
Entity Address, Address Line One	Nunn Mills Road,
Entity Address, City or Town	Northampton
Entity Address, Postal Zip Code	NN1 5PA
Entity Address, Country	GB
Country Region	44
City Area Code	1904
Local Phone Number	232425
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		101.34
Entity Central Index Key	0000008868
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	London, United Kingdom
Auditor Firm ID	876

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net sales	$ 3,202.9	$ 3,431.2	$ 4,494.1
Other revenue	176.4	187.3	269.1
Revenue from affiliates of Natura &Co	25.2	6.7	0
Total revenue	3,404.5	3,625.2	4,763.2
Costs, expenses and other:
Cost of sales	(1,439.1)	(1,588.6)	(2,010.1)
Cost of sales from affiliates of Natura &Co	(22.4)	(5.9)	0
Selling, general and administrative expenses (inclusive of provision for doubtful accounts of $62.4, $78.3, $115.4)	(2,001.4)	(2,152.9)	(2,627.5)
Operating (loss) profit	(58.4)	(122.2)	125.6
Interest expense	(63.5)	(119.6)	(127.6)
Interest expense on Loan from affiliates of Natura &Co	(50.6)	(7.5)	0
Loss on extinguishment of debt and credit facilities	0	(37.7)	(11.6)
Interest income	2.2	2.1	7.7
Other income (expense), net	1.6	(20.2)	94.2
Gain on sale of business	9.9	1.5	50.1
Total other (expenses) income	(100.4)	(181.4)	12.8
(Loss) Income from continuing operations, before taxes	(158.8)	(303.6)	138.4
Income taxes	(16.2)	(34)	(103.1)
Loss from continuing operations, net of tax	(175)	(337.6)	35.3
Loss from discontinued operations, net of tax	(18.5)	(27.9)	(36.6)
Net loss	(193.5)	(365.5)	(1.3)
Net loss attributable to noncontrolling interests	1.4	2.7	1
Net loss attributable to Avon	$ (192.1)	$ (362.8)	$ (0.3)

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Provision for doubtful accounts	$ 62.4	$ 78.3	$ 115.4

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (193.5)	$ (365.5)	$ (1.3)
Other comprehensive loss:
Foreign currency translation adjustments	(0.9)	(162.9)	(0.6)
Unrealized (losses) gains on revaluation of long-term intercompany balances	(21.3)	67.6	(5.7)
Change in derivative gains (losses) on cash flow hedges	0	0.6	(1.1)
Amortization of net actuarial loss and prior service cost, net of taxes of $0.8, $0.8 and $0.4	5.1	8.2	9.4
Adjustments of net actuarial loss and prior service cost, net of taxes of $3.2, $3.8 and $2.9	67.3	(7.1)	(8)
Sale of New Avon	0	0	(3.4)
Total other comprehensive income (loss), net of taxes	50.2	(93.6)	(9.4)
Comprehensive loss	(143.3)	(459.1)	(10.7)
Less: comprehensive loss attributable to noncontrolling interests	0.5	2.5	0.9
Comprehensive loss attributable to Avon	$ (142.8)	$ (456.6)	$ (9.8)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (PARENTHETICAL) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Amortization of net actuarial loss and prior service cost, taxes	$ 0.8	$ 0.8	$ 0.4
Adjustments of net actuarial losses and prior service cost, taxes	$ 3.2	$ 3.8	$ 2.9

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Dec. 31, 2021		Dec. 31, 2020
Current Assets
Cash, including cash equivalents of $15.5 and $51.0		$ 251.5	[1]	$ 364.9
Restricted cash		0		7.8
Accounts receivable (less allowances of $37.1 and $51.1)		198.7		259.1
Receivables from affiliates of Natura &Co		34.1		6.1
Loans to affiliates of Natura &Co		46.6		0
Inventories		384.1		459.1
Prepaid expenses and other		165.6		204.2
Held for sale assets		2.8		13.9
Total current assets		1,083.4		1,315.1
Property, plant and equipment, at cost
Land		18.5		20.8
Buildings and improvements		374.5		447.1
Equipment		549.5		680.6
Property, plant and equipment, at cost		942.5		1,148.5
Less accumulated depreciation		(578.8)		(709.9)
Property, plant and equipment, net		363.7		438.6
Right-of-use assets		111.1		153.1
Goodwill		72.1		83.2
Deferred tax asset		121.4		135.8
Loans to affiliates of Natura &Co		46.7		0
Other assets		509.4		438.5
Total assets		2,307.8		2,564.3
Liabilities
Debt maturing within one year		32.6		28
Loans from affiliates of Natura &Co		371.7		1,008.6
Accounts payable		522.8		709.4
Payables to affiliates of Natura &Co		29.4		0
Accrued compensation		81.5		89.4
Other accrued liabilities		273.4		334.7
Sales and taxes other than income		66.8		89.9
Income taxes		11.6		5.4
Total current liabilities		1,421.5		2,294.8
Long-term debt		676		675.4
Loans from affiliates of Natura &Co		736.3		0
Long-term operating lease liability		87.5		120.9
Employee benefit plans		84.6		133.3
Long-term income taxes		81.5		101.1
Other liabilities		75.1		106
Total liabilities		3,162.5		3,431.5
Leases and Commitments and contingencies (Notes 15 and 18)
Shareholders’ Deficit
Common stock, par value $0.01 - authorized 1,000 shares; issued 101.34 (2019: par value $0.25 - authorized 1,500 shares; issued 770 shares)	[2]	0		0
Additional paid-in capital		631.2		622.8
Retained earnings		(404.2)		(360.5)
Accumulated other comprehensive loss		(1,085.5)		(1,133.8)
Total Avon shareholders’ deficit		(858.5)		(871.5)
Noncontrolling interests		3.8		4.3
Total shareholders’ deficit	[3]	(854.7)		(867.2)
Total liabilities, series C convertible preferred stock and shareholders’ deficit		2,307.8		2,564.3
Discontinued Operations
Liabilities
Current liabilities of discontinued operations and liabilities held for sale		31.7		27.1
Held-for-sale
Liabilities
Current liabilities of discontinued operations and liabilities held for sale		$ 0		$ 2.3
[1]	The following table provides a reconciliation of cash, cash equivalents, restricted cash, and cash held for sale reported within the Consolidated Balance Sheet that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the years ended December 31, 2021, 2020 and 2019. December 31, 2021 December 31, 2020 December 31, 2019 Cash and cash equivalents $ 251.5 $ 364.9 $ 650.6 Restricted cash — 7.8 2.9 Long-term restricted cash — — 7.6 Held for sale cash and cash equivalents — .7 — Cash and cash equivalents, and restricted cash at end of period per the statement of cash flows $ 251.5 $ 373.4 $ 661.1
[2]	In January 2020, subsequent to the Transaction, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result of the Merger, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 21, Mergers     with Natura Cosméticos S.A.,.
[3]	The number of shares of Common Stock (par value $0.01 per share) outstanding at December 31, 2021 and 2020 was 101.34.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Cash equivalents	$ 15.5	$ 51
Allowances	$ 37.1	$ 51.1
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,000	1,000
Common stock, shares issued (in shares)	101.34	101.34

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Cash Flows from Operating Activities
Net loss		$ (193.5)	$ (365.5)		$ (1.3)
Loss from discontinued operations, net of tax		(18.5)	(27.9)		(36.6)
(Loss) income from continuing operations		(175)	(337.6)		35.3
Adjustments to reconcile net (loss) income from continuing operations to net cash (used) provided by operating activities:
Depreciation		50.4	57.3		68.1
Amortization		22.4	24.5		24.8
Provision for doubtful accounts		62.4	78.3		115.4
Provision for inventory obsolescence		26.8	37.9		37.1
Share-based compensation		6.9	26.4		15.6
Foreign exchange (gains) losses		(5.2)	(5.1)		(51.5)
Deferred income taxes		(20.2)	(0.4)		37.5
Impairment loss on assets		1	3.1		17.7
Gain on sale of business / assets		(9.9)	(1.5)		(50.1)
Certain Brazil indirect taxes		0	0		(118.3)
Other		5.9	54.2		12
Changes in assets and liabilities:
Accounts receivable		(60.1)	(81.5)		(55.2)
Inventories		(53)	(65.9)		56
Prepaid expenses and other		(14.9)	1.2		25.7
Accounts payable and accrued liabilities		(35.1)	(61.7)		(145.4)
Income and other taxes		(13.1)	2.5		28.8
Noncurrent assets and liabilities		(49.7)	(1.8)		3.4
Net cash (used) provided by operating activities of continuing operations		(260.4)	(270.1)		56.9
Cash Flows from Investing Activities
Capital expenditures		(68.3)	(44.6)		(58.5)
Disposal of assets		3.3	2.6		7.8
Net proceeds from sale of business / assets		16.9	11.3		99.9
Cash receipts from the settlement of corporate-owned life insurance policies		0	9.9		0
Other investing activities		0	0.3		1
Net cash (used) provided by investing activities of continuing operations		(48.1)	(20.5)		50.2
Cash Flows from Financing Activities
Cash dividend		0	(8.6)		0
Debt, net (maturities of three months or less)		(11.1)	13.6		(9.2)
Proceeds from debt		297	1,039.7		400
Repayment of debt		(68.5)	(956.9)		(388.2)
Repayment of debt to affiliates of Natura &Co	[1]	(38)	0		0
Repayment of debt from affiliates of Natura &Co		58.7	0		0
Repurchase of common stock		0	(0.4)		(9.6)
Net proceeds from exercise of stock options		0	0		15.6
Settlement of stock options		0	(25.8)		0
Settlement of derivative operations		0	(0.8)		37.4
Costs associated with debt issue / repayment		0	(21.7)		(26.8)
Proceeds from monetization of COFINS tax credits		(15.5)	0		19.4
Other financing activities		0	0		(0.1)
Net cash provided by financing activities of continuing operations(2)	[1]	222.6	39.1		38.5
Cash Flows from Discontinued Operations
Net cash used by operating activities of discontinued operations		(14)	(16.7)		(20.6)
Net cash used by discontinued operations		(14)	(16.7)		(20.6)
Effect of exchange rate changes on cash and cash equivalents		(22)	(19.5)		(0.3)
Net (decrease) increase in cash and cash equivalents and restricted cash		(121.9)	(287.7)		124.7
Cash and cash equivalents and restricted cash at beginning of year	[2]	373.4	661.1		536.4
Cash and cash equivalents and restricted cash at end of year		251.5	373.4	[2]	661.1	[2]
Cash paid for:
Interest		50.1	133.5		122
Income taxes, net of refunds received		$ 37	$ 21.3		$ 55.9
[1]	On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding for $150, with the proceeds used to repay maturing loans of $150 borrowed under the $250 Revolving Credit Facility with a subsidiary of Natura &Co Holding. Under the terms of the transaction and the associated Direction and Settlement Agreement, no cash flows in either investing or financing activities arose as a result of the transaction.
[2]	The following table provides a reconciliation of cash, cash equivalents, restricted cash, and cash held for sale reported within the Consolidated Balance Sheet that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the years ended December 31, 2021, 2020 and 2019. December 31, 2021 December 31, 2020 December 31, 2019 Cash and cash equivalents $ 251.5 $ 364.9 $ 650.6 Restricted cash — 7.8 2.9 Long-term restricted cash — — 7.6 Held for sale cash and cash equivalents — .7 — Cash and cash equivalents, and restricted cash at end of period per the statement of cash flows $ 251.5 $ 373.4 $ 661.1

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Cash and cash equivalents	$ 251.5	[1]	$ 364.9		$ 650.6
Restricted cash	0		7.8		2.9
Long-term restricted cash	0		0		7.6
Held for sale cash and cash equivalents	0		0.7		0
Cash and cash equivalents and restricted cash	251.5		373.4	[1]	661.1	[1]
Net proceeds from sale of business / assets	$ 16.9		$ 11.3		$ 99.9
[1]	The following table provides a reconciliation of cash, cash equivalents, restricted cash, and cash held for sale reported within the Consolidated Balance Sheet that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the years ended December 31, 2021, 2020 and 2019. December 31, 2021 December 31, 2020 December 31, 2019 Cash and cash equivalents $ 251.5 $ 364.9 $ 650.6 Restricted cash — 7.8 2.9 Long-term restricted cash — — 7.6 Held for sale cash and cash equivalents — .7 — Cash and cash equivalents, and restricted cash at end of period per the statement of cash flows $ 251.5 $ 373.4 $ 661.1

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT - USD ($) shares in Millions, $ in Millions		Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Retained Earnings		Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Balance at Dec. 31, 2018		$ (896.8)		$ 190.3	$ 2,303.6	$ 2,234.3			$ (1,030.4)	$ (4,602.3)	$ 7.7
Balance (in shares) at Dec. 31, 2018				761.8						319.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]		Accounting Standards Update 2016-13
Net income (loss)		$ (1.3)				(0.3)					(1)
Other comprehensive income (loss)		(9.4)							(9.6)		0.2
Dividends accrued - Series C convertible preferred stock		(25.5)				(25.5)
Dividends accrued- common stock		(8.7)				(8.7)
Exercise/ vesting/ expense of share-based compensation (in shares)				9.9
Exercise/ vesting/ expense of share-based compensation		28.5		$ 2.6	25.9
Repurchase of common stock (in shares)				(1.7)						(0.5)
Repurchase of common stock		(9.6)		$ (0.3)	(8.3)					$ (1)
Increase in Carrying Amount of Redeemable Preferred Stock		(60.9)				(60.9)
Purchases and sales of noncontrolling interests, net of dividends paid		(0.1)									(0.1)
Balance at Dec. 31, 2019		(983.8)	$ (2)	$ 192.6	2,321.2	2,138.9		$ (2)	(1,040)	$ (4,603.3)	6.8
Balance (in shares) at Dec. 31, 2019				770						319.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Gain on common control transaction		1.4				1.4
Capitalization of payable	[1]	91.5			91.5
Net income (loss)		(365.5)				(362.8)					(2.7)
Other comprehensive income (loss)		(93.6)							(93.8)		0.2
Conversion of Series C convertible preferred stock	[2]	486.8				(710.8)				$ 1,197.6
Conversion of Series C convertible preferred stock (in shares)	[2]									(87)
Exercise/ vesting/ expense of share-based compensation		(2)		$ (0.2)	(1.8)
Repurchase of common stock (in shares)	[3]			(770)						(232.9)
Repurchase of common stock	[3]	0		$ (192.4)	(1,788.1)	(1,425.2)				$ 3,405.7
Balance at Dec. 31, 2020	[4]	(867.2)		$ 0	622.8	(360.5)			(1,133.8)	$ 0	4.3
Balance (in shares) at Dec. 31, 2020	[4]			0						0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale on Avon Luxembourg		148.4				148.4	[5]
Net income (loss)		(193.5)				(192.1)					(1.4)
Other comprehensive income (loss)		50.2							48.3		1.9
Exercise/ vesting/ expense of share-based compensation		8.4			8.4
Purchases and sales of noncontrolling interests, net of dividends paid		(1)									(1)
Balance at Dec. 31, 2021	[4]	$ (854.7)		$ 0	$ 631.2	$ (404.2)			$ (1,085.5)	$ 0	$ 3.8
Balance (in shares) at Dec. 31, 2021	[4]			0						0
[1]	In January 2020 Natura &Co Holding paid the accrued dividends on the shares of series C preferred stock in an amount equal to U.S. $91.5 to Cerberus, resulting in a payable due to an affiliate of Natura &Co Holding for the same amount. See Note 17, Series C Convertible Preferred Stock, for discussion of preferred shares issued to Cleveland Apple Investor L.P. (“Cerberus Investor”). During 2020, the payable due to Natura &Co was capitalized and recorded as a capital contribution through Additional Paid in Capital.
[2]	On December 30, 2019, an affiliate of Cerberus Capital Management, L.P. ("Cerberus") elected to convert 435,000 shares of Series C Preferred Stock into 87,000,000 shares of the Company’s common stock, par value U.S.$0.25 per share, conditioned on the Conversion Condition (as defined below). See Note 17, Series C Convertible Preferred Stock.
[3]	In January 2020, subsequent to the Transaction, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result of the Merger, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 21, Mergers     with Natura Cosméticos S.A.,.
[4]	The number of shares of Common Stock (par value $0.01 per share) outstanding at December 31, 2021 and 2020 was 101.34.
[5]	On July 1, 2021, the Company sold Avon Luxembourg Holdings S.à r.l. and its subsidiaries ("Avon Luxembourg"), including our Mexican business, to a subsidiary of Natura &Co Holding S.A. for $150. The sale was accounted for as a transaction under common control in accordance with ASC805 - Business Combinations, with the resulting gain of $148, representing the difference between the proceeds, the net assets of Avon Luxembourg on the date of sale, and the cumulative foreign currency translation adjustment, taken directly to Retained Earnings

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT (Parenthetical) - USD ($) $ in Millions	Dec. 30, 2019	Jan. 31, 2020	Dec. 31, 2019
Purchases and sales of noncontrolling interests, dividends paid			$ 0.1
Payment of accrued preferred stock dividends		$ 91.5
Conversion of stock (in shares)	435,000
Temporary equity, conversion, common stock equivalent (in shares)	87,000,000
Common stock, par value (in dollars per share)	$ 0.25	$ 0.01	$ 0.25
Shares authorized (in shares)			1,525,000,000
Common stock, shares authorized (in shares)		1,000	1,500,000,000
Preferred stock, shares authorized (in shares)			25,000,000
Preferred stock, par value (in USD per share)		$ 0.01	$ 1
Shares canceled (in shares)		550,890,788
Common stock shares outstanding (in shares)		101.34
Net proceeds from sale of business / assets			$ 99.9
Series C Preferred Stock
Conversion of stock (in shares)	435,000

Description of the Business and

Description of the Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Description Of The Business And Summary Of Significant Accounting Policies
Description of the Business and Summary of Significant Accounting Policies	Description of the Business and Summary of Significant Accounting Policies Business When used in these notes, the terms "Avon," "Company," "we," "our" or "us" mean Avon Products, Inc. We are a global manufacturer and marketer of beauty and related products. Our business is conducted primarily in one channel, direct selling. Our reportable segments are based on geographic operations in two regions: Avon International and Avon Latin America. Our product categories are Beauty and Fashion & Home. Beauty consists of skincare, fragrance and color (cosmetics). Fashion & Home consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products and nutritional products. Sales are made to the ultimate consumer principally by independent Representatives. In December 2015, we entered into definitive agreements with affiliates of Cerberus Capital Management L.P. ("Cerberus"), which included a $435 investment in Avon by an affiliate of Cerberus through the purchase of our convertible preferred stock and the separation of the North America business (including approximately $100 of cash, subject to certain adjustments) from Avon into New Avon LLC ("New Avon"), a privately-held company that is majority-owned and managed by an affiliate of Cerberus. These transactions closed in March 2016 and Avon retained approximately 20% ownership in New Avon. In April 2019, Avon and Cerberus signed an agreement with LG Household & Health Care Ltd. for the sale of New Avon, including our 20% ownership interest. This transaction closed on August 14, 2019. See Note 3, Discontinued Operations and Assets and Liabilities Held for Sale, for additional information. The North American business, which represented the Company's operations in the United States ("U.S."), Canada and Puerto Rico, was previously its own reportable segment and has been presented as discontinued operations for all periods. As a result of this transaction, all of our consolidated revenue is derived from operations of subsidiaries outside of the U.S. On May 22, 2019, we entered into an Agreement and Plan of Mergers with Natura Cosméticos S.A., a Brazilian corporation (sociedade anônima) ("Natura Cosméticos"), Natura &Co Holding S.A., a Brazilian corporation (sociedade anônima) ("Natura &Co Holding"), and two subsidiaries of Natura &Co Holding ("Natura &Co") pursuant to which, in a series of transactions, Avon and Natura Cosméticos became direct wholly owned subsidiaries of Natura &Co (the "Transaction"). On January 3, 2020, the Company consummated the Transaction and became a fully owned subsidiary of Natura &Co Holding. In connection with the consummation of the Transaction, the Company notified the NYSE that trading of their stock should be suspended, the Company's common stock was subsequently delisted and deregistered. The Company files these financial statements with the SEC, as a voluntary filer, to comply with the terms of certain debt instruments. For additional information, see Note 21, Agreement and Plan of Mergers with Natura Cosméticos S.A.,. In December 2019, the Company declared a dividend of $0.016 per share equating to $9, this dividend was subsequently paid in January 2020 by the Company. Principles of Consolidation The consolidated financial statements include the accounts of Avon and our majority and wholly-owned subsidiaries. Intercompany balances and transactions are eliminated. Basis of Presentation and Use of Estimates We prepare our consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America, or GAAP. In preparing these statements, we are required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, we review our estimates, including those related to stand-alone selling prices ("SSP") of promised goods or services delivered under sales incentives, allowances for sales returns, allowances for doubtful accounts receivable, provisions for inventory obsolescence, the determination of discount rates and other actuarial assumptions for pension and postretirement benefit expenses, restructuring expense, income taxes and tax valuation allowances, share-based compensation, loss contingencies and the evaluation of goodwill, property, plant and equipment and capitalized software for potential impairment. Sale of Avon Luxembourg Holdings S.à r.l On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding for $150, with the proceeds used to repay maturing loans of $150 borrowed under the $250 Revolving Credit Facility with a subsidiary of Natura &Co Holding. The sale was accounted for as a transaction under common control in accordance with ASC805 - Business Combinations, with the resulting gain of $148, representing the difference between the proceeds, the net assets of Avon Luxembourg on the date of sale, and the cumulative foreign currency translation adjustment, taken directly to Retained Earnings. Under the terms of the transaction and the associated Direction and Settlement Agreement, no cash flows in either investing or financing activities arose as a result of the transaction and it has been treated as a non cash flow item in the Consolidated Statements of Cash Flows. For additional information, see the Consolidated Statements of Changes in Shareholders' Deficit and the Consolidated Statements of Cash Flows. Reclassifications During the third quarter of 2020, we identified an immaterial classification error in the Consolidated Statement of Cash Flows relating to the year ended December 31, 2019 with respect to cash flows from the settlement of derivative contracts. Our accounting policy is to classify derivative cash flows as operating, investing or financing consistent with the nature of the underlying hedged item. However, we have identified that cash flows relating to derivative contracts that economically hedge foreign exchange gains and losses on intercompany loans have been incorrectly classified as operating activities rather than financing activities. We have corrected this reclassification error through a revision to the Consolidated Statement of Cash Flows for the year ended December 31, 2019 to reclassify cash inflows of $37.4 from the settlement of derivative contracts from operating activities to financing activities. COVID-19 pandemic A novel strain of coronavirus (COVID-19) was first identified in Wuhan, China in December 2019, and subsequently declared a pandemic by the World Health Organization. Due to the uncertain and rapidly evolving nature of current conditions around the world, the impacts of COVID-19 most of which are beyond the Company’s control, continue to evolve, and the outcome is uncertain. We are therefore unable to predict accurately the impact that COVID-19 will have on our business going forward. In 2020, the most significant impact of the COVID-19 pandemic was felt during the second quarter of 2020, as many markets were subject to lockdown restrictions to varying degrees, which limited our ability to recruit and enroll Representatives, operate manufacturing facilities and distribution centers and to process and deliver orders. The pandemic primarily resulted in reduced revenue, which in turn impacted profitability and cash generation. The third quarter of 2020 showed signs of recovery in most markets. The fourth quarter of 2020 has again been impacted by the new lockdown measures imposed in parts of Europe, although not to the extent felt during the second quarter of 2020 as we were able to continue normal operations in our manufacturing facilities and distribution centers. In 2021, the economic disruption caused by the COVID-19 pandemic has resulted in inflationary pressures on the cost of certain raw materials used in the production of essential items due to the increased demand for these inputs worldwide. These inflationary pressures have been compounded by disruptions in global supply chains and climate events that hit electricity generation globally, among others. Moreover, novel strains and variants of COVID-19 emerged in 2021, and the rollout of vaccination programs worldwide have compromised the ability of certain countries to effectively contain the spread and the toll of the virus. We continue to monitor the evolution of the Covid-19 pandemic in the markets in which we operate, especially with regard to restrictive measures adopted by these jurisdictions. We continuously analyze the situation and act to minimize impacts on the operations and on the equity and financial position of the Company, with the objective of implementing appropriate measures, ensuring the continuity of operations, hedge cash, improve liquidity and promote the health and safety of all. In view of this scenario, we review the recoverability expectations of our financial and non-financial assets in the preparation of these financial statements, considering the most recent information available and reflected in the Company’s business plans. In addition, we also consider possible effects on the financial statements including revenues and the continued transition to the digital environment, allowances for doubtful accounts receivable, impairment of non-financial assets, leases, liquidity and capital resources and going concern (see below). As of the date of this report, we are unable to estimate the long-term economic impact arising from efforts to curb the spread of the COVID-19 virus and the expected reduction in activity on our business, results of operations and financial condition. We will continue to review our revenue, investments, expenses and cash outflows, as well as adjusting our relationships with suppliers. Furthermore, the actions outlined above are continuously being re-evaluated in light of global developments relating to COVID-19. Going concern Considering the uncertain nature of any possible future COVID-19 impacts which are beyond the Company’s control and the ongoing military conflicts between Russia and Ukraine, we expect some negative impact on revenue in 2022, which will, in turn, result in lower cash generation from activities. If the downturn is deeper or for longer than we anticipate, the Company could take certain further actions to ease the pressure of certain cash outflows, such as reducing discretionary expenditure, selling non-core assets, accessing government pandemic initiatives or arranging borrowing facilities with third-party banks and affiliate companies. The Company has received an irrevocable commitment from Natura &Co Holding that it will provide sufficient financial support if and when needed to enable the Company to meet its obligations as they come due in the normal course of business for a period o f not less than 12 months from the date issuance of the Consolidated Financial Statements. This includes the obligations related to the $461m 5.00% Notes, which are due to be repaid in March 2023. See Note 7, Debt and Other Financing, and Note 15, Leases and Commitments, respectively, for information on our debt and contractual financial obligations and commitments, including the loans from Natura &Co and its affiliates maturing within 1 year. Foreign Currency Financial statements of foreign subsidiaries operating in other than highly inflationary economies are translated at year-end exchange rates for assets and liabilities and average exchange rates during the year for income and expense accounts. The resulting translation adjustments are recorded within accumulated other comprehensive income (loss) ("AOCI"). Gains or losses resulting from the impact of changes in foreign currency rates on assets and liabilities denominated in a currency other than the functional currency are recorded in other expense, net. For financial statements of Avon subsidiaries operating in highly inflationary economies, the U.S. dollar is required to be used as the functional currency. Highly inflationary accounting requires monetary assets and liabilities, such as cash, receivables and payables, to be remeasured into U.S. dollars at the current exchange rate at the end of each period with the impact of any changes in exchange rates being recorded in income. We record the impact of changes in exchange rates on monetary assets and liabilities in other expense, net. Similarly, deferred tax assets and liabilities are remeasured into U.S. dollars at the current exchange rates; however, the impact of changes in exchange rates is recorded in income taxes in our Consolidated Statements of Operations. Non-monetary assets and liabilities, such as inventory, property, plant and equipment and prepaid expenses are carried forward at their historical dollar cost, which was calculated using the exchange rate at the date which hyperinflationary accounting is implemented. Argentina Currency During the quarter ended June 30, 2018, based on published official exchange rates which indicate that Argentina's three-year cumulative inflation rate has exceeded 100%, we concluded that Argentina had become a highly inflationary economy. From July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary. As such, the functional currency for Argentina has changed to the U.S. dollar, which is the consolidated group's reporting currency. As a result of highly inflationary accounting for our Argentinian subsidiary, the most significant impacts in our Consolidated Income Statements are in cost of sales, primarily due to inventory being accounted for at its historical dollar cost, and in other (expense) income, net, primarily associated with the net monetary position of Argentina. However, these impacts are not considered material to our Consolidated Income Statements. Revenue Recognition Nature of goods and services We are a global manufacturer and marketer of beauty and related products. Our product categories are Beauty and Fashion & Home. Beauty consists of skincare, fragrance and color (cosmetics). Fashion & Home consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products and nutritional products. Our business is conducted primarily in one channel, direct selling. Our reportable segments are based on geographic operations in two regions: Avon International and Avon Latin America. We primarily sell our products to the ultimate consumer through the direct selling channel principally through Representatives, who are independent contractors and not our employees. Revenue recognition Revenue is recognized when control of a product or service is transferred to a customer, which is generally the Representative. Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties, such as Value Added Taxes ("VAT") collected for taxing authorities. Principal revenue streams and significant judgments Our principal revenue streams can be distinguished into: i) the sale of Beauty and Fashion & Home products to Representatives (recorded in net sales); ii) Representative fees, primarily for the sale of brochures to Representatives and fulfillment activities related to the contract, which include fees for shipping and handling (recorded in other revenue); and iii) other, which includes the sale of products to New Avon LLC ("New Avon") and royalties from the licensing of our name and products (recorded in other revenue). i) Sale of Beauty and Fashion & Home products to Representatives We generate the majority of our revenue through the sale of Beauty and Fashion & Home products. A Representative contacts her customers directly, selling primarily through our brochure (whether paper or online), which highlights new products and special promotions (or incentives) for each sales campaign. In this sense, the Representative, together with the brochure, are the "store" through which our products are sold. A brochure introducing a new sales campaign is typically generated every three to four weeks. A purchase order is processed, and the products are picked at a distribution center and delivered to the Representative usually through a combination of local and national delivery companies. Generally, the Representative then delivers the merchandise and collects payment from the customer for her or his own account. A Representative generally receives a refund of the price the Representative paid for a product if the Representative chooses to return it. A Representative Agreement, which outlines the basic terms of the agreement between Avon and the Representative, combined with a purchase order, constitutes a contract for the purposes of Accounting Standards Codification Topic ("ASC"), Revenue from Contracts with Customers ("ASC 606"). Revenue from Contracts with Customers We account for individual products and services separately in the contract if they are distinct (i.e., if a product or service is separately identifiable from the other items in the contract and if a Representative can benefit from the product or service on its own or with other resources that are readily available), which is recognized at a point in time, when control of a product is transferred to a Representative. In addition, we offer incentives to Representatives to support sales growth. Certain of these sales incentives are distinct promises to a Representative, and therefore are a separate performance obligation. As a result, revenue is allocated to the performance obligation for sales incentives and is deferred on the balance sheet until the associated performance obligations are satisfied. Typically included within a contract is variable consideration, such as sales returns and late payment fees. Revenue is only recorded to the extent it is probable that it will not be reversed, and therefore revenue is adjusted for variable consideration. Variable consideration is generally estimated using the expected value method, which considers possible outcomes weighted by their probability. Specifically for sales returns, a refund liability will be recorded for the estimated cash to be refunded for the products expected to be returned, and a returns asset will be recorded for the products which we expect to be returned and re-sold, each of these based on historical experience. The estimate of sales returns as well as the measurement of the returns asset and the refund liability is updated at the end of each month for changes in expectations regarding the amount of salvageable returns, reconditioning costs and any additional decreases in the value of the returned products. Late payment fees are recorded when the uncertainty associated with collecting such fees are resolved (i.e., when collected). The Representative generally receives a credit period of one sales campaign if they meet certain criteria; however, the specific credit terms are outlined in the Representative Agreement. Generally, the Representative remits payment during each sales campaign, which relates to the prior campaign cycle. The Representative is generally precluded from submitting an order for the current sales campaign until the accounts receivable balance past due for prior campaigns is paid; however, there are circumstances where the Representative fails to make the required payment. Our contracts with Representatives often include multiple promises to transfer products and/or services to the Representative, and determining which of these products and/or services are considered distinct performance obligations that should be accounted for separately. In addition, in assessing the recognition of revenue for the following performance obligations, management has exercised significant judgment in the following areas: estimation of variable consideration and the stand-alone selling prices ("SSP") of promised goods or services in order to determine and allocate the transaction price. Performance obligation - Avon products and appointment kits The Representative purchases Avon products and appointment kits through a purchase order. Avon offers appointment kits for purchase to Representatives, which may contain various Avon products. We recognize revenue for Avon products and appointment kits in net sales in our Consolidated Statements of Operations when the Representative obtains control of the products, which occurs upon delivery of the product to the Representative. Transaction price is the amount we expect to receive in exchange for those products adjusted for variable consideration as discussed above and the estimated SSP of other performance obligations as discussed below. The cost of these products and appointment kits is recognized in cost of sales in our Consolidated Statements of Operations. Performance obligation - Sales incentives Types of sales incentives include status programs, loyalty points, prospective discounts, and gift with purchase, among others. A Representative is eligible for certain status programs if specified sales levels are met. Status programs offer additional benefits such as free or discounted products and services. Loyalty points offer the option to redeem for additional Avon or other products or services. Prospective discounts are offered in some countries when certain sales levels are reached in a given time period. The revenue attributable to the prospective discount performance obligation is for the option to purchase additional product at a discounted amount. Certain benefits within status programs, loyalty points, prospective discounts and certain other sales incentives constitute a material right and, therefore, a distinct performance obligation in the contract with the Representative. Transaction price is allocated to the material right (performance obligation) based on estimated SSP and is deferred on the balance sheet until the associated performance obligations are satisfied. The cost of incentives is presented in inventories in our Consolidated Balance Sheets. We recognize revenue allocated to the material right in net sales in our Consolidated Statements of Operations at the point in time that the Representative receives the benefits of the material right or obtains control of the products, which occurs upon delivery to the Representative or upon expiration of the material right. For sales incentives that are delivered with the associated products order (such as gift with purchase), no deferral is required. SSP represents the estimated market value, or the estimated amount that could be charged for that material right when the entity sells it separately in similar circumstances to similar customers. Judgment is required to determine the SSP for each distinct performance obligation. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, including for certain sales incentives, we determine the SSP using information that may include market prices and other observable inputs. ii) Representative fees, primarily for the sale of brochures to Representatives and fulfillment activities related to the contract ("Representative fees") The purchase order in the contract with the Representative explicitly identifies activities that we will perform. This includes fees that we charge Representatives, primarily for the sale of brochures to Representatives and fulfillment activities, and also includes late payment fees (discussed above). Brochures represent promotional materials that are given directly by the Representatives to their customers as a marketing activity. Under ASC 606, brochures that are sold by Avon to Representatives through purchase orders represent separate performance obligations in the contract as these are promises made between Avon and the Representative. Although the brochures are used similar to marketing materials, the Representative generally orders and pays for the brochures, and we allocate consideration for purposes of revenue recognition. The revenue associated with brochures that are sold to Representatives is recognized in other revenue and the related cost is recognized in cost of sales in our Consolidated Statements of Operations. We recognize revenue when the Representative obtains control of the brochures, which occurs upon delivery to the Representative. When brochures are given away for free to Representatives as promotional items, the cost is recognized in selling, general and administrative expenses in our Consolidated Statements of Operations. We often charge the Representative for shipping and handling (including order processing) and payment processing activities on the invoice, and such activities are considered to be fulfillment costs. The consideration received represents part of the transaction price in the contract that is allocated to the performance obligations in the contract. We recognize revenue for fulfillment activities in other revenue in our Consolidated Statements of Operations when such services are provided to the Representative. The cost of these activities is recognized in SG&A expenses in our Consolidated Statements of Operations. iii) Other revenue We also recognize revenue from the sale of products to New Avon, as part of a manufacturing and supply agreement, since the separation of the Company's North America business into New Avon on March 1, 2016, and royalties from the licensing of our name and products, in other revenue in our Consolidated Statements of Operations. Contract costs Incremental costs to obtain contracts, such as bonuses or commissions, are recognized as an asset if the entity expects to recover them. However, ASC 340-40, Other Assets and Deferred Costs , offers a practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the entity otherwise would have recognized is one year or less. We elected the practical expedient and expense costs to obtain contracts when incurred because our amortization period is one year or less. Costs to fulfill contracts with Representatives are comprised of shipping and handling (including order processing) and payment processing services, which are expensed as incurred. The fees for these services are included in the transaction price. Cash and Cash Equivalents Cash equivalents are stated at cost plus accrued interest, which approximates fair value. Cash equivalents are generally high-quality, short-term money market instruments with an original maturity of three months or less and consist of time deposits with a number of U.S. and non-U.S. commercial banks and money market fund investments. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. We classify inventory into various categories based upon its stage in the product life cycle, future marketing sales plans and the disposition process. We assign a degree of obsolescence risk to products based on this classification to estimate the level of obsolescence provision. Brochure Costs Brochures represent promotional materials that are given directly by the Representatives to their customers as a marketing activity. Brochures that are sold by Avon to Representatives through purchase orders represent separate performance obligations in the contract as these are promises made between Avon and the Representative. Although the brochures are used similar to marketing materials, the Representative generally orders and pays for the brochures, and Avon allocates consideration for purposes of revenue recognition. The revenue associated with brochures that are sold to Representatives is recognized in other revenue and the related cost is recognized in cost of sales in our Consolidated Statements of Operations. We recognize revenue when the Representative obtains control of the brochures, which occurs upon delivery to the Representative. When brochures are given away for free to Representatives as promotional items, the cost is recognized in SG&A expenses in our Consolidated Statements of Operations. Brochure costs and associated fees that are presented as inventory were $4.1 at December 31, 2021 and $7.6 at December 31, 2020. Brochure costs and associated fees that are presented as prepaid expenses and other were $4.0 at December 31, 2021 and $6.7 at December 31, 2020. Brochure costs expensed to COGS and SG&A in 2021 amounted to $54.8 and $72.6, respectively. In 2020 brochure costs expensed to COGS and SG&A were $75.8 and $77.1, respectively. In 2019 brochure costs expensed to COGS and SG&A were of $101.1 and $93.9, respectively. The fees charged to Representatives for brochures sold recorded in Other revenue in 2021, 2020 and 2019 amounted to $49.3, $66.8 and $96.9, respectively. Property, Plant and Equipment and Capitalized Software Property, plant and equipment are stated at cost and are depreciated using a straight-line method over the estimated useful lives of the assets. The estimated useful lives generally are as follows: buildings, 45 years; land improvements, 20 years; machinery and equipment, 15 years; and office equipment, five Certain systems development costs related to the purchase, development and installation of computer software, and implementation costs incurred in a hosting arrangement that is a service contract, are capitalized and amortized over the estimated useful life of the related project. Costs incurred prior to the development stage, as well as maintenance, training costs, and general and administrative expenses are expensed as incurred. The other assets balance included unamortized capitalized software costs of $74.9 at December 31, 2021 and $76.0 at December 31, 2020. The amortization expense associated with capitalized software was $22.4, $24.5 and $24.7 for the years ended December 31, 2021, 2020 and 2019, respectively. We evaluate our property, plant and equipment and capitalized software for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated pre-tax undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. The fair value of the asset is determined using revenue and cash flow projections, and royalty and discount rates, as appropriate. Leases We determine if an arrangement is a lease at the lease commencement date. In addition to our lease agreements, we review all material new vendor arrangements for potential embedded lease obligations. The asset balance related to operating and finance leases is presented within right-of-use (ROU) asset and property, plant and equipment, respectively, on our Consolidated Balance Sheet. The short-term liability balance related to operating and finance leases is presented within other accrued liabilities on our Consolidated Balance Sheets. The long-term liability balance is presented within long-term operating lease liability and long-term debt on our Consolidated Balance Sheets for operating and finance leases, respectively. The lease liability is recognized based on the present value of the remaining fixed or in-substance fixed lease payments discounted using our incremental borrowing rates. We use a specific incremental borrowing rate for our material leases, which is determined based on the geography, nature of the asset and term of the lease. These rates are determined based on inputs provided by external banks and updated periodically. The lease liability includes the exercise of a purchase option only if we are reasonably certain to exercise as of the commencement date of the lease. The residual value guarantee amount is only included in the lease liability calculation to the extent payment is probable to the lessor as of the commencement of the lease. The ROU asset is calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date (i.e. prepaid rent) and initia

New Accounting Standards

New Accounting Standards	12 Months Ended
	Dec. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Standards	New Accounting Standards New Accounting Standards Implemented Except for the changes below, we have consistently applied the accounting policies to all periods presented in these consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2020, using a modified retrospective transition approach. The adoption did not have a material impact on our condensed consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The adoption resulted in a cumulative effect decrease to retained earnings of approximately $2 to reflect a change in the allowance for doubtful accounts. ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General. ASU 2018-14 modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. Early adoption is permitted. The amendments in this Update are effective for fiscal years ending after December 15, 2020, therefore we adopted this standard effective December 31, 2020. The adoption did not have a material impact on our Consolidated Financial Statements. ASU 2017-04, Intangibles - Goodwill and other (Topic 350) In January 2017, the FASB issued Accounting Standards Update ("ASU") 2017-04 Intangibles - Goodwill and other , which simplifies the test for goodwill impairment. This Update eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of the assets acquired and liabilities assumed in a business combination. Instead an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, however the loss recognized should not exceed the total amount of goodwill allocated to the reporting unit. The guidance requires prospective adoption. We adopted the guidance for the goodwill impairment test that we have conducted since 2020, and adoption of the guidance did not have a significant impact on our financial statements. ASU 2019-12, Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Income Taxes , which is intended to simplify the accounting standard and improve the usefulness of information provided in the financial statements. We adopted this new accounting guidance as of January 1, 2021. The adoption did not have a material impact on our Consolidated Financial Statements. ASU 2020-04, Reference Rate Reform (Topic 848) In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The ASU provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. In January 2021, the FASB issued ASU 2021-01 which clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company has implemented a transition plan to identify and modify its loans and other financial instruments with attributes that are either directly or indirectly influenced by LIBOR and, as a result, has elected to apply the optional expedient included in ASU 2020-04 to account for modifications of contracts within the scope of Topics 310, Receivables, and 470, Debt, to be accounted for by prospectively adjusting the effective interest rate. Accounting Standards to be Implemented ASU 2021-08, Business Combinations (Topic 805) In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. ASU 2021-08 is effective for our fiscal year beginning after December 15, 2022. The adoption is not expected to have a material impact on our Consolidated Financial Statements.

Discontinued Operations and Ass

Discontinued Operations and Assets and Liabilities Held for Sale	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations and Assets and Liabilities Held for Sale	Discontinued Operations and Assets and Liabilities Held for Sale Discontinued Operations On December 17, 2015, the Company entered into definitive agreements with affiliates controlled by Cerberus. The agreements resulted in the separation of the Company's North America business, which represented the Company's operations in the United States, Canada and Puerto Rico, from the Company into The Avon Company, formerly New Avon, ("New Avon") a privately-held company majority-owned and managed by Cerberus NA Investor LLC (an affiliate of Cerberus). The Company retained an investment of 19.9% ownership interest in New Avon. These transactions closed on March 1, 2016; from that date, resolution of contingent liabilities relating to Avon's ownership and operation of the North America business prior to its separation from the Company into New Avon have been treated as discontinued operations. In April 2019, we signed an agreement with LG Household & Health Care Ltd. to sell our 19.9% ownership interest in New Avon, which was completed during August 2019. Refer to the Divestitures section below for information relating to the sale of New Avon. The Company incurred costs during the years ended December 31, 2021, 2020 and 2019 following the resolution of certain contingent liabilities related to its ownership and operation of the North America business prior to its separation into New Avon. The major classes of financial statement components comprising the loss on discontinued operations, net of tax for New Avon are shown below: Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 21, 2019 Selling, general and administrative expenses $ (18.5) $ (27.9) $ (36.6) Operating loss $ (18.5) $ (27.9) $ (36.6) Loss from discontinued operations, net of tax $ (18.5) $ (27.9) $ (36.6) Assets and Liabilities Held for Sale The major classes of assets and liabilities comprising held for sale assets and held for sale liabilities on the Consolidated Balance Sheet at December 31, 2021 and December 31, 2020 are shown in the following table. Year ended December 31, 2021 2020 Current held for sale assets Inventories $ — $ 2.6 Property, Plant & Equipment (net) 2.8 9.2 Cash and cash equivalents — .7 Other assets — 1.4 $ 2.8 $ 13.9 Current held for sale liabilities Accounts payable $ — $ .5 Other liabilities — 1.8 $ — $ 2.3 At December 31, 2020, assets held for sale include one property and one business in Avon International segment and one property in the Avon Latin America Segment. At December 31, 2021, assets held for sale include one property in the Avon Latin America Segment. Divestitures Disposal of Avon Beauty Arabia in Saudi Arabia On December 23, 2021, the Company completed the sale of its 51% share of the business and assets of Avon Beauty Arabia in exchange for converting the business to a distributorship model together with the write off of a $3.9 loan balance. In the fourth quarter of 2021 we recognized a loss of $1.1 before and after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the write off of the loan balance, the carrying value of the business and assets of the Avon Beauty Arabia on the date of sale, and associated disposal costs. Disposal of Cosmetics Manufacturing Operations in India On November 17, 2021, the Company completed the sale of the business and assets of the Cosmetics Manufacturing Operation in India for a total selling price of $2.9, the proceeds of which are presented as investing activities in the Consolidated Statement of Cash Flows. In the fourth quarter of 2021 we recognized a gain of $1.1 before and after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the proceeds, the carrying value of the business and assets of the Cosmetics Manufacturing Operation in India on the date of sale, and associated disposal costs. Sale of Avon Luxembourg Holdings S.à r.l On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding for $150, with the proceeds used to repay maturing loans of $150 borrowed under the $250 Revolving Credit Facility with a subsidiary of Natura &Co Holding. The sale was accounted for as a transaction under common control in accordance with ASC805 - Business Combinations, with the resulting gain of $148, representing the difference between the proceeds, the net assets of Avon Luxembourg on the date of sale and the cumulative foreign currency translation adjustment, taken directly to Retained Earnings. For additional information, see the Consolidated Statements of Changes in Shareholders' Deficit. Spanish Distribution Center In September 2021, we completed the sale of our Spanish Distribution Center for a total selling price of $14.7, the proceeds of which are presented as investing activities in the Consolidated Statement of Cash Flows. In the third quarter of 2021 we recognized a gain of $8.3 before and $6.2 after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the proceeds, the carrying value of the branch of the Spanish Distribution Center on the date of sale, and associated disposal costs. Italy Branch In June 2021, we completed the sale of a branch of our Italian business for a total selling price of $1.7, the proceeds of which will be received in installments between October 2021 and December 2026, and will be presented as investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2021, we recorded a gain of $1.4 before and after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the proceeds and the carrying value of the branch of the Italian business on the date of sale. Avon Shanghai In August 2020, we signed an agreement to sell Avon Management Shanghai ("Avon Shanghai") to an affiliate of Natura &Co for a selling price of $2.9. In August 2020, we completed the sale of the entity and received proceeds of $2.9. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows as the sale was to an affiliate under common control by Natura &Co. The gain on sale of $1.4 was recorded directly to Retained earnings. Hungary Distribution Center in Gödöllő In April 2020, we signed an agreement to sell the Hungary Distribution Center in Gödöllő for a selling price of $3.4 and received a deposit of $.3. In June 2020, we completed the sale of the asset and the remaining proceeds of $3.1 were received. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2020, we recorded a gain of $.1 before and after tax, which is reported separately in the Consolidated Statements of Operations. The gain represents the difference between the proceeds and the carrying value of the Hungary Distribution Center on the date of sale. China Wellness Plant In March 2020, we signed an agreement to sell the China Wellness Plant for a total selling price of $6.6 before expenses. In the six-month period ended June 30, 2020, we received a cash deposit for the selling price of $6.6, which included $3.3 of restricted cash held in escrow. In August 2020, we completed the sale of the China Wellness Plant and $3.3 of restricted cash in escrow was transferred to Avon. In the third quarter of 2020, we recorded a gain of $1.4 before and after tax, which is reported separately in the Consolidated Statements of Operations. The gain represents the difference between the net proceeds (after associated expenses) and the carrying value of the China Wellness Plant on the date of sale. Rye Office On June 26, 2019, we completed the sale of the Rye office for a selling price of $23.2, less expenses of approximately $.8, resulting in proceeds of $22.4. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2019, we recorded a gain on sale of $9.9 before and after tax, which is reported separately in the Consolidated Statements of Operations. The gain recorded represents the difference between the proceeds and the carrying value of the Rye office on the date of sale. Malaysia Maximin On May 9, 2019, we completed the sale of all of our equity interests in Maximin Corporation Sdn Bhd ("Malaysia Maximin") for a total selling price of $7.8. The cash proceeds of $7.6, net of expenses, are presented within investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2019, we recorded a gain on sale of $3.3 before tax, which is reported separately in the Consolidated Statements of Operations, and $3.0 after tax. The gain recorded represents the difference between the proceeds and the carrying value of Malaysia Maximin on the date of sale. China manufacturing On February 15, 2019, we completed the sale to TheFaceShop Co., Ltd., an affiliate of LG Household & Health Care Ltd. ("TheFaceShop"), of all of the equity interests in Avon Manufacturing (Guangzhou), Ltd. for a total selling price of $71.0, less expenses of approximately $1.1. The selling price included $23.5 relating to outstanding intercompany loans payable to Avon Manufacturing (Guangzhou), Ltd. from other Avon subsidiaries that was presented as financing activities in the Consolidated Statement of Cash Flows, this was subsequently settled in April 2019. The cash proceeds of $46.4, net of loan amounts, are presented as investing activities in the Consolidated Statement of Cash Flows, which includes $7.6 of restricted cash as of December 31, 2019. This was subsequently reclassified to short-term restricted cash in the three month period ended March 31, 2020. The restriction on this cash was removed in the three-month period ended March 31, 2021. In the first quarter of 2019, we recorded a gain on sale of $10.3 before tax, which is reported separately in the Consolidated Statements of Operations, and $8.2 after tax, representing the difference between the proceeds, including the settlement of the intercompany loans, and the carrying value of Avon Manufacturing (Guangzhou), Ltd. on the date of sale. New Avon In April 2019, we signed an agreement with LG Household & Health Care Ltd. to sell our 19.9% ownership interest in New Avon. During August 2019, we completed the sale of New Avon for a selling price of $24.5. Expenses were approximately $1.1, resulting in cash proceeds of $23.4. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows. In the third quarter of 2019, we recorded a gain on sale of $26.8 before and after tax, which is reported in the Consolidated Statements of Operations as Gain on sale of business/asset. The gain recorded represents the total proceeds and the release of AOCI of $3.4. Our recorded investment balance in New Avon at August 14, 2019 was zero. On May 22, 2019, the Company entered into the Agreement and Plan of Mergers (as amended by Amendment Number One to Agreement and Plant of Mergers, dated as of October 3, 2019, and as further amended by Amendment Number Two to Agreement and Plan of Mergers, dated as of November 5, 2019, the "Merger Agreement") among the Company, Natura Cosméticos S.A., a Brazilian corporation (sociedade anônima) ("Natura Cosméticos"), Natura &Co Holding S.A., a Brazilian corporation (sociedade anônima), Nectarine Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of Natura &Co Holding ("Merger Sub I"), and Nectarine Merger Sub II, Inc., a Delaware corporation and a direct wholly owned subsidiary of Merger Sub I ("Merger Sub II"), pursuant to which (i) Natura &Co Holding, after the completion of certain restructuring steps, holds all issued and outstanding shares of Natura Cosméticos, (ii) Merger Sub II merged with and into the Company, with the Company surviving the merger (the "First Merger") and (iii) Merger Sub I merged with and into Natura &Co Holding (the "Second Merger"), with Natura &Co Holding surviving the merger and as a result of which the Company and Natura Cosméticos became wholly owned direct subsidiaries of Natura &Co Holding (collectively, the "Transaction"). The Transaction was consummated on January 3, 2020, and at this time, the Company became a wholly owned direct subsidiary of Natura &Co Holding. In connection with the Transaction, trading of the Company’s stock was suspended by the NYSE, and the Company’s common stock was subsequently delisted and deregistered. On completion of the Transaction, each share of t he Company’s common stock issued and outstanding immediately prior to the consummation of the Transaction was converted into the ultimate right to receive, (i) 0.300 validly issued and allotted, fully paid-up American Depositary Shares of Natura &Co Holding, ("Natura &Co Holding ADSs") against the deposit of two shares of common stock of Natura &Co Holding ("Natura &Co Holding Shares", subject to adjustment in accordance with the terms of the Merger Agreement, and any cash in lieu of fractional Natura &Co Holding ADSs or (ii) 0.600 validly issued and allotted, fully paid-up Natura &Co Holding Shares, subject to adjustment in accordance with the terms of the Merger Agreement, and any cash in lieu of fractional Natura &Co Holding Shares. The Company’s Series C Preferred Stock held by Cerberus Investor were converted to common stock prior to consummation of the Transaction and were therefore automatically converted into common stock of Natura &Co; see Note 17, Series C Convertible Preferred Stock. Natura &Co Holding Shares are listed on the B3 S.A. - Brasil, Bolsa, Balcão stock exchange, and Natura &Co Holding ADSs are listed on the NYSE. Additionally, upon the consummation of the Transaction, Avon common stock ceased to be traded on the NYSE. In January 2020, subsequent to the Transaction, the Company restated the certificate of incorporation. The certificate of incorporation was restated to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, are common stock and (ii) 25,000,000 shares, par value $1.00 per share, are preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result, all of the issued and outstanding common stock of the Company, being 550,890,788 were canceled and converted into 101.34 common stock, par value $0.01 per share, and all outstanding treasury shares were canceled. The Company incurred costs of $46 and $44 in relation to the Transaction, primarily professional fees during the years ended December 31, 2020 and 2019, respectively. During January 2020, it was announced that the employment of certain senior officers of the Company would be terminated, in connection with the Transaction. The Company incurred severance of approximately $25 and acceleration of share based compensation of approximately $10 relating to these terminations triggered by change in control provisions. As a result of the Transaction, the Company made payments of approximately $26 related to the settlement of stock options. In addition, any remaining restricted stock units and performance restricted stock units were exchanged for awards of Natura &Co Holding. The replacement awards contain substantially the same terms and conditions of the original awards except for the removal of the performance conditions. As such, the replacement awards contain only a service vesting condition. On consummation of the Transaction, a deferred compensation scheme relating to former employees of the Company became payable which resulted in extinguishing the liability and a cash outflow of approximately $12. In January 2020, upon completion of the Transaction, the Company’s revolving credit facility was canceled, triggered by change in control provisions. As a result, debt issuance costs of $7.8 were written off. As a result of the Transaction, the Company will no longer have access to certain tax attributes of approximately $546 to approximately $616 in certain taxing jurisdictions. These tax attributes had been formerly reflected as deferred tax assets which were subject to a full valuation allowance and as a result, there was no impact to net income in 2020 from the write-off of the deferred tax asset and the associated valuation allowances.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions On January 3, 2020, the Company became a wholly owned subsidiary of Natura &Co Holding. From this point, Natura &Co Holding, its subsidiaries and affiliates became related parties of the Company. On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, beginning on July 1, 2021, transactions and balances between Avon International and Avon Luxembourg are no longer eliminated on consolidation and instead are treated as transactions and balances with Related Parties. The following tables present the related party transactions with Natura &Co and its affiliates and the Instituto Avon in Brazil, all of which were on an arm's-length basis. There are no other related party transactions. Year Ended December 31, Year Ended December 31, 2021 2020 Statement of Operations Data Revenue from affiliates of Natura &Co (2)(3) $ 25.2 $ 6.7 Cost of sales from affiliaties of Natura &Co (2)(3) $ (22.4) $ (5.9) Gross profit from affiliates of Natura &Co (2)(3) $ 2.8 $ .8 Interest income from Instituto Avon (1) $ — $ .1 Interest expense on Loan from affiliates of Natura &Co (5) $ (50.6) $ (7.5) Interest income on Loan to affiliates of Natura &Co (5) $ 1.6 $ — December 31, 2021 December 31, 2020 Balance Sheet Data Receivables due from Instituto Avon (1) $ — $ .8 Trade Receivables due from affiliates of Natura &Co (2) $ 32.7 $ 6.1 Other receivables due from affiliates of Natura &Co (7) $ 1.4 $ — Loans to affiliates of Natura &Co maturing within one year (7) $ 46.6 $ — Loans to affiliates of Natura &Co maturing after one year (7) $ 46.7 $ — Trade Payables due to affiliates of Natura &Co (7) $ (24.5) $ — Other payables due to affiliates of Natura &Co (4) $ (4.9) $ — Loans from affiliates of Natura &Co maturing within one year (5) $ (371.7) $ (1,008.6) Loans from affiliates of Natura &Co maturing after one year (5) $ (736.3) $ — Investments in affiliates of Natura &Co (6) $ .1 $ — (1) During the second quarter of 2018, the Company entered into an agreement to loan the Instituto Avon, an independent non-government charitable organization in Brazil, R$12 million (Brazilian real) for an unsecured 5-year term at a fixed interest rate of 7% per annum, to be paid back in five equal annual installments. The Instituto Avon was created by an Avon subsidiary in Brazil, with the board and executive team comprised of Avon Brazil management. The purpose of the loan was to provide the Instituto Avon with the means to donate funds to Fundação Pio XII (a leading cancer prevention and treatment organization in Brazil and owner of the Hospital do Câncer de Barretos), in order to invest in equipment with the objective of expanding breast cancer prevention and treatment. During the fourth quarter of 2021, the loan was repaid in full. (2) During the second quarter of 2020, the Company entered into manufacturing agreements with affiliates of Natura &Co Holding. The Company recorded revenue from related party of $25.2 and $6.7 associated with these agreements during the years ended December 31, 2021 and 2020, respectively. The Company recorded gross profit from related party of $2.8 and $.8 associated with these agreements during the years ended December 31, 2021 and 2020, respectively. Trade receivables due from affiliates of Natura &Co primarily relate to these manufacturing agreements. (3) The Company is party to a license agreement with Avon Mexico, whereby Avon Mexico pays the Company a variable royalty. The Company recorded revenue from related party of $1 associated with these agreements during the year ended December 31, 2021. The Company recorded gross profit from related party of $1 associated with these agreements during the year ended December 31, 2021. (4) T he payable to Natura &Co relates to the vesting and settlement of share based compensation awards denominated in Natura &Co American Depository Receipts including the 2018 long-term employee incentive program which vested and were automatically exercised in March 2021. (5) Loans from affiliates of Natura &Co Holding at December 31, 2021 of $1,108.0 include $736.3 outstanding under a Promissory Note between Avon Beauty Limited and a subsidiary of Natura &Co Holding, and $207.3 outstanding under a Promissory Note with a subsidiary of Natura &Co Holding and an affiliate of the Company. In addition loans from affiliates of Natura &Co Holding at December 31, 2021 include $164.4 of intercompany loans between Avon Luxembourg and Avon Products, Inc. affiliates that, following the sale of Avon Luxembourg to a subsidiary of Natura &Co Holding on July 1, 2021, were redesignated as loans from affiliates of Natura & Co Holding. Loans from affiliates of Natura &Co Holding at December 31, 2020 of $1,008.6 include $965 outstanding under a Promissory Note between Avon International Operations Inc. and a subsidiary of Natura &Co Holding. Loans from affiliates of Natura &Co Holding at December 31, 2020 also include $41.6 outstanding under the Revolving Credit Facility between Avon Luxembourg and Natura &Co International S.à r.l.. See Note 15, Debt and Other Financing, for further information relating to these loans. (6) During the second quarter of 2021, Avon Cosméticos LTDA., made an investment of R$.5 in Natura &Co Pay Holding Financeira S.A., representing a 10% holding in the company. This is presented in other assets in our Consolidated Balance Sheets. (7) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, transactions and balances between Avon International and Avon Luxembourg are no longer eliminated on consolidation and instead are treated as transactions and balances with Related Parties.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of revenue In the following tables, revenue is disaggregated by product or service type. All revenue is recognized at a point in time, when control of a product is transferred to a customer: Twelve Months Ended December 31, 2021 Reportable segments Avon International Avon LATAM Total reportable segments Affiliates of Natura Total Beauty: Skincare $ 577.6 $ 465.8 $ 1,043.4 $ — $ 1,043.4 Fragrance 514.2 375.8 890.0 — 890.0 Color 238.0 181.9 419.9 — 419.9 Total Beauty 1,329.8 1,023.5 2,353.3 — 2,353.3 Fashion & Home: Fashion 258.3 159.8 418.1 — 418.1 Home 69.6 340.4 410.0 — 410.0 Total Fashion & Home 327.9 500.2 828.1 — 828.1 Certain Brazil taxes* — 21.5 21.5 — 21.5 Product sales 1,657.7 1,545.2 3,202.9 — 3,202.9 Representative fees 66.4 107.8 174.2 — 174.2 Other .5 1.7 2.2 25.2 27.4 Other revenue 66.9 109.5 176.4 25.2 201.6 Total revenue $ 1,724.6 $ 1,654.7 $ 3,379.3 $ 25.2 $ 3,404.5 Twelve Months Ended December 31, 2020 Reportable segments Avon International Avon LATAM Total reportable segments Affiliates of Natura Total Beauty: Skincare $ 594.7 $ 515.9 $ 1,110.6 $ — $ 1,110.6 Fragrance 516.0 456.4 972.4 — 972.4 Color 265.8 197.5 463.3 — 463.3 Total Beauty 1,376.5 1,169.8 2,546.3 — 2,546.3 Fashion & Home: Fashion 267.4 192.5 459.9 — 459.9 Home 55.6 369.4 425.0 — 425.0 Total Fashion & Home 323.0 561.9 884.9 — 884.9 Product sales 1,699.5 1,731.7 3,431.2 — 3,431.2 Representative fees 66.7 108.4 175.1 — 175.1 Other 6.4 5.8 12.2 6.7 18.9 Other revenue 73.1 114.2 187.3 6.7 194.0 Total revenue $ 1,772.6 $ 1,845.9 $ 3,618.5 $ 6.7 $ 3,625.2 Twelve Months Ended December 31, 2019 Reportable segments Avon International Avon LATAM Total Beauty: Skincare $ 671.5 $ 699.9 $ 1,371.4 Fragrance 639.9 604.7 1,244.6 Color 381.6 340.0 721.6 Total Beauty 1,693.0 1,644.6 3,337.6 Fashion & Home: Fashion 383.8 235.0 618.8 Home 61.7 408.3 470.0 Total Fashion & Home 445.5 643.3 1,088.8 Certain Brazil taxes** — 67.7 67.7 Product sales 2,138.5 2,355.6 4,494.1 Representative fees 91.5 152.7 244.2 Other 4.3 20.6 24.9 Other revenue 95.8 173.3 269.1 Total revenue $ 2,234.3 $ 2,528.9 $ 4,763.2 * 2021 includes approximately $22, to reflect the impact of certain Brazil indirect taxes which were recorded in product sales, in our Consolidated Income Statements. See Note 20 Supplemental Balance Sheet Information. ** 2019 includes the impact of certain Brazil indirect taxes which was recorded in product sales of approximately $68, in our Consolidated Income Statements. See Note 20 Supplemental Balance Sheet Information. Contract balances The timing of revenue recognition generally is different from the timing of a promise made to a Representative. As a result, we have contract liabilities, which primarily relate to the advance consideration received from Representatives prior to transfer of the related good or service for material rights, such as loyalty points and status programs, and are primarily classified within other accrued liabilities (with the long-term portion in other liabilities) in our Consolidated Balance Sheets. Generally, we record accounts receivable when we invoice a Representative. In addition, we record an estimate of an allowance for doubtful accounts on receivable balances based on an analysis of historical data and, as applicable, current conditions and reasonable and supportable forecasts that affect collectability, including seasonality and changing trends and the impact of COVID-19. The allowance for doubtful accounts is reviewed for adequacy, at a minimum, on a quarterly basis. We generally have no detailed information concerning, or any communication with, any ultimate consumer of our products beyond the Representative. We have no legal recourse against the ultimate consumer for the collection of any accounts receivable balances due from the Representative to us. If the financial condition of the Representatives were to deteriorate, resulting in their inability to make payments, additional allowances may be required. The following table provides information about receivables and contract liabilities from contracts with customers at December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Accounts receivable, net of allowances of $37.1 and $51.1 $ 198.7 $ 259.1 Contract liabilities $ 37.1 $ 52.1

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory, Net [Abstract]
Inventories	Inventories Inventories at December 31 consisted of the following: 2021 2020 Raw materials $ 103.4 $ 131.3 Finished goods 280.7 327.8 Total $ 384.1 $ 459.1

Debt and Other Financing

Debt and Other Financing	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt and Other Financing	Debt and Other Financing Debt Debt at December 31 consisted of the following: 2021 2020 Debt maturing within one year: Short term debt $ 32.6 $ 28.0 Loans from affiliates of Natura &Co 371.7 1,008.6 Total $ 404.3 $ 1,036.6 Long-term debt: Finance lease liabilities 1.3 1.5 5.00% Notes, due March 2023 460.8 460.1 6.95% Notes, due March 2043 213.9 213.8 Loans from affiliates of Natura &Co, due 2028 736.3 — Total 1,412.3 675.4 The carrying value of long-term debt is presented net of debt issuance costs and includes any related discount or premium, as applicable. Unsecured Notes In March 2013, we issued, in a public offering, $500.0 principal amount of 4.60% Notes due March 15, 2020 (the "4.60% Notes"), $500.0 principal amount of 5.00% Notes due March 15, 2023 (the "5.00% Notes") and $250.0 principal amount of 6.95% Notes due March 15, 2043 (the "6.95% Notes") (collectively, the "2013 Notes"). In March 2008, we issued $350.0 principal amount of 6.50% Notes due March 1, 2019 (the "6.50% Notes"). Interest on the 2013 Notes is payable semi-annually on March 15 and September 15 of each year. The indenture governing the 2013 Notes contains interest rate adjustment provisions depending on the credit ratings assigned to the 2013 Notes with S&P and Moody's. As described in the indenture, the interest rates on the 2013 Notes increase or decrease by .25% for each one-notch movement below investment grade on each of the credit ratings assigned to the 2013 Notes by S&P or Moody's. These adjustments are limited to a total increase of 2% above the respective interest rates in effect on the date of issuance of the 2013 Notes. In August 2016, we completed cash tender offers which resulted in a reduction of principal of $68.1 of our 6.50% Notes and $50.1 of our 4.60% Notes. In the fourth quarter of 2016, we repurchased $44.0 of our 6.50% Notes, $40.0 of our 4.60% Notes, $11.1 of our 5.00% Notes and $6.2 of our 6.95% Notes. In June 2018, we prepaid the remaining principal amount of our 6.50% Notes. The prepayment price was equal to the remaining principal amount of $237.8, plus a make-whole premium of $6.2 and accrued interest of $4.6. In connection with the prepayment, we incurred a loss on extinguishment of debt of $2.9 before tax in the second quarter of 2018 consisting of the $6.2 make-whole premium, and the write-off of $.3 of debt issuance costs and discounts related to the initial issuances of the notes that were prepaid, partially offset by a write off of a deferred gain of $3.6 associated with the March 2012 interest-rate swap agreement termination. In the fourth quarter of 2018, we repurchased $23.0 of our 4.60% Notes and $27.0 of our 5.00% Notes. The aggregate repurchase price was equal to the principal amount of the notes, less a discount received of $2.4 and accrued interest of $.7. In connection with these repurchases of debt, we incurred a gain on extinguishment of debt of $2.1 before tax in the fourth quarter of 2018 consisting of the $2.4 discount received for the repurchases, partially offset by $.3 for the write-off of debt issuance costs and discounts related to the initial issuance of the notes that were repurchased. In July 2019, we repurchased $274.8 of our 4.60% Notes by way of a tender offer. The aggregate repurchase price was equal to the principal amount of $274.8 less a discount received of $.6, plus an early tender premium of $8.2 and accrued interest of $5.4. In December 2019, we prepaid the remaining principal amount of our 4.6% Notes. The prepayment price was equal to the remaining principal amount of $112.2, plus a make-whole premium of $1.4 and accrued interest of $1.7. In connection with these repurchases of debt, we incurred a loss on extinguishment of debt of $8.1 before tax in the third quarter and $1.5 before tax in the fourth quarter of 2019. In September 2020, we repurchased $27.8 of our 6.95% Notes due March 15, 2043. The aggregate repurchase price was equal to the principal amount of the notes, plus a premium of $3.8 and accrued interest of $1.2. In connection with the repurchase, we incurred a loss on extinguishment of debt of $4.1 before tax in the third quarter of 2020 consisting of the $3.8 premium paid for the repurchases, and $.3 for the write-off of debt issuance costs and discounts related to the initial issuance of the notes that were repurchased. At December 31, 2021 and 2020, the carrying values of our unsecured notes were comprised of the following: 2021 2020 Remaining Principal Unamortized Discounts Unamortized Debt Issuance Costs Total Remaining Principal Unamortized Discounts Unamortized Debt Issuance Costs Total 5.00% Notes, due March 2023 461.9 (.5) (.6) 460.8 461.9 (1.0) (.8) 460.1 6.95% Notes, due March 2043 216.1 (1.7) (.5) 213.9 216.1 (.5) (1.8) 213.8 The indentures governing our outstanding notes described above contain certain customary covenants, customary events of default, cross-default provisions and change in control provisions. In July and September 2019, bondholder consents for the 5% Notes and the 6.95% Notes, respectively, were obtained to amend the definition of "change of control" to permit the acquisition of Avon by Natura. No repayment of notes was triggered by the Transaction with Natura &Co. At December 31, 2021 and 2020, we had recorded accrued interest on our unsecured notes of $14.7 and $15.2, respectively, which is classified within other accrued liabilities in our Consolidated Balance Sheets. Senior Secured Notes In August 2016, Avon International Operations, Inc. ("AIO"), a wholly-owned subsidiary of the Company, issued, in a private placement exempt from registration under the Securities Act of 1933, as amended, $500.0 in aggregate principal amount of 7.875% Senior Secured Notes, with a maturity date of August 15, 2022 (the "2016 Notes"). In July 2019, Avon International Capital, p.l.c. ("AIC"), a wholly-owned subsidiary of the Company, issued, in a private placement exempt from registration under the Securities Act of 1933, as amended, $400.0 in aggregate principal amount of 6.5% Senior Secured Notes, with a maturity date August 15, 2022 (the "2019 Notes"). In November 2020, in connection with the Natura & Co Promissory Note, we redeemed the outstanding principal amount of our 2016 Notes due August 15, 2022 and the outstanding principal amount of our 2019 Notes due August 15, 2022. With respect to the 2016 Notes, the aggregate redemption amount paid was equal to the outstanding principal amount of $500, plus a premium of $9.8 and accrued interest of $8.4. With respect to the 2019 Notes, the aggregate redemption amount paid was equal to the outstanding principal amount of $400, plus a premium of $7.9 and accrued interest of $5.6. In connection with the redemption, we incurred a loss on extinguishment of debt of $25.6 before tax in the fourth quarter of 2020 consisting of the $17.7 premiums, and the write-off of $7.9 of debt issuance costs related to the initial issuances of the notes that were redeemed. Certain hedging and cash management obligations of the Company and certain subsidiaries are secured by first priority security interests in substantially all of its assets, subject to certain exceptions. At December 31, 2021 and 2020, the carrying values of our senior secured notes was nil. Maturities of Long-Term Debt Annual maturities of long-term debt, which includes our notes, loans from affiliates of Natura &Co and capital leases outstanding at December 31, 2021, are as follows: 2022 2023 2024 2025 2026 2027 and Beyond Total Maturities $ — $ 462.7 $ .3 $ .2 $ .1 $ 952.4 $ 1,415.7 Other Financing Natura Revolving Credit Facility In May 2020, the Company’s subsidiary, Avon Luxembourg entered into a Revolving Credit Facility Agreement with Natura &Co International S.à r.l., a subsidiary of Natura &Co Holding and an affiliate of the Company, in the initial amount of $100, increased to $250 in March 2021, which may be used for working capital and other general corporate purposes (the "Facility"). Borrowings under the Facility bear interest at a rate per annum of LIBOR plus a margin determined on an arm's length basis, and the Facility is to mature on May 31, 2022. On July 1, 2021, the Company sold Avon Luxembourg to a subsidiary of Natura &Co Holding and the Company no longer has access to this facility. Related Party loans In November 2020, AIO entered into a Promissory Note with a subsidiary of Natura &Co Holding S.A. and an affiliate of the Company in the amount of $960. The Promissory Note bears interest at a rate per annum of 3.13% and matures on November 2, 2022 (“the Natura &Co Loan”). On July 1, 2021, as part of the sale of Avon Luxembourg to a subsidiary of Natura &Co Holding the $960 loan was partially repaid with the proceeds from a loan maturing in 2028. As at December 31, 2021, $207 was outstanding under the Natura &Co Loan and $736 was outstanding under the loan maturing in 2028 which is between Avon Beauty Limited, and Natura &Co Luxembourg Holdings S.à r.l. ("Natura &Co Lux Loan"). In addition, loans from affiliates of Natura &Co Holding at December 31, 2021 of $164 includes a number of intercompany loans between Avon Luxembourg and Avon Products, Inc. affiliates that, following the sale of Avon Luxembourg to a subsidiary of Natura &Co Holding S.A. on July 1, 2021, were redesignated as loans from affiliates of Natura & Co Holding. Other short-term financing At December 31, 2021, we utilized approximately $33 of short-term financing from third-party banks across multiple markets bearing an average interest rate of per annum of 7.7%. Revolving Credit Facility In June 2015, AIO, a wholly-owned subsidiary of the Company, entered into a five-year $400.0 senior secured revolving credit facility (the "2015 facility"). In February 2019, AIC, a wholly-owned subsidiary of the Company, entered into a three-year €200.0 senior secured revolving credit facility (the "2019 facility"). The 2019 facility replaced the 2015 facility and the 2015 facility was terminated at such time. In the first quarter of 2019, $2.0 was recorded for the write-off of unamortized issuance costs related to the 2015 revolving credit facility. In the first quarter of 2019, the Company capitalized $11.0 of issue costs relating to the new revolving credit facility; the cash outflow is presented in other financing activities within the Consolidated Statement of Cash Flows. As of December 31, 2019, there were no amounts outstanding under the 2019 facility and on January 3, 2020, the facility was automatically cancelled upon change of control, and as a result $7.8 was of unamortized issuance costs were written off, see Note 21, Agreement and Plan of Mergers with Natura Cosméticos S.A., to the Consolidated Financial Statements included herein. Letters of Credit At December 31, 2021 and 2020, we also had letters of credit outstanding totaling $11.3 and $16.9, respectively. These balances primarily relate to a letter of credit issued to a lessor of certain equipment, a lease which was transferred to New Avon in connection with the separation of the Company's North America business, and letters of credit which guarantee various insurance activities. Long-Term Credit Ratings Our long-term credit ratings are: Moody’s ratings of Stable Outlo ok with Ba3 f or corporate family debt; S&P ratings of Stable Outlook with BB- for corporate family debt and senior unsecured debt; and Fitch rating of Stable Outlook with BB for corporate family and unsecured debt. Our credit ratings remain below investment grade which may impact our ability to access financing transactions on favorable terms.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) The tables below present the changes in AOCI by component and the reclassifications out of AOCI during 2021 and 2020: Foreign Currency Translation Adjustments Net Investment Hedges Pension and Postretirement Benefits Total Balance at December 31, 2020 $ (1,038.2) $ (4.3) $ (91.3) $ (1,133.8) Other comprehensive income (loss) other than reclassifications (24.1) — 67.3 43.2 Sale of Avon Luxembourg .1 (.1) — Reclassifications into earnings: Amortization of net actuarial loss and prior service cost, net of tax of $.8 (1) — — 5.1 5.1 Total reclassifications into earnings — — 5.1 5.1 Balance at December 31, 2021 $ (1,062.2) $ (4.3) $ (19.0) $ (1,085.5) Foreign Currency Translation Adjustments Cash Flow Hedges Net Investment Hedges Pension and Postretirement Benefits Total Balance at December 31, 2019 $ (942.7) $ (.6) $ (4.3) $ (92.4) $ (1,040.0) Other comprehensive loss other than reclassifications (95.5) — — (7.1) (102.6) Reclassifications into earnings: Derivative gains on cash flow hedges, net of tax of $0 — .6 — — .6 Amortization of net actuarial loss and prior service cost, net of tax of $.8 (1) — — — 8.2 8.2 Total reclassifications into earnings — .6 — 8.2 8.8 Balance at December 31, 2020 $ (1,038.2) $ — $ (4.3) $ (91.3) $ (1,133.8) (1) Gross amount reclassified to other expense, net, and related taxes reclassified to income taxes.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income from continuing operations, before taxes for the years ended December 31 was as follows: 2021 2020 2019 United States $ 19.3 $ (89.6) $ (108.3) Foreign (178.1) (214.0) 246.7 Total $ (158.8) $ (303.6) $ 138.4 The provision for income taxes for the years ended December 31 was as follows: 2021 2020 2019 Federal: Current $ .2 $ (9.5) $ (9.0) Deferred — 8.9 8.5 Total Federal .2 (.6) (0.5) Foreign: Current 35.5 31.4 79.0 Deferred (20.0) 2.6 28.9 Total Foreign 15.5 34.0 107.9 State and Local: Current .5 .6 (4.3) Deferred — — — Total State and other .5 .6 (4.3) Total $ 16.2 $ 34.0 $ 103.1 The continuing operations effective tax rate for the years ended December 31 was as follows: 2021 2020 2019 Statutory federal rate 21.0 % 21.0 % 21.0 % State and local taxes, net of federal tax benefit (.3) (.2) (2.7) Tax on foreign income 67.1 (1.8) 62.1 Tax on uncertain tax positions 3.7 1.1 16.6 Reorganizations — (10.0) 185.6 Net change in valuation allowances (103.1) (21.4) (208.0) Other 1.4 .1 (.1) Effective tax rate (10.2) % (11.2) % 74.5 % In 2021, the Company’s effective tax rate continues to be impacted by the country mix of earnings. The country mix includes losses in certain jurisdictions that cannot be benefited and income tax expense in certain jurisdictions where taxable income is generated. In 2021, the Company adjusted its reserves for uncertain tax positions associated with current year activity and events, primarily due to the expiration of statutes of limitation. Included in Tax on Foreign Income is the effect of tax rate changes including the increase in the United Kingdom tax rate from 19% to 25% which resulted in a deferred tax benefit of $89. In 2021, the Net Change in Valuation Allowances line in the rate reconciliation above includes $164 of net benefits that could not be recognized. The $164 of benefits which were not recognized consisted of the following key items: 1) $71 of increased Valuation Allowances due to additional Deferred Tax Assets generated during 2021 which cannot be benefitted; 2) $89 of increased Valuation Allowances on Deferred Tax Assets due to a tax rate change offsetting equivalent and associated accruals of deferred tax benefits reflected in the “Tax on Foreign Income” line above; and 3) $4 of increased Valuation Allowances due to changes in judgment regarding the ability to use certain Deferred Tax Assets which existed at the beginning of 2021. In 2020, the Company’s effective tax rate continues to be impacted by the country mix of earnings. The country mix includes losses in certain jurisdictions that cannot be benefited and income tax expense in certain jurisdictions where taxable income is generated. In 2020, the Company adjusted its reserves for uncertain tax positions associated with current year activity and events, primarily due to the expiration of statutes of limitation. Included in Tax on Foreign Income is the effect of tax rate changes including the increase in the United Kingdom tax rate from 17% to 19% which resulted in a deferred tax benefit of $21.0. Included in the Re-organizations line is the effect of a true-up for a change in estimate of $30.5 regarding the amount of net operating losses generated as part of the 2018 restructuring transactions. In 2020, the Net Change in Valuation Allowances line in the rate reconciliation above includes $65.1 of net benefits that could not be recognized. The $65.1 of benefits which were not recognized consisted of the following key items: 1) $69.9 of increased Valuation Allowances due to additional Deferred Tax Assets generated during 2020 which cannot be benefitted; 2) $21.0 of increased Valuation Allowances on Deferred Tax Assets due to a tax rate change offsetting equivalent and associated accruals of deferred tax benefits reflected in the “Tax on Foreign Income” line above; 3) $4.7 of increased Valuation Allowances due to changes in judgment regarding the ability to use certain Deferred Tax Assets which existed at the beginning of 2020; and 4) $30.5 decrease which offsets the true-up effect for the change in estimate of the benefit of net operating losses generated as part of the 2018 restructuring transactions. In 2019, as a result of continued business model changes related to the move of the Company’s headquarters from the US to the UK, the Company recognized one-time tax charges of $256.9 reflected in the "Reorganizations" line above associated primarily with the rationalization and re-alignment of the Company’s legal entity structure which resulted in the use of approximately $256.9 of Foreign Tax Credits, deferred tax assets and other tax attributes. In 2019, the Net Change in Valuation Allowances line in the rate reconciliation above includes: 1) $232.5 of decreases to the Valuation Allowances primarily associated with the utilization of Foreign Tax Credits and deferred tax assets offsetting the one-time tax charges of $256.9 noted in the "Reorganizations" line above; and 2) $66.5 of decreases due to a tax rate change offsetting equivalent and associated write-offs of deferred tax assets reflected in the “Tax on Foreign Income” line above. Deferred tax assets (liabilities) at December 31 consisted of the following: 2021 2020 Deferred tax assets: Tax loss and deduction carryforwards $ 425.0 $ 1,997.5 Intangibles 218.5 188.3 Tax credit carryforwards 119.7 119.0 Interest carryforwards 76.3 48.3 All other future deductions 199.8 199.1 Valuation allowance (815.4) (2,327.6) Total deferred tax assets 223.9 224.6 Deferred tax liabilities $ (105.0) $ (90.8) Net deferred tax assets $ 118.9 $ 133.8 As of December 31, 2021, excluded from the above table are approximately $1,638 of deferred tax assets for Avon Luxembourg Holdings S.à r.l. and subsidiaries that previously were offset with a full valuation allowance. As discussed in Note 3. Discontinued Operations and Assets and Liabilities Held for Sale, Avon Luxembourg Holdings S.à r.l. and subsidiaries were divested as of July 1, 2021. We monitor the realizability of our deferred tax assets on a continuous basis. Should macroeconomic and socio-political conditions change or our business operations do not improve, approximately $67 of deferred tax assets could potentially need to be offset with the recording of a valuation allowance during the next 12 months. The deferred tax assets are associated with Avon subsidiary operations that suffered a loss in earnings before tax during 2021. As of December 31, 2020, excluded from the above table are approximately $635 of worthless deferred tax assets that previously were offset with a full valuation allowance. Approximately $465 of these deferred tax assets cannot be used due to change of control limitation resulting from the merger with Natura. The remaining $170 is primarily associated with U.S. foreign tax credits of $70 and state net operating/capital losses of $100 which the Company has determined that use of such deferred tax assets would be remote. Deferred tax assets (liabilities) at December 31 were classified as follows: 2021 2020 Deferred tax assets: Other assets $ 121.4 $ 135.8 Total deferred tax assets 121.4 135.8 Deferred tax liabilities: Long-term income taxes $ (2.5) $ (2.0) Total deferred tax liabilities (2.5) (2.0) Net deferred tax assets $ 118.9 $ 133.8 The Company continuously assesses available positive and negative evidence to estimate whether sufficient future taxable income will be generated to utilize our existing deferred tax assets that are not subject to a valuation allowance. As of December 31, 2021, the COVID-19 pandemic is negative evidence the Company must consider. As of December 31, 2021, the increase in negative evidence due to COVID-19, primarily lower revenue and profit performance, resulted in approximately $8 of valuation allowances being recorded against deferred tax assets. The Company will continue to monitor the COVID-19 pandemic and other effects that could impact the conclusions regarding the realizability of its remaining deferred tax assets. Potential negative evidence, including such things as the worsening of the economies in the markets we operate in and reduced profitability of our markets could give rise to a need for a valuation allowance to reduce our deferred tax assets in upcoming quarters. During 2021, excluding the reductions associated with the divested deferred tax assets noted above, the Company recorded a net increase in its valuation allowances of $126. The $126 of benefits primarily relates to current year losses that could not be benefitted and the effects of currency translation. During 2020, excluding the reductions associated with the worthless deferred tax assets noted above, the Company recorded a net increase in its valuation allowances of $2.6. The $2.6 includes the effect of $65.1 of benefits related to operations and other activity which could not be recognized as noted in the rate reconciliation above offset with the write-off of $81.8 of Valuation Allowance associated with Deferred Tax Assets which can no longer be utilized due to change of control restrictions resulting from the Natura merger and $19.4 of increases primarily driven by currency translation and other miscellaneous effects. At December 31, 2021, the valuation allowance primarily represents amounts for certain foreign tax loss carryforwards, substantially all U.S. deferred tax assets and certain other foreign deferred tax assets. The recognition of deferred tax assets was based on the evaluation of current and estimated future profitability of the operations, reversal of deferred tax liabilities and the likelihood of utilizing tax credit and/or loss carryforwards. Tax planning strategies were also considered and evaluated as support for the realization of deferred tax assets. Where these sources of income existed along with sufficient positive evidence that indicated it was more likely than not that such sources of income could be relied upon, then the deferred tax assets were not reduced by a valuation allowance. At December 31, 2021, we had recognized deferred tax assets of $119.7 relating to tax credit carryforwards (U.S. foreign tax credits, research and experimentation credits and other tax credits) for which a valuation allowance of $119.7 has been provided. The tax credit carryforwards consist of U.S. foreign tax credits of $87.6 which are subject to expiration between 2022 and 2027; U.S. research and experimentation credits of $23.7 which are subject to expiration between 2027 and 2042 and other tax credits of $8.4 which are subject to expiration between 2022 and 2033. At December 31, 2021, we had recognized deferred tax assets of $393.7 relating to foreign loss carryforwards for which a valuation allowance of $322.4 has been provided and for which $22.4 has also been offset in accordance with ASU2013-11. At December 31, 2021, we had recognized deferred tax assets of $31.4 relating to federal loss carryforwards for which a valuation allowance of $31.4 has been provided At December 31, 2021 we had foreign tax loss carryforwards of $2,599.0, of which $1,059.2 are not subject to expiration and $1,539.8 are subject to expiration between 2022 and 2051. At December 31, 2021, we had federal tax loss carryforwards of $149.3 which are not subject to expiration. At December 31, 2021, we continue to assert that substantially all of our foreign earnings are indefinitely reinvested. At December 31, 2021 the company’s undistributed foreign earnings of approximately $1.2 billion and would generate an approximate $7.9 of income tax if repatriated from the local subsidiaries. Uncertain Tax Positions At December 31, 2021, we had $251.7 of total gross unrecognized tax benefits of which approximately $95.8 would favorably impact the provision for income taxes, if recognized. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Balance at December 31, 2018 137.6 Additions based on tax positions related to the current year 13.3 Additions for tax positions of prior years 186.6 Reductions for tax positions of prior years (3.0) Reductions due to lapse of statute of limitations (.6) Reductions due to settlements with tax authorities (2.2) Balance at December 31, 2019 331.7 Additions based on tax positions related to the current year 90.6 Additions for tax positions of prior years .6 Reductions for tax positions of prior years (34.1) Reductions due to lapse of statute of limitations (16.5) Reductions due to settlements with tax authorities (.2) Balance at December 31, 2020 372.1 Additions based on tax positions related to the current year 6.8 Additions for tax positions of prior years 24.1 Reductions for tax positions of prior years (136.8) Reductions due to lapse of statute of limitations (11.2) Reductions due to settlements with tax authorities (3.3) Balance at December 31, 2021 $ 251.7 We accrue interest and penalties related to unrecognized tax benefits in the provision for income taxes. We accrued interest and penalties, net of taxes of $0.5 and $1.0, for the years ended December 31, 2021 and 2020, respectively, and reversed previously recorded expenses for interest and penalties, net of tax of $1.0 for the year ended December 31, 2019. At December 31, 2021 and 2020 we had $7.1 and $6.8, respectively, recorded for interest and penalties, net of tax benefit. The unrecognized tax benefits, including interest and penalties, were classified within long-term income taxes in our Consolidated Balance Sheets. We file income tax returns in the U.S. and foreign jurisdictions. As of December 31, 2021, the tax years that remained subject to examination by major tax jurisdiction for our most significant subsidiaries were as follows: Jurisdiction Open Years Brazil 2016-2021 Philippines 2017-2021 Poland 2014-2021 Russia 2019-2021 United Kingdom 2019-2021 United States (Federal) 2017-2021 We anticipate that it is reasonably possible that the total amount of unrecognized tax benefits could increase in the range of $5 to $10 within the next twelve months.

Financial Instruments and Risk

Financial Instruments and Risk Management	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Risk Management	Financial Instruments and Risk Management We operate globally, with manufacturing and distribution facilities in various countries around the world. We may reduce our exposure to fluctuations in the fair value and cash flows associated with changes in interest rates and foreign exchange rates by creating offsetting positions, including through the use of derivative financial instruments. If we use foreign currency-rate sensitive and interest-rate sensitive instruments to hedge a certain portion of our existing and forecasted transactions, we would expect that any gain or loss in value of the hedge instruments generally would be offset by decreases or increases in the value of the underlying forecasted transactions. We do not enter into derivative financial instruments for trading or speculative purposes, nor are we a party to leveraged derivatives. The master agreements governing our derivative contracts generally contain standard provisions that could trigger early termination of the contracts in certain circumstances. Derivatives are recognized in the Consolidated Balance Sheets at their fair values. The following table presents the fair value of derivative instruments at December 31, 2021: Asset Liability Balance Sheet Fair Balance Sheet Fair Derivatives not designated as hedges: Foreign exchange forward contracts Prepaid expenses and other $ — Accounts payable $ 2.7 Total derivatives $ — $ 2.7 Derivatives are recognized in the Consolidated Balance Sheets at their fair values. The following table presents the fair value of derivative instruments at December 31, 2020: Asset Liability Balance Sheet Fair Balance Sheet Fair Derivatives not designated as hedges: Foreign exchange forward contracts Prepaid expenses and other $ 2.8 Accounts payable $ 6.0 Total derivatives $ 2.8 $ 6.0 Interest Rate Risk Approximately 5% and 4% of our debt portfolio at December 31, 2021 and 2020, respectively, was exposed to floating interest rates, which relates to our short term debt portfolio. Foreign Currency Risk We may use foreign exchange forward contracts to manage a portion of our foreign currency exchange rate exposures. At December 31, 2021, we had outstanding foreign exchange forward contracts with notional amounts totaling approximately $171 for various currencies, none of which were designated as cash flow hedges. We may use foreign exchange forward contracts to manage foreign currency exposure of certain intercompany loans. The change in fair value of these contracts is immediately recognized in earnings and substantially offsets the foreign currency impact recognized in earnings relating to the associated intercompany loans. During the years ended December 31, 2021 and 2020, we recorded losses of $.3 and $5.7, respectively, in other expense, net in our Consolidated Statements of Operations related to these undesignated foreign exchange forward contracts. Credit Risk of Financial Instruments Our foreign currency derivatives are typically comprised of over-the-counter forward contracts, swaps or options with major international financial institutions. Although our theoretical credit risk is the replacement cost at the then estimated fair value of these instruments, we believe that the risk of incurring credit risk losses is remote and that such losses, if any, would not be material. Non-performance of the counterparties on the balance of all the foreign exchange agreements would not have resulted in any write-off at December 31, 2021. In addition, in the event of non-performance by such counterparties, we would be exposed to market risk on the underlying items being hedged as a result of changes in foreign exchange rates.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value	Fair Value Assets and Liabilities Recorded at Fair Value The fair value measurement provisions required by GAAP establish a fair value hierarchy, which prioritizes the inputs used in measuring fair value into three broad levels as follows: • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. • Level 3 - Unobservable inputs based on our own assumptions. Assets and Liabilities Recorded at Fair Value on a Recurring Basis The following table presents the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis at December 31, 2021: Level 1 Level 2 Total Liabilities: Foreign exchange forward contracts $ — $ 2.7 $ 2.7 Total $ — $ 2.7 $ 2.7 The following table presents the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis at December 31, 2020: Level 1 Level 2 Total Assets: Available-for-sale securities $ 4.2 $ — $ 4.2 Foreign exchange forward contracts $ — $ 2.8 $ 2.8 Total $ 4.2 $ 2.8 $ 7.0 Liabilities: Foreign exchange forward contracts $ — $ 6.0 $ 6.0 Total $ — $ 6.0 $ 6.0 Other than our defined benefit pension and postretirement plan assets, the assets and liabilities measured at fair value on a recurring basis are comprised of foreign exchange forward contracts (see Note 10, Financial Instruments and Risk Management) and available-for-sale securities, which were immaterial at December 31, 2021 and 2020. See Note 13, Employee Benefit Plans, for the fair value hierarchy for our plan assets. The available-for-sale securities include securities held in a trust in order to fund future benefit payments for non-qualified retirement plans (see Note 13, Employee Benefit Plans). Fair Value of Financial Instruments Our financial instruments include cash and cash equivalents, available-for-sale securities, short-term investments, accounts receivable, debt maturing within one year, accounts payable, long-term debt and foreign exchange forward contracts. The carrying value for cash and cash equivalents, accounts receivable, accounts payable and short-term investments approximate fair value because of the short-term nature of these instruments. The net asset (liability) amounts recorded in the balance sheet (carrying amount) and the estimated fair values of our remaining financial instruments at December 31 consisted of the following: 2021 2020 Carrying Fair Value Carrying Fair Value Available-for-sale securities $ — $ — $ 4.2 $ 4.2 Loans to affiliates of Natura &Co maturing within one year 46.6 46.6 — — Loans to affiliates of Natura &Co maturing after one year 46.7 46.7 — — Debt maturing within one year (32.6) (32.6) (28.0) (28.0) Loans from affiliates of Natura &Co maturing within one year (371.7) (371.7) (1,008.6) (1,008.6) Long-term debt (1) (676.0) (754.2) (675.4) (782.4) Loans from affiliates of Natura &Co maturing after one year (736.3) (736.3) — — Foreign exchange forward contracts (2.7) (2.7) (3.2) (3.2) (1) The carrying value of long-term debt is presented net of debt issuance costs and includes any related discount or premium, as applicable. The methods and assumptions used to estimate fair value are as follows: • Available-for-sale securities - The fair values of these investments were the quoted market prices for issues listed on securities exchanges. • Long-term debt - The fair values of our debt and other financing were determined using Level 2 inputs based on indicative market prices. • Foreign exchange forward contracts - The fair values of forward contracts were estimated based on quoted forward foreign exchange prices at the reporting date.

Share-Based Compensation Plans

Share-Based Compensation Plans	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Plans	Share-Based Compensation Plans The Avon Products, Inc. 2013 Stock Incentive Plan, as amended and restated (the "2013 Plan") and the Avon Products, Inc. 2016 Omnibus Incentive Plan (the "2016 Plan"), which are shareholder-approved plans, provide for several types of share-based incentive compensation awards including stock options, restricted stock, restricted stock units and performance restricted stock units. Following shareholder approval of the 2016 Plan in May 2016, there were no further awards made under the 2013 Plan. The 2016 Plan was amended and restated (the “Amended and Restated 2016 Plan”) following shareholder approval in May 2019. Under the Amended and Restated 2016 Plan, the maximum number of shares was amended to 20,451,976 shares of common stock, which includes 5,000,000 additional shares and 15,451,976 unused shares under the 2016 Plan as of March 15, 2019, where the maximum number of shares are reduced as follows: (i) in the case of the grant of an award of an option or SAR, by each share subject to such an award and (ii) in the case of the grant of an award payable in shares other than an option or SAR by 1.35 multiplied by each share subject to such an award. Shares issued under share-based awards will be primarily funded with issuance of new shares. We issued stock options and restricted stock under the 2016 Plan (including under the Amended and Restated 2016 Plan), and restricted stock units and performance restricted stock units under the 2013 Plan and the 2016 Plan (including under the Amended and Restated 2016 Plan). We also have outstanding stock options under our prior shareholder-approved plans. Stock option awards were granted with an exercise price generally at a premium to the closing market price of our stock at the date of grant. Stock options generally vest in thirds over the three-year period following each option grant date and have ten-year contractual terms. Restricted stock units granted to Associates generally vest and settle after three years. Restricted stock units awarded to non-management directors vest in approximately one year and settle upon a director's departure from the Board of Directors. Performance restricted stock units generally vest after three years only upon the satisfaction of certain market or performance conditions. On January 3, 2020, upon the completion of the Transaction with Natura &Co, our share-based compensation awards were either cancelled in exchange for the right to receive an amount in cash or converted into an award denominated in Natura &Co shares. Subsequent to the Transaction, the 2013 Plan and the 2016 Plan (including under the Amended and Restated 2016 Plan) were replaced by the Natura &Co Stock-Based Compensation Plan. Under the Natura &Co Stock-Based Compensation Plan, Natura has issued nominal cost options and performance share units ("performance shares" or "PSUs"). Nominal cost options were granted in exchange for Avon restricted stock units and performance restricted stock units and vest as a single tranche in line with the vesting date of the original Avon awards. Nominal cost options will automatically exercise on vest date. Performance share units generally vest after three years only upon the satisfaction of certain market and/or performance conditions. For the years ended December 31: 2021 2020 2019 Compensation cost for stock-based compensation $ 13.4 $ 24.9 $ 15.6 Total income tax (cost)/ benefit recognized for share-based arrangements (.2) 1.9 1.3 All of the compensation cost for share based compensation for 2021, 2020 and 2019 was recorded in SG&A expenses in our Consolidated Statements of Operations. Stock Options During 2019 we granted premium-priced stock options, in which the exercise price was equal to a 25% premium from the closing market price of our stock price at the date of grant. The premium-priced stock options vest on a three-year graded vesting schedule. The fair value of each premium-priced stock option is estimated on the date of grant using a Monte-Carlo simulation. When estimating the fair value of each option, we used the following weighted-average assumptions for options granted during the year ended December 31, 2019: 2019 Risk-free rate (1) 2.4% Expected term (2) 7 years Expected Avon volatility (3) 45% Expected dividends —% (1) The risk-free rate was based upon the rate on a zero coupon U.S. Treasury bill, for periods within the contractual life of the option, in effect at the time of grant. (2) The expected term of the option was based on the vesting terms of the respective option and a contractual life of 10 years. (3) Expected Avon volatility was based on the daily historical volatility of our stock price, over a period similar to the expected life of the option. The weighted-average grant-date fair value per share of options granted was $1.13. On January 3, 2020, upon the completion of the Transaction with Natura &Co, each of the approximately 14.9 million outstanding stock options, whether or not then vested or exercisable, was automatically canceled in exchange for the right to receive an amount in cash, without interest, equal to the number of Avon Common Shares underlying such stock option immediately prior to the effective time of the Transaction multiplied by the excess, if any, of the per share cash-out price over the exercise price per share. The “per share cash out price” was the closing price of an Avon Common Share on the NYSE on the closing date of the Transaction. No amount was payable upon cancellation of stock option with an exercise price per share that is greater than the per share cash-out price. In accordance with ASC 718, Stock-based compensation, we have accounted for the cash settlement as a repurchase of an equity instrument concurrent with the acceleration of vesting of the award. Options that were cancelled without compensation were treated as a repurchase of equity for no consideration. The cash settlement value of $20.5 was recognized through equity and $3.5 of unrecognized compensation expense of the unvested options was accelerated and recorded in SG&A expenses in our Consolidated Statements of Operations. We recognized expense on stock options using a graded vesting method, which recognizes the associated expense based on the timing of option vesting dates. At December 31, 2021 and 2020, there were no outstanding stock options as they were cancelled as per above. Restricted Stock Units and Performance Restricted Stock Units During 2019 we granted performance restricted stock units that would vest and settle after three years based on the relative total shareholder return of our common stock against companies included in the S&P 400 index as of the date of grant over a three year performance period ("2019 PRSUs"). The grant date fair value per share of these awards already reflects the estimated probability of achieving the market condition, and therefore we record the expense ratably over the performance period. The fair value of the PRSUs was estimated on the date of grant using a Monte-Carlo simulation that estimates the fair value based on the Company's share price activity, expected term of the award, risk-free interest rate, expected dividends and the expected volatility of the stock of the Company. When estimating the fair value of the PRSUs, we used the following weighted-average assumptions: 2019 PRSUs Risk-free rate (1) 2.4% Expected Avon volatility (2) 54.8% Expected average volatility (3) 29.9% Expected dividends —% (1) The risk-free rate was based upon the rate on a zero coupon U.S. Treasury bill, for periods within the three year performance period, in effect at the time of grant. (2) Expected Avon volatility was based on the weekly historical volatility of our stock price, over a period similar to the three year performance period of the 2019 PRSUs. (3) Expected average volatility was based on the weekly historical volatility of the stock prices of each member of companies included in the S&P 400 index as of the date of the grant, over a period similar to the three year performance period of the 2019 PRSUs. The weighted-average grant-date fair value per share of the 2019 PRSUs was $2.63. On January 3, 2020, upon the completion of the Transaction with Natura &Co, each of the approximately 4.4 million outstanding Restricted Stock Units ("RSU") was converted into Natura &Co Holding nominal cost options equal to the number of Avon Common Shares subject to each RSU immediately prior to the Transaction multiplied by the Exchange Ratio of 0.30. In addition, each of the approximately 3.0 million outstanding PRSUs was converted into an award denominated in Natura &Co Holding Shares, that is subject only to time-based vesting, equal to the number of Avon Common Shares subject to each PRSU immediately prior to the Transaction, giving effect to market conditions that are deemed to be attained, multiplied by the Exchange Ratios of 0.30. The terms and conditions, including service conditions but excluding market conditions, applicable to each RSU and PRSU will continue in full force and effect with respect to the nominal cost options as described below. In accordance with ASC 718, Stock-based compensation , we accounted for the modification as a Type I (probable-to-probable) modification and the incremental fair value of approximately $3.4 will be recognized over the remaining service period of the awards. At December 31, 2021 and 2020, there were no outstanding RSUs and PRUs as they were exchanged for Natura &Co Holding Nominal Cost Options. Natura &Co Holding Nominal cost options As discussed above, each outstanding Avon RSU and PRSU at the time of the Transaction was exchanged for Natura &Co Holding Nominal Cost Options. These nominal cost options vest in a single tranche in line with the original vesting schedule of three years and will automatically exercise on the vest date. We accounted for the exchange as a Type I (probable-to-probable) modification where the cumulative amount of the compensation cost that should be recognized over the vesting period is the original grant-date fair value plus incremental fair value of $3.4 resulting from the modification. During 2021, Natura &Co granted employees of the Company and its subsidiaries a further 1,660,941 nominal cost options with a weighted-average grant date fair value of $9.72 per unit. These 2021 nominal cost options normally vest in a single tranche in line with the original vesting schedule of three years and will automatically exercise on the vest date. For certain participants, vesting automatically occurs either 50% on both the 3rd and 4th anniversary of the grant date or 50% on both the 4th and 5th anniversary of the grant date. A summary of nominal cost options at December 31, 2021 and changes during 2021, is as follows: Nominal cost options Weighted-Average January 1, 2021 1,547 $ 11.51 Granted 1,661 9.72 Exercised (600) (12.12) Forfeited (282) (12.10) Outstanding at December 31, 2021 2,326 $ 10.00 The total fair value of restricted stock units and performance restricted stock units that vested during 2021 was $10.5 based upon market prices on the vesting dates. We recognize expense over the requisite service period. At December 31, 2021, there was $11.4 of unrecognized compensation cost related to nominal cost options outstanding. That cost is expected to be recognized over a weighted-average period of 3.0 years. Natura &Co Holding Performance Share Units (PSUs) On March 27, 2020, Natura &Co’s Board of Directors approved the new long-term stock-based incentive plan (the “Long-Term Incentive Plan”) for 2020. The Long-Term Incentive Plan consists of the granting of PSUs, the rights of participants in relation to the PSUs will only be fully acquired to the extent that (i) the participant remains continuously linked as an employee of the Company and its subsidiaries until the 3rd anniversary of the grant date; and (ii) performance conditions are met. For certain participants, there is a different condition for item (i) above, in which 50% of the PSUs granted will be acquired on the 3rd anniversary of the grant date and the remaining 50% will be acquired on the 4th anniversary of the grant date. During 2021 and 2020, Natura &Co granted 627,983 and 1,543,244 PSUs respectively with a weighted-average grant date fair value of $17.32 and $20.91 per unit respectively. A summary of performance share units at December 31, 2021 and changes during 2021, is as follows: Performance Share Units Weighted-Average January 1, 2021 1,543 $ 20.91 Granted 628 17.32 Exercised — — Forfeited (317) (20.45) Outstanding at December 31, 2021 1,854 $ 19.78 We recognize expense over the requisite service period to the extent that it is expected that the performance conditions are probable of being achieved. At December 31, 2021, there was $27.5 of unrecognized compensation cost related to the PSUs outstanding. That cost is expected to be recognized over a weighted-average period of 1.6 years. Restricted Stock In December 2019, 2,083,872 RSUs and 3,276,774 PRSUs were exchanged for 4,808,534 Restricted Stock. The exchange was done in advance of the Transaction with Natura &Co Holding. The Company accounted for the modification as a Type I (probable-to-probable) modification and the incremental fair value of approximately $1.5 will be recognized over the remaining service period of the awards. The Restricted Stock would vest and settle after three years from the grant date of the original award. The Company retained and cancelled 1,400,010 Restricted Stock to satisfy withholding tax obligations of the grantees. The cancellation resulted in the acceleration and recognition of $1.7 of compensation cost for the year ended December 31, 2019 and was included as part of the $44 of Transaction related costs. On January 3, 2020, upon the completion of the Transaction with Natura & Co, the 3,408,524 Restricted Stock outstanding was converted at the exchange ratio of 0.30 into an award denominated in Natura &Co Holding equity. The terms and conditions, including service-based vesting conditions, continue in full force and effect with respect to such award of Natura &Co Holding Restricted Stock. During January 2020, it was announced that the employment of certain senior officers of the Company would be terminated, in connection with the Transaction. As a result, Restricted Stock held by these senior officers immediately vested and we recognized approximately $10 relating to the acceleration of unamortized expense. Restricted Stock Units and Performance Restricted Stock Units Funded With Treasury Shares In March 2019 and March 2018, we granted 200,000 and 200,000 performance restricted stock units, respectively, that will be funded with treasury shares, outside of the 2016 Plan, in reliance upon the NYSE rules. These performance restricted stock units have a weighted-average grant-date fair value of $2.98 and $2.79 for the 2019 and 2018 grants respectively, and would vest and settle at the end of 2020 only upon the satisfaction of certain performance conditions over a one year performance period. During 2019 none of these performance restricted stock units vested, and 400,000 performance restricted stock units were outstanding at December 31, 2019. During 2019 we recognized compensation cost of $.5, for these performance restricted stock units. In February 2018 we granted 600,000 restricted stock units that will be funded from treasury shares, outside of our shareholder-approved plans, in reliance upon the NYSE rules. The restricted stock units granted in February 2018 have a weighted-average grant-date fair value of $2.25 and vest and settle in full after three years. During 2019 none of these restricted stock units vested, and there were 600,000 restricted stock units outstanding at December 31, 2019. During 2019 we recognized compensation cost of $.4 for these restricted stock units. As at December 31, 2019, there were no outstanding RSUs or PRSUs funded with Treasury Shares as they were all exchanged for Avon Restricted Stock. During 2020 all Avon Restricted Stock was exchanged for Natura Restricted Stock, as described above.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2021
Retirement Benefits, Description [Abstract]
Employee Benefit Plans	Employee Benefit Plans Defined Contribution Plans We offer a defined contribution plan for employees in the United Kingdom ("UK"), which allows eligible participants to contribute eligible compensation through payroll deductions. We double employee contributions up to the first 5% of eligible compensation and therefore the maximum level provided by Avon is 10% of eligible compensation. We made matching contributions in cash to the UK defined contribution plan of $8.1 in 2021, $7.6 in 2020 and $7.5 in 2019, which follow the same investment allocation that the participant has selected for his or her own contributions. We also offer a qualified defined contribution plan for U.S.-based employees, the Avon Personal Savings Account Plan (the "PSA"), which allows eligible participants to contribute up to 25% of eligible compensation through payroll deductions. We match employee contributions dollar for dollar up to the first 3% of eligible compensation and fifty cents for each dollar contributed from 4% to 6% of eligible compensation. We made matching contributions in cash to the PSA of $.9 in 2021, $1.0 in 2020 and $1.3 in 2019, which follow the same investment allocation that the participant has selected for his or her own contributions. Prior to the separation of the North America business, the costs associated with the contributions to the PSA were allocated between Discontinued Operations and Global as the plan included both North America and U.S. Corporate Avon associates. See Note 3, Discontinued Operations and Assets and Liabilities Held for Sale. For U.S.-based employees hired on or after January 1, 2015, we made additional contributions to a Retirement Savings Account ("RSA") within the PSA. Such contributions will range from 3% to 6% of a participant's eligible compensation depending on the sum of the participant's age and length of service (as of December 31 of the prior year). Investment of such contributions will follow the same investment allocation that the participant has selected for his or her own contributions to the PSA. A participant will be vested in the RSA generally after three Defined Benefit Pension and Postretirement Plans Avon and certain subsidiaries have contributory and noncontributory defined benefit retirement plans for substantially all employees of those subsidiaries. Benefits under these plans are generally based on an employee’s length of service and average compensation near retirement, and certain plans have vesting requirements. Plans are funded based on legal requirements and cash flow. Our largest non-U.S. defined benefit pension plan is in the UK. The UK defined benefit pension plan was frozen for future accruals as of April 1, 2013. The U.S. defined benefit pension plan, the Avon Products, Inc. Personal Retirement Account Plan (the "PRA"), is closed to employees hired on or after January 1, 2015. Qualified retirement benefits for U.S.-based employees hired on or after January 1, 2015 will be provided solely through the PSA, as described above. Following the separation of the North America business (see further Note 3, Discontinued Operations and Assets and Liabilities Held for Sale), we continue to retain certain U.S. pension and other postretirement liabilities primarily associated with employees who are actively employed by Avon in the U.S. providing services other than with respect to the North America business. We recognize the funded status of defined benefit pension and other postretirement benefit plans on the balance sheet. Each overfunded plan is recognized as an asset and each underfunded plan is recognized as a liability. The recognition of prior service costs or credits and net actuarial gains or losses, as well as subsequent changes in the funded status, are recognized as components of AOCI, net of tax, in shareholders’ equity, until they are amortized as a component of net periodic benefit cost. We recognize prior service costs or credits and actuarial gains and losses beyond a 10% corridor to earnings based on the estimated future service period of the participants. The determination of the 10% corridor utilizes a calculated value of plan assets for our more significant plans, whereby gains and losses are smoothed over three Reconciliation of Benefit Obligations, Plan Assets and Funded Status The following table summarizes changes in the benefit obligation, plan assets and the funded status of our significant defined benefit pension and postretirement plans. We use a December 31 measurement date for all of our employee benefit plans. Pension Plans U.S. Plans Non-U.S. Plans Postretirement Benefits 2021 2020 2021 2020 2021 2020 Change in Benefit Obligation: Beginning balance $ (67.9) $ (71.7) $ (767.5) $ (685.9) $ (7.7) $ (26.8) Service cost (.9) (1.2) (4.3) (4.3) — — Interest cost (1.0) (1.4) (8.7) (11.7) (.3) (.7) Actuarial gain (loss) 1.8 (6.2) 54.6 (61.8) .4 (1.5) Benefits paid 7.7 12.6 25.7 27.8 .6 5.4 Actual expenses and taxes — — .4 .5 — — Plan amendments — — — — — 4.1 Curtailments — — .2 — — — Settlements — — 1.8 1.1 — — Special termination benefits — — — — (3.0) 5.8 Transfers — — — — — 4.9 Foreign currency changes and other — — 13.5 (33.2) .3 1.1 Sale of Avon Luxembourg — — 13.1 — — — Ending balance $ (60.3) $ (67.9) $ (671.2) $ (767.5) $ (9.7) $ (7.7) Change in Plan Assets: Beginning balance $ 59.7 $ 63.3 $ 762.0 $ 695.4 $ — $ — Actual return on plan assets 1.6 8.0 29.3 62.0 — — Company contributions .7 1.0 10.1 3.3 .6 10.2 Benefits paid (7.7) (12.6) (25.7) (27.8) (.6) (5.3) Actual expenses and taxes — — (.4) — — — Settlements — — (1.8) (1.1) — — Transfers — — — — — (4.9) Foreign currency changes and other — — (9.1) 30.2 — — Ending balance $ 54.3 $ 59.7 $ 764.4 $ 762.0 $ — $ — Funded Status: Funded status at end of year $ (6.0) $ (8.2) $ 93.2 $ (5.5) $ (9.7) $ (7.7) Amount Recognized in Balance Sheet: Other assets $ — $ — $ 162.4 $ 103.1 $ — $ — Accrued compensation (.7) (.9) (1.2) (2.1) (6.3) (3.6) Employee benefit plans liability (5.3) (7.4) (68.0) (106.5) (3.4) (4.1) Net amount recognized $ (6.0) $ (8.3) $ 93.2 $ (5.5) $ (9.7) $ (7.7) Pretax Amounts Recognized in Accumulated Other Comprehensive Loss: Net actuarial loss $ 14.7 $ 19.6 $ 122.8 $ 204.7 .8 $ 1.9 Prior service (credit) cost — (.1) 2.0 1.5 (.8) (5.3) Total pretax amount recognized $ 14.7 $ 19.5 $ 124.8 $ 206.2 $ — $ (3.4) Supplemental Information: Accumulated benefit obligation $ 59.5 $ 66.8 $ 159.4 $ 200.6 N/A N/A Plans with Projected Benefit Obligation in Excess of Plan Assets: Projected benefit obligation $ 60.3 $ 67.9 $ 170.0 $ 220.1 N/A N/A Fair value plan assets 54.3 59.7 100.8 111.5 N/A N/A Plans with Accumulated Benefit Obligation in Excess of Plan Assets: Accumulated benefit obligation 59.5 7.3 153.6 190.1 N/A N/A Fair value plan assets 54.3 — 91.7 98.3 N/A N/A For the year ended December 31, 2021, actuarial gains on benefit obligations were primarily due to a increase in discount rates for all plans. For the years ended December 31, 2020 and 2019, actuarial losses on the benefit obligations were primarily due to a decrease in discount rates for all plans. The U.S. pension plans include a funded qualified plan (the PRA) and unfunded non-qualified plans. At December 31, 2021, the PRA had benefit obligations of $53.6 and plan assets of $54.3. At December 31, 2020, the PRA had benefit obligations of $60.4 and plan assets of $59.7. We believe we have adequate investments and cash flows to fund the liabilities associated with the unfunded non-qualified plans. The Non-U.S. pension plans include a funded qualified pension plan in the UK. At December 31, 2021, the UK qualified pension plan had benefit obligations of $492.0 and plan assets of $653.6. At December 31, 2020, the UK qualified pension plan had benefit obligations of $545.5 and plan assets of $648.4. Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Loss Pension Benefits U.S. Plans Non-U.S. Plans Postretirement Benefits 2021 2020 2019 2021 2020 2019 2021 2020 2019 Net Periodic Benefit Cost: Service cost $ .9 $ 1.2 $ 1.7 $ 4.3 $ 4.3 $ 4.0 $ — $ — $ .1 Interest cost 1.0 1.4 2.3 8.7 11.7 15.3 .3 .7 1.2 Expected return on plan assets (2.0) (2.6) (3.4) (16.0) (16.0) (31.0) — — — Amortization of prior service credit — — — — (.1) — (4.5) (.2) (.2) Amortization of net actuarial losses 2.4 2.9 2.8 7.5 6.3 4.9 .7 — — Amortization of transition obligation — — — — — — — — — Settlements/curtailments 1.0 2.6 3.0 .1 .1 (.6) — — — Special termination benefits — — — — — — 3.0 (4.2) — Other — — — — — — — — — Net periodic benefit cost $ 3.3 $ 5.5 $ 6.4 $ 4.6 $ 6.3 $ (7.4) $ (.5) $ (3.7) $ 1.1 Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive (Loss) Income: Actuarial losses (gains) $ (1.4) $ .8 $ (3.0) $ (68.1) $ 15.9 $ 13.1 $ (.4) $ 1.5 $ 2.5 Prior service cost (credit) — — — — — — 4.5 (4.1) (1.3) Amortization of prior service credit — — — — — — — .2 .2 Amortization of net actuarial losses (3.4) (5.5) (5.7) (7.6) (6.4) (4.6) (.7) (1.6) — Foreign currency changes — — — (5.9) 11.6 1.7 — — — Total recognized in other comprehensive loss* $ (4.8) $ (4.7) $ (8.7) $ (81.6) $ 21.1 $ 10.2 $ 3.4 $ (4.0) $ 1.4 Total recognized in net periodic benefit cost and other comprehensive loss $ (1.5) $ .8 $ (2.3) $ (77.0) $ 27.4 $ 2.8 $ 2.9 $ (7.7) $ 2.5 * Amounts represent the pre-tax effect classified within other comprehensive loss. The net of tax amounts are classified within our Consolidated Statements of Comprehensive Loss. Assumptions Weighted-average assumptions used to determine benefit obligations recorded in our Consolidated Balance Sheets as of December 31 were as follows: Pension Benefits Postretirement U.S. Plans Non-U.S. Plans Benefits 2021 2020 2021 2020 2021 2020 Discount rate 2.81 % 2.43 % 2.09 % 1.45 % 3.61 % 3.95 % Rate of compensation increase 4.00 % 4.00 % 2.56 % 2.51 % N/A N/A Interest crediting rate 1.78 % 1.62 % 2.75 % 2.68 % N/A N/A The discount rate used for determining the present value of future pension obligations for each individual defined benefit pension plan is based on a review of bonds that receive a high-quality rating from a recognized rating agency. The discount rates for our more significant plans, including the UK defined benefit pension plan and the PRA, were based on the internal rates of return for a portfolio of high-quality bonds with maturities that are consistent with the projected future benefit payment obligations of each plan. The weighted-average discount rate for U.S. and non-U.S. defined benefit pension plans determined on this basis has increased to 2.15% at December 31, 2021, from 1.53% at December 31, 2020. Weighted-average assumptions used to determine net benefit cost recorded in our Consolidated Statements of Operations for the years ended December 31 were as follows: Pension Benefits U.S. Plans Non-U.S. Plans Postretirement Benefits 2021 2020 2019 2021 2020 2019 2021 2020 2019 Discount rate 2.42 % 3.16 % 4.24 % 1.45 % 2.05 % 2.92 % 3.95 % 3.66 % 5.17 % Rate of compensation increase 4.00 % 4.00 % 4.00 % 2.51 % 2.54 % 2.69 % N/A N/A N/A Rate of return on assets 4.15 % 4.90 % 5.50 % 2.32 % 2.55 % 5.27 % N/A N/A N/A Interest crediting rate 1.49 % 2.49 % 3.36 % 2.74 % 2.69 % 2.69 % N/A N/A N/A In determining the long-term rates of return, we consider the nature of each plan’s investments, an expectation for each plan’s investment strategies, historical rates of return and current economic forecasts, among other factors. We generally evaluate the expected rate of return on plan assets annually and adjust as necessary. In determining the net cost for the year ended December 31, 2021, the assumed rate of return on assets globally was 2.45%, which represents the weighted-average rate of return on all plan assets. A significant portion of our pension plan assets relate to the UK defined benefit pension plan. The assumed rate of return for determining 2021 net periodic benefit cost for the UK defined benefit pension plan was 2.10%. In addition, the 2021 rate of return assumption for the UK defined benefit pension plan was based on an asset allocation of approximately 76% in liability driven investments, and approximately 24% in equity securities, emerging market debt and high yield securities. In addition to the physical assets, the asset portfolio for the UK defined benefit pension plan has derivative instruments which increase our exposure to fixed income (in order to better match liabilities). Similar assessments were performed in determining rates of return on other non-U.S. defined benefit pension plan assets, to arrive at our weighted-average assumed rate of return of 2.32% for determining 2021 net cost for all non-US defined benefit pension plan assets. Plan Assets Our U.S. and non-U.S. funded defined benefit pension plans target and weighted-average asset allocations at December 31, 2021 and 2020, by asset category were as follows: U.S. Pension Plan Non-U.S. Pension Plans % of Plan Assets % of Plan Assets Target at Year-End Target at Year-End Asset Category 2022 2021 2020 2022 2021 2020 Equity securities 30 % 30 % 31 % 23 % 23 % 21 % Debt securities 70 70 69 72 72 74 Other — — — 5 5 5 Total 100 % 100 % 100 % 100 % 100 % 100 % The following tables present the fair value hierarchy for pension assets measured at fair value on a recurring basis at December 31, 2021 : U.S. Pension Plan Asset Category Level 1 Level 2 Total Equity Securities: Domestic equity $ — $ 8.3 $ 8.3 International equity — 6.6 6.6 Emerging markets — 1.6 1.6 — 16.5 16.5 Fixed Income Securities: Corporate bonds — 21.6 21.6 Government securities — 8.8 8.8 Other — 7.3 7.3 — 37.7 37.7 Other Cash — .1 .1 — .1 .1 Total $ — $ 54.3 $ 54.3 Non-U.S. Pension Plans Asset Category Level 1 Level 2 Level 3 Total Equity Securities: Domestic equity $ — $ 29.4 $ — $ 29.4 International equity — 145.2 — 145.2 — 174.6 — 174.6 Fixed Income Securities: Corporate bonds — 257.6 — 257.6 Government securities — 256.9 — 256.9 Other — 36.5 — 36.5 — 551.0 — 551.0 Other Cash 34.3 — — 34.3 Derivatives — 2.2 — 2.2 Real estate — — 2.3 2.3 34.3 2.2 2.3 38.8 Total $ 34.3 $ 727.8 $ 2.3 $ 764.4 The following tables present the fair value hierarchy for pension assets measured at fair value on a recurring basis at December 31, 2020: U.S. Pension Plan Asset Category Level 1 Level 2 Total Equity Securities: Domestic equity $ — $ 9.3 $ 9.3 International equity — 7.5 7.5 Emerging markets — 1.9 1.9 — 18.7 18.7 Fixed Income Securities: Corporate bonds — 23.7 23.7 Government securities — 9.4 9.4 Other — 7.8 7.8 — 40.9 40.9 Total $ — $ 59.7 $ 59.7 Non-U.S. Pension Plans Asset Category Level 1 Level 2 Level 3 Total Equity Securities: Domestic equity $ — $ 26.0 $ — $ 26.0 International equity — 132.0 — 132.0 — 158.0 — 158.0 Fixed Income Securities: Corporate bonds — 32.4 — 32.4 Government securities — 497.4 — 497.4 Other — 37.3 — 37.3 — 567.1 — 567.1 Other: Cash 33.3 — — 33.3 Derivatives — 2.0 — 2.0 Real estate — — 1.6 1.6 33.3 2.0 1.6 36.9 Total $ 33.3 $ 727.1 $ 1.6 $ 762.0 A reconciliation of the beginning and ending balances for our Level 3 investments is provided in the table below: Amount Balance at January 1, 2020 $ 1.6 Balance at December 31, 2020 1.6 Actual return on plan assets held .7 Balance at December 31, 2021 2.3 Investments in equity securities classified as Level 1 in the fair value hierarchy are valued at quoted market prices. Investments in equity securities classified as Level 2 in the fair value hierarchy include collective funds that are valued at quoted market prices for non-active securities. Fixed income securities are based on broker quotes for non-active securities. Mutual funds are valued at quoted market prices. Real estate is valued by reference to investment and leasing transactions at similar types of property, supplemented by third party appraisals. Derivative instruments are not publicly traded, and each derivative contract is specifically negotiated with a unique financial counterparty. The derivative instruments are valued based upon valuation statements received from the financial counterparties, which use underlying yield curves or market indices. The overall objective of the plan assets associated with the PRA and the UK defined benefit pension plan is to provide the means to pay benefits to participants and their beneficiaries in the amounts and at the times called for by the plan. This is expected to be achieved through the investment of our contributions and other trust assets and by utilizing investment policies designed to achieve adequate funding over a reasonable period of time. In some of our defined benefit pension plans, we have adopted investment strategies which are designed to match the movements in the pension liability through an increased allocation towards debt securities. In addition, we also utilize derivative instruments in our UK defined benefit pension plans to hedge certain risks. Derivative instruments may include, but are not limited to, futures, options, swaps or swaptions. Investment types, including the use of derivatives are based on written guidelines established for each investment manager and monitored by the plan's investment committee. Pension trust assets are invested so as to achieve a return on investment, based on levels of liquidity and investment risk that are prudent and reasonable as circumstances change from time to time. While we recognize the importance of the preservation of capital, we also adhere to the theory of capital market pricing which maintains that varying degrees of investment risk should be rewarded with compensating returns. Consequently, prudent risk-taking is justifiable. The asset allocation decision includes consideration of the non-investment aspects of the PRA and the UK defined benefit pension plan, including future retirements, lump-sum elections, growth in the number of participants, company contributions, and cash flow. These characteristics of the plan place certain demands upon the level, risk, and required growth of trust assets. We regularly conduct analyses of the plan’s current and likely future financial status by forecasting assets, liabilities, benefits and company contributions over time. In so doing, the impact of alternative investment policies upon the plan’s financial status is measured and an asset mix which balances asset returns and risk is selected. Our decision with regard to asset mix is reviewed periodically. Asset mix guidelines include target allocations and permissible ranges for each asset category. Assets are monitored on an ongoing basis and rebalanced as required to maintain an asset mix within the permissible ranges. The guidelines will change from time to time, based on an ongoing evaluation of the factors discussed above. Cash flows We expect to make contributions related to continuing operations in the range of $10 to $15 to our defined benefit pension and postretirement plans during 2022. Total benefit payments expected to be paid from the plans are as follows: Pension Benefits U.S. Plans Non-U.S. Plans Total Postretirement 2022 $ 5.7 $ 26.2 $ 31.9 $ 6.3 2023 4.8 26.8 31.6 .3 2024 5.0 27.9 32.9 .3 2025 4.1 28.0 32.1 .3 2026 3.9 27.7 31.6 .3 2027-2031 14.7 149.6 164.3 1.4 Postemployment Benefits We provide postemployment benefits, which include salary continuation, severance benefits, disability benefits and continuation of health care benefits to eligible former employees. The accrued cost for such postemployment benefits was $6.5 at December 31, 2021 and $9.1 at December 31, 2020 and was included in employee benefit plans in our Consolidated Balance Sheets. Supplemental Retirement Programs In the U.S., in addition to qualified retirement plans (i.e., the PSA and the PRA), we also maintain unfunded non-qualified plans. We offer a non-qualified deferred compensation plan, the Avon Products, Inc. Deferred Compensation Plan (the "DCP"), for certain higher paid key employees. The DCP is an unfunded, unsecured plan for which obligations are paid to participants out of our general assets. The DCP allows for the deferral of up to 50% of a participant’s base salary, the deferral of up to 100% of incentive compensation bonuses, and the deferral of contributions that would normally have been made to the PSA but are not deferred because the amount was in excess of U.S. Internal Revenue Code limits on contributions to the PSA. Participants may elect to have their deferred compensation invested in one or more of three permitted investment alternatives. Expense associated with the DCP was zero in 2021, $.1 in 2020 and $.8 in 2019. The benefit obligation under the DCP was $.7 at December 31, 2021 and $.8 at December 31, 2020 and was included in other liabilities and accrued compensation in our Consolidated Balance Sheets. The Transaction triggered a change of control provision in the DCP, resulting in the settlement of the majority of the obligation in 2020. We maintain supplemental retirement programs consisting of the Supplemental Executive Retirement Plan of Avon Products, Inc. ("SERP") and the Benefit Restoration Pension Plan of Avon Products, Inc. ("BRP") under which non-qualified supplemental pension benefits are paid to higher paid key employees in addition to amounts received under our qualified defined benefit retirement plan, which is subject to IRS limitations on covered compensation. The SERP has not been offered to new employees in the last ten years, and the BRP is closed to employees hired on or after January 1, 2015 in conjunction with the closure of the PRA. The annual cost of these programs has been included in the determination of the net periodic benefit cost shown previously and amounted to $1.0 in 2021, $1.2 in 2020 and $1.3 in 2019. The benefit obligation under these programs was $6.7 at December 31, 2021 and $7.6 at December 31, 2020 and was included in employee benefit plans and accrued compensation in our Consolidated Balance Sheets. We also maintain a Supplemental Life Plan ("SLIP") under which additional death benefits are provided to certain active and retired officers. The SLIP has not been offered to new officers in over ten years. We established a grantor trust to provide assets that may be used for the benefits payable under the SERP and SLIP. The trust is irrevocable and, although subject to creditors’ claims, assets contributed to the trust can only be used to pay such benefits with certain exceptions. The assets held in the trust are included in other assets and at December 31 consisted of the following: 2021 2020 Corporate-owned life insurance policies $ 24.6 $ 28.5 Cash and cash equivalents 5.8 5.2 Total $ 30.4 $ 33.7 The assets are recorded at fair market value, except for investments in corporate-owned life insurance policies which are recorded at their cash surrender values as of each balance sheet date, which is a proxy of fair value. Changes in the cash surrender value during the period are recorded as a gain or loss within SG&A expenses in our Consolidated Statements of Operations.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting, Measurement Disclosures [Abstract]
Segment Information	Segment Information We determine segment profit by deducting the related costs and expenses from segment revenue. Segment profit includes an allocation of central expenses to the extent they support the operating activity of the segment. Segment profit excludes certain CTI restructuring initiatives, certain significant asset impairment charges, and other expenses, which are not allocated to a particular segment, if applicable. This is consistent with the manner in which we assess our performance and allocate resources. Summarized financial information concerning our reportable segments as of December 31 is shown in the following tables: Total Revenue 2021 2020 2019 Avon International $ 1,724.6 $ 1,772.6 $ 2,234.3 Avon Latin America (1) 1,654.7 1,845.9 2,528.9 Total revenue from reportable segments (2) 3,379.3 3,618.5 4,763.2 Revenue from affiliates to Natura &Co 25.2 6.7 — Total revenue $ 3,404.5 $ 3,625.2 $ 4,763.2 Operating (Loss) Profit 2021 2020 2019 Segment Profit Avon International $ 49.9 $ 27.4 $ 170.9 Avon Latin America (1) (10.9) (39.1) 194.1 Total (loss) profit from reportable segments (3) 39.0 (11.7) 365.0 Unallocated global expenses (4) (27.0) (11.6) (35.8) Certain Brazil Indirect taxes (5) (1.7) 10.6 — CTI restructuring initiatives (68.7) (23.7) (139.3) Costs related to the Transaction (6) — (85.8) (64.3) Operating (loss) profit $ (58.4) $ (122.2) $ 125.6 (1) 2021 includes the impact of certain Brazil indirect taxes, which was recorded in product sales in the amount of approximately $21 in our Consolidated Income Statements. 2019 includes the impact of certain Brazil indirect taxes, which was recorded in product sales in the amount of approximately $68 in our Consolidated Income Statements. See Note 20 Supplemental Balance Sheet Information. (2) Total revenue from reportable segments also includes revenue from other business activities of $4.7, $14.5 and $18.1 for the years ended December 31, 2021, 2020 and 2019, respectively, allocated to Avon International and Avon Latin America segments. Other business activities include revenue from the sale of products to New Avon since the separation of the Company’s North America business into New Avon on March 1, 2016 and ongoing royalties from the licensing of our name and products. Previously reported amounts have been allocated to Avon International and Avon Latin America segments to conform to the current year presentation. (3) Total profit from reportable segments also includes profit from other business activities and central expenses allocated to Avon International and Avon Latin America segments. Other business activities of $1.5, $7.3, and $2.4 for the years ended December 31, 2021, 2020 and 2019, respectively, include profit from the sale of products to New Avon since the separation of the Company’s North America business into New Avon on March 1, 2016 and ongoing royalties from the licensing of our name and products. Central expenses of $206.7, $197.6, and $214.7 for the years ended December 31, 2021, 2020 and 2019, respectively, include corporate general and administrative expenses allocated to Avon International and Avon Latin America to the extent they support the operating activity of the segment. Previously reported amounts have been allocated to segments to conform to the current year presentation. (4) For the years ended December 31, 2021, 2020 and 2019, unallocated global expenses primarily include stewardship and other expenses not directly attributable to reportable segments. (5) The year ended December 31, 2021 includes the impact of certain Brazil taxes, which were recorded in selling, general and administrative expenses, net in the amounts of approximately $2 . The year ended December 31, 2020 includes the impact of certain Brazil indirect taxes, which were recorded in selling, general and administrative expenses, net in the amounts of approximately $11 . (6) For the year ended December 31, 2020, costs related to the Transaction primarily include professional fees of approximately $46, severance payments of approximately $25 and acceleration of share based compensation of approximately $10 relating to these terminations triggered by change in control provisions. For the year ended 31 December 2019, costs related to the Transaction primarily include professional fees and impairment losses on assets. Refer to Note 21, Merger with Natura Cosméticos S.A. for more information relating to the Natura transaction. (7) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, from the same date, the results of Avon Luxembourg are no longer included within Avon's consolidated results. The year ended December 31, 2021 includes the results of Avon Luxembourg for the period from January 1 to June 30, 2021. The years ended December 31, 2020 and 2019 include the results of Avon Luxembourg. Total Assets 2021 2020 2019 Avon International (1) $ 1,362.0 $ 1,364.4 $ 1,712.4 Avon Latin America (2) 945.8 1,199.9 1,373.9 Total assets $ 2,307.8 $ 2,564.3 $ 3,086.3 (1) Avon International includes assets of $420.7 at December 31, 2019, that were not previously allocated to our reportable segments. (2) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, balances at December 31, 2021 do not include the assets of Avon Luxembourg. Balances at December 31, 2020 and 2019 include the assets of Avon Luxembourg. Capital Expenditures 2021 2020 2019 Avon International (1) $ 53.3 $ 36.0 $ 39.6 Avon Latin America (2) 15.0 8.6 18.9 Total capital expenditures $ 68.3 $ 44.6 $ 58.5 (1) Avon International includes capital expenditures of $13.8 for the year ended December 31, 2019, that were not previously allocated to our reportable segments. (2) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, from the same date, the results of Avon Luxembourg are no longer included within Avon's consolidated results. The year ended December 31, 2021 includes the results of Avon Luxembourg for the period from January 1 to June 30, 2021. The years ended December 31, 2020 and 2019 include the results of Avon Luxembourg. Depreciation and Amortization 2021 2020 2019 Avon International (1) $ 48.1 $ 49.5 $ 51.6 Avon Latin America (2) 24.7 32.3 41.3 Total depreciation and amortization $ 72.8 $ 81.8 $ 92.9 (1) Avon International includes depreciation and amortization of $19.9 for the year ended December 31, 2019 that was not previously allocated to our reportable segments. (2) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, from the same date, the results of Avon Luxembourg are no longer included within Avon's consolidated results. The year ended December 31, 2021 includes the results of Avon Luxembourg for the period from January 1 to June 30, 2021. The years ended December 31, 2020 and 2019 include the results of Avon Luxembourg. Total Revenue by Major Country A major country is defined as one with total revenues greater than 10% of consolidated total revenues. 2021 2020 2019 Brazil $ 627.0 $ 729.9 $ 1,034.4 Mexico (1) 249.2 420.2 509.4 All other 2,528.3 2,475.1 3,219.4 Total $ 3,404.5 $ 3,625.2 $ 4,763.2 (1) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, from the same date, the results of Avon Luxembourg are no longer included within Avon's consolidated results. The year ended December 31, 2021 includes the results of Avon Luxembourg for the period from January 1 to June 30, 2021. The years ended December 31, 2020 and 2019 include the results of Avon Luxembourg. Long-Lived Assets by Major Country A major country is defined as one with long-lived assets greater than 10% of consolidated long-lived assets, and also includes our country of domicile (the U.S.). Long-lived assets primarily include property, plant and equipment associated with our continuing operations. Long-lived assets in Brazil, Poland and Mexico consist primarily of property, plant and equipment related to manufacturing and distribution facilities, long-lived assets in the U.S. consist primarily of property, plant and equipment, including our global research and development facility and right-of-use assets related to equipment. 2021 2020 2019 U.S. $ 122.7 $ 135.3 $ 149.4 Brazil 75.4 86.4 116.1 Poland 95.0 96.8 99.3 Mexico (1)(2) — 55.2 67.8 All other 183.9 220.8 137.6 Total $ 477.0 $ 594.5 $ 570.2 (1) Mexico's long-lived assets are greater than 10% of total long-lived assets in 2019 only (2) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, balances at December 31, 2021 do not include the assets of Avon Luxembourg. Balances at December 31, 2020 and 2019 include the assets of Avon Luxembourg. In the above table, long lived assets have been calculated by including property, plant and equipment, net and right-of-use assets which are difficult to move and are relatively illiquid. In 2019, our definition of long lived assets also included certain intangible assets and other long term receivables and excluded right-of use assets which resulted in the following disclosure in previous filings. 2019 Brazil $ 203.3 U.S. 120.8 Poland 86.3 All other 335.6 Total 746.0

Leases and Commitments

Leases and Commitments	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases and Commitments	Leases and Commitments In February 2016, the FASB issued ASU 2016-02, Leases, which requires all assets and liabilities arising from leases to be recognized in our Consolidated Balance Sheets. We adopted this new accounting guidance effective January 1, 2019. We have operating and finance leases for corporate and market offices, warehouses, automotive and other equipment. Some of our leases may include options to extend or terminate the lease. Certain leases also include options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Classification 2021 2020 Assets Operating right-of-use assets Right-of-use asset $ 111.1 $ 153.1 Finance right-of-use assets Property, Plant and Equipment 2.2 2.4 Total right-of-use assets 113.3 155.5 Liabilities Current Operating lease liabilities Other accrued liabilities $ 37.1 $ 46.2 Finance lease liabilities Other accrued liabilities 1.2 1.1 Total current lease liabilities 38.3 47.3 Noncurrent Operating lease liabilities Long-term operating lease liability $ 87.5 $ 120.9 Finance lease liabilities Long-term debt 1.3 1.5 Total noncurrent lease liabilities $ 88.8 $ 122.4 Total lease liability $ 127.1 $ 169.7 The table below shows the lease income and expenses recorded in the Consolidated Statement of Operations incurred during the years ended December 31: Lease Costs Classification 2021 2020 Operating lease cost (1) Selling, general and administrative expenses $ 51.7 $ 63.6 Finance lease cost Amortization of right-of-use assets Selling, general and administrative expenses 1.3 1.2 Interest on lease liabilities Interest Expense .2 .3 Short-term leases costs Selling, general and administrative expenses 11.0 2.3 Sublease income (2) Selling, general and administrative expenses (14.5) (15.3) Net lease cost $ 49.7 $ 52.1 (1) Includes variable lease costs which are immaterial. These are presented in selling, general and administrative expenses in our Consolidated Statements of Operations. (2) Sublease portfolio consists of the sublease of our previous principal executive office located at 777 Third Avenue, New York, NY. The maturity analysis of the finance and operating lease liabilities is reflected below. This table also reflects the reconciliation of the undiscounted cash flows to the discounted finance and operating lease liabilities as recognized in the December 31, 2021 Consolidated Balance Sheet: Maturity of Lease Liabilities Operating Leases Finance Leases Total 2022 45.7 1.3 47.0 2023 36.3 .8 37.1 2024 26.7 .3 27.0 2025 22.0 .2 22.2 2026 12.2 .1 12.3 Thereafter 5.1 — 5.1 Total lease payments $ 148.0 $ 2.7 $ 150.7 Less: Interest 23.4 .2 23.6 Present value of lease liabilities $ 124.6 $ 2.5 $ 127.1 The Company has calculated the weighted-average remaining lease term, presented in years below, and the weighted-average discount rate for our operating and finance lease population. As noted in our lease accounting policy (See Note 1, Description of the Business and Summary of Significant Accounting Policies), the Company uses the incremental borrowing rate as the lease discount rate. Lease Term and Discount Rate 2021 2020 Weighted-average remaining lease term (years) Operating leases 4.0 4.2 Finance leases 2.7 2.5 Weighted-average discount rate Operating leases 8.3 % 8.5 % Finance leases 9.6 % 10.5 % The table below sets out the classification of lease payments in the Consolidated Statement of Cash Flows. The ROU assets obtained in exchange for new finance and operating lease liabilities represent the new operating and finance leases entered into during the years ended December 31. Other Information 2021 2020 Operating Cash Flows From Operating Leases $ 54.0 $ 63.7 Operating Cash Flows From Finance Leases .2 .3 Financing Cash Flows From Finance Leases 1.3 1.3 Cash Paid For Amounts Included In Measurement of Liabilities $ 55.5 $ 65.3 Right-of-use Assets Obtained In Exchange For New Finance Liabilities $ 1.4 $ .9 Right-of-use Assets Obtained In Exchange For New Operating Liabilities $ 8.8 $ 24.9 Purchase obligations include commitments to purchase paper, inventory and other services. At December 31, 2021, our purchase obligations by due date were as follows: Year Purchase Obligations 2022 $ 159.2 2023 51.8 2024 21.9 2025 1.7 2026 1.7 Later years 1.9 Total $ 238.2

Restructuring Initiatives

Restructuring Initiatives	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring Initiatives	Restructuring Initiatives Transformation Plan and Open Up Avon Natura &Co - Avon Integration Subsequent to the merger of Natura and Avon in January 2020, an integration plan (the "Avon Integration") was established to create the right global infrastructure to support the future ambitions of the Natura &Co Group while also identifying synergies and opportunities to leverage our combined strength, scale and reach. Synergies will be derived mainly from procurement, manufacturing/distribution and administrative, as well as top line synergies, primarily between Avon LATAM and Natura &Co Latin America. Open Up Avon, Open Up & Grow and Transformation Plan In January 2016, we initiated a transformation plan (the " Transformation Plan"), in order to enable us to achieve our long-term goals of mid-single-digit Constant $ revenue growth and low double-digit operating margin. There are no further restructuring actions to be taken associated with our Transformation Plan as, beginning in the third quarter of 2018, all new restructuring actions approved operate under our new Open Up Avon plan described below. In September 2018, we initiated a new strategy in order to return Avon to growth ( " Open Up Avon"). The Open Up Avon strategy is integral to our ability to return Avon to growth, built around the necessity of incorporating new approaches to various elements of our business, including increased utilization of third-party providers in manufacturing and technology, a more fit for purpose asset base, and a focus on enabling our Representatives to more easily interact with the company and achieve relevant earnings. These savings have been and are expected to continue to be achieved through restructuring actions (that have may continue to result in charges related to severance, contract terminations and inventory and other asset write-offs), as well as other cost-savings strategies that would not result in restructuring charges. In January 2019, we announced significant advancements in this strategy, including a structural reset of inventory processes and a reduction in global workforce. In May 2020, the new leadership of Avon International refreshed our strategy ("Open Up & Grow") which aims to return Avon International to growth over the next three years. Open Up & Grow replaces and builds on the success of the Open Up Avon strategy, launched in 2018 to strengthen competitiveness through enhancing the representative experience, improving brand position and relevance, accelerating digital expansion and improving costs. Over the next three years, savings are expected to continue to be achieved through restructuring actions (that may continue to result in charges related to severance, contract terminations and asset write-offs), as well as other cost-savings strategies that would not result in restructuring charges. Costs to Implement Restructuring Initiatives - Twelve Months Ended December 31, 2021 , 2020 and 2019 During the twelve months ended December 31, 2021, we recorded net costs to implement of $58.8, of which $15.4 related to Avon Integration, $44.0 related to Open Up & Grow, and a net benefit of $0.6 related to the Transformation Plan and other restructuring initiatives, in our Consolidated Statements of Operations. During the twelve months ended December 31, 2020, we recorded costs to implement of $22.2 of which $16.1 related to Avon Integration, $10.9 related to Open Up Avon, and a net benefit of $4.8 related to the Transformation Plan and other restructuring initiatives, in our Consolidated Statements of Operations. During the twelve months ended December 31, 2019, we recorded costs to implement of $116.7 of which $106.6 related to Open Up Avon, and $9.4 related to the Transformation Plan and other restructuring initiatives. The costs during the twelve months ended December 31, 2021, 2020 and 2019 consisted of the following: Year ended December 31, 2021 2020 2019 CTI recorded in operating profit - COGS Manufacturing asset write-offs $ — $ — $ 11.1 Inventory write-off — (1.8) 1.4 — (1.8) 12.5 CTI recorded in operating profit - SG&A Net charges for employee-related costs, including severance benefits 36.7 5.2 56.4 Implementation costs, primarily related to professional service fees 17.5 10.3 44.9 Dual running costs 1.1 3.1 9.1 Contract termination and other net costs 10.5 3.9 7.9 Impairment of other assets 1.0 .8 5.3 Accelerated depreciation .3 .4 1.3 Variable lease charges 1.6 1.8 1.9 Foreign Currency Translation Adjustment Write-offs — — .7 68.7 25.5 127.5 CTI recorded in operating profit 68.7 23.7 140.0 CTI recorded in other (income) expense Gain on sale of business / assets (9.9) (1.5) (23.3) Total CTI $ 58.8 $ 22.2 $ 116.7 Avon Integration $ 15.4 $ 16.1 $ — Open Up & Grow $ 44.0 $ 10.9 $ 106.6 Transformation Plan & Other $ (.6) $ (4.8) $ 9.4 The tables below include restructuring costs such as employee-related costs, inventory and asset write-offs, foreign currency translation write-offs and contract terminations, and do not include other costs to implement restructuring initiatives such as professional services fees, dual running costs, accelerated depreciation and gain on sale of business. The liability balance included in other accrued liabilities in our Consolidated Balance Sheet for the restructuring actions associated with Avon Integration at December 31, 2021 and 2020 is $1.6 and $.7, respectively, related to employee related costs. The liability balance included in other accrued liabilities in our Consolidated Balance Sheet for the restructuring actions associated with Open Up & Grow at December 31, 2021 is as follows: Employee-Related Costs Inventory/ Asset Write-offs Contract Terminations/Other Total Balance at December 31, 2019 $ 17.8 $ — $ 6.4 $ 24.2 2020 charges 2.7 .7 3.8 7.2 Adjustments (3.0) (1.8) — (4.8) Cash payments (7.8) — (7.4) (15.2) Non-cash write-offs — 1.1 — 1.1 Foreign exchange (.7) — — (.7) Balance at December 31, 2020 $ 9.0 $ — $ 2.8 $ 11.8 2021 charges 33.8 1.0 3.4 38.2 Adjustments (1.3) — — (1.3) Cash payments (26.8) — (5.0) (31.8) Non-cash write-offs — (1.0) — (1.0) Foreign exchange (.7) — — (.7) Balance at December 31, 2021 $ 14.0 $ — $ 1.2 $ 15.2 The liability balance included in other accrued liabilities in our Consolidated Balance Sheet for the restructuring actions associated with our Transformation Plan at December 31, 2021 and 2020 is $1.5 and $3.5, respectively, related to employee related costs. The majority of cash payments, if applicable, associated with the year-end liability are expected to be made during 2022. The following table presents the restructuring charges incurred to date, under the Avon Integration , Open Up & Grow and the Transformation Plan, along with the estimated charges expected to be incurred on approved initiatives under the plans: Employee- Related Costs Inventory/ Asset Write-offs Contract Foreign Currency Translation Adjustment Write-offs Total Avon Integration Charges incurred to-date $ 12.4 $ .2 $ 12.6 Estimated charges to be incurred on approved initiatives — — — — — Total expected charges on approved initiatives $ 12.4 $ — $ .2 $ — $ 12.6 Open Up & Grow Charges incurred to-date $ 115.8 $ 107.4 $ 15.9 $ (10.9) $ 228.2 Estimated charges to be incurred on approved initiatives $ .3 — — — $ .3 Total expected charges on approved initiatives $ 116.1 $ 107.4 $ 15.9 $ (10.9) $ 228.5 Transformation Plan Charges incurred to-date $ 122.7 $ 2.5 $ 40.9 $ 3.4 $ 169.5 Estimated charges to be incurred on approved initiatives — — — — — Total expected charges on approved initiatives $ 122.7 $ 2.5 $ 40.9 $ 3.4 $ 169.5 The charges, net of adjustments, of initiatives under the Open Up & Grow and the Transformation Plan, along with the estimated charges expected to be incurred on approved initiatives under the plans, by reportable segment are as follows: Avon International Avon LATAM Total Avon Integration 2020 6.2 4.6 $ 10.8 2021 (1.2) 3.0 $ 1.8 Charges incurred to-date 5.0 7.6 12.6 Estimated charges to be incurred on approved initiatives — — — Total expected charges on approved initiatives $ 5.0 $ 7.6 $ 12.6 Open Up & Grow 2018 52.8 64.3 $ 117.1 2019 34.7 36.9 71.6 2020 3.2 (.8) 2.4 2021 36.9 .2 37.1 Charges incurred to-date 127.6 100.6 228.2 Estimated charges to be incurred on approved initiatives .3 — .3 Total expected charges on approved initiatives $ 127.9 $ 100.6 $ 228.5

Series C Convertible Preferred

Series C Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Series C Convertible Preferred Stock	Series C Convertible Preferred Stock On March 1, 2016, the Company issued and sold to Cerberus Investor 435,000 shares of newly issued series C preferred stock for an aggregate purchase price of $435 pursuant to an Investment Agreement, dated as of December 17, 2015, between the Company and Cerberus Investor. In connection with the issuance of the series C preferred stock, the Company incurred direct and incremental expenses of $8.7, comprised of financial advisory fees and legal expenses, which reduced the carrying value of the series C preferred stock. Cumulative preferred dividends accrue daily on the series C preferred stock at a rate of 1.25% per quarter. The series C preferred stock had accrued unpaid dividends of $91.3 at December 31, 2019. On December 19, 2019, the Company and Natura &Co Holding announced that as of such date, all regulatory approvals required by the Merger Agreement to complete the Transactions have been obtained. As a result, the series C preferred stock were probable of becoming redeemable and the redemption value was adjusted. Subsequently, on December 30, 2019, Cerberus elected to convert the series C preferred stock, as described below, and the series C preferred stock was no longer probable of becoming redeemable. We recognize changes in redemption value immediately as they occur and the carrying value of the security is adjusted to equal what the redemption amount would be as if redemption were to occur at the end of the reporting date based on the conditions that exist as of that date. As a result, we recognized an increase of $60.9 in the carrying value of the series C preferred stock for the year ended December 31, 2019. On December 30, 2019, Cerberus elected to convert 435,000 shares of series C preferred stock, representing all shares of series C preferred stock outstanding, into shares of the Company’s common stock, par value U.S.$0.25 per share, pursuant to the holder of the Company’s Series C Preferred Stock’s rights under the Company’s certificate of incorporation. The foregoing election is conditioned upon the filing of the certificates of merger with respect to the First Merger (the "Conversion Condition"). On January 3, 2020, the Company consummated a transaction to become a wholly owned subsidiary of Natura &Co Holding. Upon consummation of the transaction, the Company's common stock was converted to Natura &Co Holding common stock. Natura &Co Holding subsequently paid the accrued dividend of $91.5 to Cerberus in January 2020. See Note 21, Agreement and Plan of Mergers with Natura Cosméticos S.A.,.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2021
Loss Contingency [Abstract]
Contingencies	Contingencies Brazilian Tax Assessments Tax on Manufactured Products – minimum pricing rules In December 2012 and in October 2017, our Brazilian subsidiary, Avon Industrial LTDA (Avon Brazil Manufacturing) received excise tax ("IPI") assessments for the years 2008 and 2014. As in prior IPI cases that have been resolved in Avon’s favor, the assessments assert that the establishment in 1995 of separate manufacturing and distribution companies in Brazil was done without a valid business purpose, and that Avon Brazil Manufacturing did not observe minimum pricing rules to define the taxable basis of the tax on manufactured products. The structure adopted in 1995 is comparable to that used by many other companies in Brazil. We believe that our Brazilian corporate structure is appropriate, both operationally and legally, and that the assessments are unfounded. These matters are being contested at the administrative level, where proceedings are currently in progress. As of December 31, 2021 and 2020, the total amount under discussion classified as reasonably possible was $360 and $378, respectively. Tax on Manufactured Products – Decree equated certain commercial companies (not subject to IPI taxation) to industrial companies (IPI taxpayers) In May 2015, an executive decree established the levy of IPI on the sales of cosmetic products by Avon Brazil. Avon Brazil filed an objection to this levy on the basis that it is not constitutional since this tax is already paid by Avon Brazil Manufacturing. In December 2016, Avon Brazil received a favorable decision from the Federal District Court regarding this objection. This decision has been appealed by the Brazilian federal tax authority. At December 31, 2021 and 2020, the total amount under discussion classified as reasonably possible was $243 and $231, respectively. Brazilian Financial Indemnities As of December 31, 2021 and 2020, the Company has issued a number of guarantees totaling $157 and $185, respectively, which it could be required to make in the event of adverse judgments in a number of lawsuits in Brazil. Talc-Related Litigation The Company has been named a defendant in numerous personal injury lawsuits filed in U.S. courts, alleging that certain talc products the Company sold in the past were contaminated with asbestos. Many of these actions involve a number of co-defendants from a variety of different industries, including manufacturers of cosmetics and manufacturers of other products that, unlike the Company’s products, were designed to contain asbestos. As of December 31, 2021, there were 151 individual cases pending against the Company. During the three months ended December 31, 2021, 19 new cases were filed and 20 cases were dismissed, settled or otherwise resolved. The value of the settlements was not material, either individually or in the aggregate, to the Company’s results of operations for the year ended December 31, 2021. Additional similar cases arising out of the use of the Company’s talc products are reasonably anticipated. We believe that the claims asserted against us in these cases are without merit. We are defending vigorously against these claims and will continue to do so. To date there have been no findings of liability enforceable against the Company. However, nationwide trial results in similar cases filed against other manufacturers of cosmetic talc products have ranged from outright dismissals to very large jury awards of both compensatory and punitive damages. Given the inherent uncertainties of litigation, we cannot predict the outcome of all individual cases pending against the Company, and we are only able to make a specific estimate for a small number of individual cases that have advanced to the later stages of legal proceedings. For the remaining cases, we provide an estimate of exposure on an aggregated and ongoing basis, which takes into account the historical outcomes of all cases we have resolved to date. Any accruals currently recorded on the Company’s balance sheet with respect to these cases are not material. However, any adverse outcomes, either in an individual case or in the aggregate, could be material. Future costs to litigate these cases, which we expense as incurred, are not known but may be significant, though some costs will be covered by insurance. Brazilian Labor-Related Litigation On an ongoing basis, the Company is subject to numerous and diverse labor-related lawsuits filed by employees in Brazil. These cases are assessed on an aggregated and ongoing basis based on historical outcomes of similar cases. The claims made are often for significantly larger sums than have historically been paid out by the Company. Our practice continues to be to recognize a liability based on our assessment of historical payments in similar cases. Our best estimate of the probable loss for such cases at December 31, 2021 and 2020 was approximately $11 and $8, respectively. Accordingly, we have recognized a liability for this amount. Shareholder Litigation On February 14, 2019, a purported shareholder’s class action complaint (Bevinal v. Avon Products, Inc., et al., No. 19-cv-1420) was filed in the United States District Court for the Southern District of New York against the Company and certain former officers of the Company. The complaint was subsequently amended and recaptioned "In re Avon Products, Inc. Securities Litigation". The amended complaint is brought on behalf of a purported class consisting of all purchasers or acquirers of Avon common stock between January 21, 2016 and November 1, 2017, inclusive. The complaint asserts violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") based on allegedly false or misleading statements and alleged market manipulation with respect to, among other things, changes made to Avon’s credit terms for Representatives in Brazil. Avon and the individual defendants filed a motion to dismiss which the court denied. During 2020, the parties reached an agreement on a settlement of this class action. The terms of settlement include releases by members of the class of claims against the Company and the individual defendants and payment of $14.5 million. Approximately $2 million of the settlement was paid by the Company (which represented the remaining deductible under the Company’s applicable insurance policies) and the remainder of the settlement was paid by the Company’s insurers. On August 31, 2020, the court granted preliminary approval of the settlement, and on February 3, 2021, the court entered an order and judgment granting final approval of the settlement. This judgment is now final. Other Matters Various other lawsuits and claims, arising in the ordinary course of business or related to businesses previously sold, are pending or threatened against Avon. In management’s opinion, based on its review of the information available at this time, the total cost of resolving such other contingencies at December 31, 2021, is not expected to have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Goodwill Avon International Avon LATAM Total Gross balance at December 31, 2020 $ 109.3 $ 63.2 $ 172.5 Accumulated impairments (89.3) — (89.3) Net balance at December 31, 2020 $ 20.0 $ 63.2 $ 83.2 Changes during the period ended December 31, 2021: Foreign exchange (2.4) (8.7) (11.1) Gross balance at December 31, 2021 $ 106.9 $ 54.5 $ 161.4 Accumulated impairments (89.3) — (89.3) Net balance at December 31, 2021 $ 17.6 $ 54.5 $ 72.1

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information At December 31, 2021 and 2020, prepaid expenses and other included the following: Components of Prepaid expenses and other 2021 2020 Prepaid taxes and tax refunds receivable $ 84.0 $ 117.6 Receivables other than trade 27.8 34.9 Prepaid brochure costs, paper and other literature 8.3 12.0 Other 45.5 39.7 Prepaid expenses and other $ 165.6 $ 204.2 At December 31, 2021 and 2020, other assets included the following: Components of Other assets 2021 2020 Capitalized software (Note 1) 74.9 76.0 Judicial deposits 47.2 50.9 Net overfunded pension plans (Note 13) 162.5 103.0 Long-term receivables including taxes 180.2 157.0 Trust assets associated with supplemental benefit plans (Note 13) 30.4 33.7 Other 14.2 17.9 Other assets $ 509.4 $ 438.5

Merger with Natura Cosm_ticos S

Merger with Natura Cosméticos S.A.	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Merger with Natura Cosméticos S.A.	Discontinued Operations and Assets and Liabilities Held for Sale Discontinued Operations On December 17, 2015, the Company entered into definitive agreements with affiliates controlled by Cerberus. The agreements resulted in the separation of the Company's North America business, which represented the Company's operations in the United States, Canada and Puerto Rico, from the Company into The Avon Company, formerly New Avon, ("New Avon") a privately-held company majority-owned and managed by Cerberus NA Investor LLC (an affiliate of Cerberus). The Company retained an investment of 19.9% ownership interest in New Avon. These transactions closed on March 1, 2016; from that date, resolution of contingent liabilities relating to Avon's ownership and operation of the North America business prior to its separation from the Company into New Avon have been treated as discontinued operations. In April 2019, we signed an agreement with LG Household & Health Care Ltd. to sell our 19.9% ownership interest in New Avon, which was completed during August 2019. Refer to the Divestitures section below for information relating to the sale of New Avon. The Company incurred costs during the years ended December 31, 2021, 2020 and 2019 following the resolution of certain contingent liabilities related to its ownership and operation of the North America business prior to its separation into New Avon. The major classes of financial statement components comprising the loss on discontinued operations, net of tax for New Avon are shown below: Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 21, 2019 Selling, general and administrative expenses $ (18.5) $ (27.9) $ (36.6) Operating loss $ (18.5) $ (27.9) $ (36.6) Loss from discontinued operations, net of tax $ (18.5) $ (27.9) $ (36.6) Assets and Liabilities Held for Sale The major classes of assets and liabilities comprising held for sale assets and held for sale liabilities on the Consolidated Balance Sheet at December 31, 2021 and December 31, 2020 are shown in the following table. Year ended December 31, 2021 2020 Current held for sale assets Inventories $ — $ 2.6 Property, Plant & Equipment (net) 2.8 9.2 Cash and cash equivalents — .7 Other assets — 1.4 $ 2.8 $ 13.9 Current held for sale liabilities Accounts payable $ — $ .5 Other liabilities — 1.8 $ — $ 2.3 At December 31, 2020, assets held for sale include one property and one business in Avon International segment and one property in the Avon Latin America Segment. At December 31, 2021, assets held for sale include one property in the Avon Latin America Segment. Divestitures Disposal of Avon Beauty Arabia in Saudi Arabia On December 23, 2021, the Company completed the sale of its 51% share of the business and assets of Avon Beauty Arabia in exchange for converting the business to a distributorship model together with the write off of a $3.9 loan balance. In the fourth quarter of 2021 we recognized a loss of $1.1 before and after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the write off of the loan balance, the carrying value of the business and assets of the Avon Beauty Arabia on the date of sale, and associated disposal costs. Disposal of Cosmetics Manufacturing Operations in India On November 17, 2021, the Company completed the sale of the business and assets of the Cosmetics Manufacturing Operation in India for a total selling price of $2.9, the proceeds of which are presented as investing activities in the Consolidated Statement of Cash Flows. In the fourth quarter of 2021 we recognized a gain of $1.1 before and after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the proceeds, the carrying value of the business and assets of the Cosmetics Manufacturing Operation in India on the date of sale, and associated disposal costs. Sale of Avon Luxembourg Holdings S.à r.l On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding for $150, with the proceeds used to repay maturing loans of $150 borrowed under the $250 Revolving Credit Facility with a subsidiary of Natura &Co Holding. The sale was accounted for as a transaction under common control in accordance with ASC805 - Business Combinations, with the resulting gain of $148, representing the difference between the proceeds, the net assets of Avon Luxembourg on the date of sale and the cumulative foreign currency translation adjustment, taken directly to Retained Earnings. For additional information, see the Consolidated Statements of Changes in Shareholders' Deficit. Spanish Distribution Center In September 2021, we completed the sale of our Spanish Distribution Center for a total selling price of $14.7, the proceeds of which are presented as investing activities in the Consolidated Statement of Cash Flows. In the third quarter of 2021 we recognized a gain of $8.3 before and $6.2 after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the proceeds, the carrying value of the branch of the Spanish Distribution Center on the date of sale, and associated disposal costs. Italy Branch In June 2021, we completed the sale of a branch of our Italian business for a total selling price of $1.7, the proceeds of which will be received in installments between October 2021 and December 2026, and will be presented as investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2021, we recorded a gain of $1.4 before and after tax, which is reported separately in the Consolidated Statements of Operations representing the difference between the proceeds and the carrying value of the branch of the Italian business on the date of sale. Avon Shanghai In August 2020, we signed an agreement to sell Avon Management Shanghai ("Avon Shanghai") to an affiliate of Natura &Co for a selling price of $2.9. In August 2020, we completed the sale of the entity and received proceeds of $2.9. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows as the sale was to an affiliate under common control by Natura &Co. The gain on sale of $1.4 was recorded directly to Retained earnings. Hungary Distribution Center in Gödöllő In April 2020, we signed an agreement to sell the Hungary Distribution Center in Gödöllő for a selling price of $3.4 and received a deposit of $.3. In June 2020, we completed the sale of the asset and the remaining proceeds of $3.1 were received. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2020, we recorded a gain of $.1 before and after tax, which is reported separately in the Consolidated Statements of Operations. The gain represents the difference between the proceeds and the carrying value of the Hungary Distribution Center on the date of sale. China Wellness Plant In March 2020, we signed an agreement to sell the China Wellness Plant for a total selling price of $6.6 before expenses. In the six-month period ended June 30, 2020, we received a cash deposit for the selling price of $6.6, which included $3.3 of restricted cash held in escrow. In August 2020, we completed the sale of the China Wellness Plant and $3.3 of restricted cash in escrow was transferred to Avon. In the third quarter of 2020, we recorded a gain of $1.4 before and after tax, which is reported separately in the Consolidated Statements of Operations. The gain represents the difference between the net proceeds (after associated expenses) and the carrying value of the China Wellness Plant on the date of sale. Rye Office On June 26, 2019, we completed the sale of the Rye office for a selling price of $23.2, less expenses of approximately $.8, resulting in proceeds of $22.4. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2019, we recorded a gain on sale of $9.9 before and after tax, which is reported separately in the Consolidated Statements of Operations. The gain recorded represents the difference between the proceeds and the carrying value of the Rye office on the date of sale. Malaysia Maximin On May 9, 2019, we completed the sale of all of our equity interests in Maximin Corporation Sdn Bhd ("Malaysia Maximin") for a total selling price of $7.8. The cash proceeds of $7.6, net of expenses, are presented within investing activities in the Consolidated Statement of Cash Flows. In the second quarter of 2019, we recorded a gain on sale of $3.3 before tax, which is reported separately in the Consolidated Statements of Operations, and $3.0 after tax. The gain recorded represents the difference between the proceeds and the carrying value of Malaysia Maximin on the date of sale. China manufacturing On February 15, 2019, we completed the sale to TheFaceShop Co., Ltd., an affiliate of LG Household & Health Care Ltd. ("TheFaceShop"), of all of the equity interests in Avon Manufacturing (Guangzhou), Ltd. for a total selling price of $71.0, less expenses of approximately $1.1. The selling price included $23.5 relating to outstanding intercompany loans payable to Avon Manufacturing (Guangzhou), Ltd. from other Avon subsidiaries that was presented as financing activities in the Consolidated Statement of Cash Flows, this was subsequently settled in April 2019. The cash proceeds of $46.4, net of loan amounts, are presented as investing activities in the Consolidated Statement of Cash Flows, which includes $7.6 of restricted cash as of December 31, 2019. This was subsequently reclassified to short-term restricted cash in the three month period ended March 31, 2020. The restriction on this cash was removed in the three-month period ended March 31, 2021. In the first quarter of 2019, we recorded a gain on sale of $10.3 before tax, which is reported separately in the Consolidated Statements of Operations, and $8.2 after tax, representing the difference between the proceeds, including the settlement of the intercompany loans, and the carrying value of Avon Manufacturing (Guangzhou), Ltd. on the date of sale. New Avon In April 2019, we signed an agreement with LG Household & Health Care Ltd. to sell our 19.9% ownership interest in New Avon. During August 2019, we completed the sale of New Avon for a selling price of $24.5. Expenses were approximately $1.1, resulting in cash proceeds of $23.4. These proceeds are presented as investing activities in the Consolidated Statement of Cash Flows. In the third quarter of 2019, we recorded a gain on sale of $26.8 before and after tax, which is reported in the Consolidated Statements of Operations as Gain on sale of business/asset. The gain recorded represents the total proceeds and the release of AOCI of $3.4. Our recorded investment balance in New Avon at August 14, 2019 was zero. On May 22, 2019, the Company entered into the Agreement and Plan of Mergers (as amended by Amendment Number One to Agreement and Plant of Mergers, dated as of October 3, 2019, and as further amended by Amendment Number Two to Agreement and Plan of Mergers, dated as of November 5, 2019, the "Merger Agreement") among the Company, Natura Cosméticos S.A., a Brazilian corporation (sociedade anônima) ("Natura Cosméticos"), Natura &Co Holding S.A., a Brazilian corporation (sociedade anônima), Nectarine Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of Natura &Co Holding ("Merger Sub I"), and Nectarine Merger Sub II, Inc., a Delaware corporation and a direct wholly owned subsidiary of Merger Sub I ("Merger Sub II"), pursuant to which (i) Natura &Co Holding, after the completion of certain restructuring steps, holds all issued and outstanding shares of Natura Cosméticos, (ii) Merger Sub II merged with and into the Company, with the Company surviving the merger (the "First Merger") and (iii) Merger Sub I merged with and into Natura &Co Holding (the "Second Merger"), with Natura &Co Holding surviving the merger and as a result of which the Company and Natura Cosméticos became wholly owned direct subsidiaries of Natura &Co Holding (collectively, the "Transaction"). The Transaction was consummated on January 3, 2020, and at this time, the Company became a wholly owned direct subsidiary of Natura &Co Holding. In connection with the Transaction, trading of the Company’s stock was suspended by the NYSE, and the Company’s common stock was subsequently delisted and deregistered. On completion of the Transaction, each share of t he Company’s common stock issued and outstanding immediately prior to the consummation of the Transaction was converted into the ultimate right to receive, (i) 0.300 validly issued and allotted, fully paid-up American Depositary Shares of Natura &Co Holding, ("Natura &Co Holding ADSs") against the deposit of two shares of common stock of Natura &Co Holding ("Natura &Co Holding Shares", subject to adjustment in accordance with the terms of the Merger Agreement, and any cash in lieu of fractional Natura &Co Holding ADSs or (ii) 0.600 validly issued and allotted, fully paid-up Natura &Co Holding Shares, subject to adjustment in accordance with the terms of the Merger Agreement, and any cash in lieu of fractional Natura &Co Holding Shares. The Company’s Series C Preferred Stock held by Cerberus Investor were converted to common stock prior to consummation of the Transaction and were therefore automatically converted into common stock of Natura &Co; see Note 17, Series C Convertible Preferred Stock. Natura &Co Holding Shares are listed on the B3 S.A. - Brasil, Bolsa, Balcão stock exchange, and Natura &Co Holding ADSs are listed on the NYSE. Additionally, upon the consummation of the Transaction, Avon common stock ceased to be traded on the NYSE. In January 2020, subsequent to the Transaction, the Company restated the certificate of incorporation. The certificate of incorporation was restated to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, are common stock and (ii) 25,000,000 shares, par value $1.00 per share, are preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result, all of the issued and outstanding common stock of the Company, being 550,890,788 were canceled and converted into 101.34 common stock, par value $0.01 per share, and all outstanding treasury shares were canceled. The Company incurred costs of $46 and $44 in relation to the Transaction, primarily professional fees during the years ended December 31, 2020 and 2019, respectively. During January 2020, it was announced that the employment of certain senior officers of the Company would be terminated, in connection with the Transaction. The Company incurred severance of approximately $25 and acceleration of share based compensation of approximately $10 relating to these terminations triggered by change in control provisions. As a result of the Transaction, the Company made payments of approximately $26 related to the settlement of stock options. In addition, any remaining restricted stock units and performance restricted stock units were exchanged for awards of Natura &Co Holding. The replacement awards contain substantially the same terms and conditions of the original awards except for the removal of the performance conditions. As such, the replacement awards contain only a service vesting condition. On consummation of the Transaction, a deferred compensation scheme relating to former employees of the Company became payable which resulted in extinguishing the liability and a cash outflow of approximately $12. In January 2020, upon completion of the Transaction, the Company’s revolving credit facility was canceled, triggered by change in control provisions. As a result, debt issuance costs of $7.8 were written off. As a result of the Transaction, the Company will no longer have access to certain tax attributes of approximately $546 to approximately $616 in certain taxing jurisdictions. These tax attributes had been formerly reflected as deferred tax assets which were subject to a full valuation allowance and as a result, there was no impact to net income in 2020 from the write-off of the deferred tax asset and the associated valuation allowances.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 24, 2022, Russia launched a military invasion of Ukraine. The ongoing military conflict between Ukraine and Russia has provoked strong reactions from the United States, the UK, the EU and various other countries around the world, including the imposition of broad financial and economic sanctions against Russia. The Company has sales operations in multiple countries including in Russia and Ukraine. While as of the date of this report there have not been any material impacts from the above mentioned matter, management is continuously monitoring the developments to assess any potential future impacts that may arise as a result of the ongoing crisis.

VALUATION AND QUALIFYING ACCOUN

VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	AVON PRODUCTS, INC. AND SUBSIDIARIES VALUATION AND QUALIFYING ACCOUNTS Years ended December 31, 2021, 2020 and 2019 Additions (In millions) Balance at Charged to Costs and Expenses Charged Deductions Balance 2021 Allowance for doubtful accounts receivable $ 51.1 $ 62.4 $ — $ (76.4) (1) $ 37.1 Refund liability 9.1 — 75.9 (80.7) (2) 4.3 Allowance for inventory obsolescence 70.4 26.8 — (42.4) (3) 54.8 Deferred tax asset valuation allowance 2,327.6 125.7 — (1,637.9) (4) 815.4 2020 Allowance for doubtful accounts receivable $ 66.6 $ 78.3 $ — $ (93.8) (1) $ 51.1 Refund liability 10.7 — 101.4 (103.0) (2) 9.1 Allowance for inventory obsolescence 82.0 37.9 — (49.5) (3) 70.4 Deferred tax asset valuation allowance 2,960.0 (632.4) — — 2,327.6 2019 Allowance for doubtful accounts receivable $ 93.0 $ 115.4 $ — $ (141.8) (1) $ 66.6 Refund liability 12.3 — 132.6 (134.2) (2) 10.7 Allowance for inventory obsolescence 146.1 37.1 — (101.2) (3) 82.0 Deferred tax asset valuation allowance 3,257.5 (297.5) — — 2,960.0 (1) Accounts written off, net of recoveries and foreign currency translation adjustment. (2) Returned product reused or destroyed and foreign currency translation adjustment. (3) Obsolete inventory destroyed and foreign currency translation adjustment. (4) Deductions associated with divestiture of Luxembourg Holdings and subsidiaries.

Description of the Business a_2

Description of the Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Description Of The Business And Summary Of Significant Accounting Policies
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Avon and our majority and wholly-owned subsidiaries. Intercompany balances and transactions are eliminated.
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates We prepare our consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America, or GAAP. In preparing these statements, we are required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, we review our estimates, including those related to stand-alone selling prices ("SSP") of promised goods or services delivered under sales incentives, allowances for sales returns, allowances for doubtful accounts receivable, provisions for inventory obsolescence, the determination of discount rates and other actuarial assumptions for pension and postretirement benefit expenses, restructuring expense, income taxes and tax valuation allowances, share-based compensation, loss contingencies and the evaluation of goodwill, property, plant and equipment and capitalized software for potential impairment.
Reclassifications	Reclassifications During the third quarter of 2020, we identified an immaterial classification error in the Consolidated Statement of Cash Flows relating to the year ended December 31, 2019 with respect to cash flows from the settlement of derivative contracts. Our accounting policy is to classify derivative cash flows as operating, investing or financing consistent with the nature of the underlying hedged item. However, we have identified that cash flows relating to derivative contracts that economically hedge foreign exchange gains and losses on intercompany loans have been incorrectly classified as operating activities rather than financing activities. We have corrected this reclassification error through a revision to the Consolidated Statement of Cash Flows for the year ended December 31, 2019 to reclassify cash inflows of $37.4 from the settlement of derivative contracts from operating activities to financing activities.
Foreign Currency	Foreign Currency Financial statements of foreign subsidiaries operating in other than highly inflationary economies are translated at year-end exchange rates for assets and liabilities and average exchange rates during the year for income and expense accounts. The resulting translation adjustments are recorded within accumulated other comprehensive income (loss) ("AOCI"). Gains or losses resulting from the impact of changes in foreign currency rates on assets and liabilities denominated in a currency other than the functional currency are recorded in other expense, net. For financial statements of Avon subsidiaries operating in highly inflationary economies, the U.S. dollar is required to be used as the functional currency. Highly inflationary accounting requires monetary assets and liabilities, such as cash, receivables and payables, to be remeasured into U.S. dollars at the current exchange rate at the end of each period with the impact of any changes in exchange rates being recorded in income. We record the impact of changes in exchange rates on monetary assets and liabilities in other expense, net. Similarly, deferred tax assets and liabilities are remeasured into U.S. dollars at the current exchange rates; however, the impact of changes in exchange rates is recorded in income taxes in our Consolidated Statements of Operations. Non-monetary assets and liabilities, such as inventory, property, plant and equipment and prepaid expenses are carried forward at their historical dollar cost, which was calculated using the exchange rate at the date which hyperinflationary accounting is implemented. Argentina Currency During the quarter ended June 30, 2018, based on published official exchange rates which indicate that Argentina's three-year cumulative inflation rate has exceeded 100%, we concluded that Argentina had become a highly inflationary economy. From July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary. As such, the functional currency for Argentina has changed to the U.S. dollar, which is the consolidated group's reporting currency.
Revenue Recognition	Revenue Recognition Nature of goods and services We are a global manufacturer and marketer of beauty and related products. Our product categories are Beauty and Fashion & Home. Beauty consists of skincare, fragrance and color (cosmetics). Fashion & Home consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products and nutritional products. Our business is conducted primarily in one channel, direct selling. Our reportable segments are based on geographic operations in two regions: Avon International and Avon Latin America. We primarily sell our products to the ultimate consumer through the direct selling channel principally through Representatives, who are independent contractors and not our employees. Revenue recognition Revenue is recognized when control of a product or service is transferred to a customer, which is generally the Representative. Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties, such as Value Added Taxes ("VAT") collected for taxing authorities. Principal revenue streams and significant judgments Our principal revenue streams can be distinguished into: i) the sale of Beauty and Fashion & Home products to Representatives (recorded in net sales); ii) Representative fees, primarily for the sale of brochures to Representatives and fulfillment activities related to the contract, which include fees for shipping and handling (recorded in other revenue); and iii) other, which includes the sale of products to New Avon LLC ("New Avon") and royalties from the licensing of our name and products (recorded in other revenue). i) Sale of Beauty and Fashion & Home products to Representatives We generate the majority of our revenue through the sale of Beauty and Fashion & Home products. A Representative contacts her customers directly, selling primarily through our brochure (whether paper or online), which highlights new products and special promotions (or incentives) for each sales campaign. In this sense, the Representative, together with the brochure, are the "store" through which our products are sold. A brochure introducing a new sales campaign is typically generated every three to four weeks. A purchase order is processed, and the products are picked at a distribution center and delivered to the Representative usually through a combination of local and national delivery companies. Generally, the Representative then delivers the merchandise and collects payment from the customer for her or his own account. A Representative generally receives a refund of the price the Representative paid for a product if the Representative chooses to return it. A Representative Agreement, which outlines the basic terms of the agreement between Avon and the Representative, combined with a purchase order, constitutes a contract for the purposes of Accounting Standards Codification Topic ("ASC"), Revenue from Contracts with Customers ("ASC 606"). Revenue from Contracts with Customers We account for individual products and services separately in the contract if they are distinct (i.e., if a product or service is separately identifiable from the other items in the contract and if a Representative can benefit from the product or service on its own or with other resources that are readily available), which is recognized at a point in time, when control of a product is transferred to a Representative. In addition, we offer incentives to Representatives to support sales growth. Certain of these sales incentives are distinct promises to a Representative, and therefore are a separate performance obligation. As a result, revenue is allocated to the performance obligation for sales incentives and is deferred on the balance sheet until the associated performance obligations are satisfied. Typically included within a contract is variable consideration, such as sales returns and late payment fees. Revenue is only recorded to the extent it is probable that it will not be reversed, and therefore revenue is adjusted for variable consideration. Variable consideration is generally estimated using the expected value method, which considers possible outcomes weighted by their probability. Specifically for sales returns, a refund liability will be recorded for the estimated cash to be refunded for the products expected to be returned, and a returns asset will be recorded for the products which we expect to be returned and re-sold, each of these based on historical experience. The estimate of sales returns as well as the measurement of the returns asset and the refund liability is updated at the end of each month for changes in expectations regarding the amount of salvageable returns, reconditioning costs and any additional decreases in the value of the returned products. Late payment fees are recorded when the uncertainty associated with collecting such fees are resolved (i.e., when collected). The Representative generally receives a credit period of one sales campaign if they meet certain criteria; however, the specific credit terms are outlined in the Representative Agreement. Generally, the Representative remits payment during each sales campaign, which relates to the prior campaign cycle. The Representative is generally precluded from submitting an order for the current sales campaign until the accounts receivable balance past due for prior campaigns is paid; however, there are circumstances where the Representative fails to make the required payment. Our contracts with Representatives often include multiple promises to transfer products and/or services to the Representative, and determining which of these products and/or services are considered distinct performance obligations that should be accounted for separately. In addition, in assessing the recognition of revenue for the following performance obligations, management has exercised significant judgment in the following areas: estimation of variable consideration and the stand-alone selling prices ("SSP") of promised goods or services in order to determine and allocate the transaction price. Performance obligation - Avon products and appointment kits The Representative purchases Avon products and appointment kits through a purchase order. Avon offers appointment kits for purchase to Representatives, which may contain various Avon products. We recognize revenue for Avon products and appointment kits in net sales in our Consolidated Statements of Operations when the Representative obtains control of the products, which occurs upon delivery of the product to the Representative. Transaction price is the amount we expect to receive in exchange for those products adjusted for variable consideration as discussed above and the estimated SSP of other performance obligations as discussed below. The cost of these products and appointment kits is recognized in cost of sales in our Consolidated Statements of Operations. Performance obligation - Sales incentives Types of sales incentives include status programs, loyalty points, prospective discounts, and gift with purchase, among others. A Representative is eligible for certain status programs if specified sales levels are met. Status programs offer additional benefits such as free or discounted products and services. Loyalty points offer the option to redeem for additional Avon or other products or services. Prospective discounts are offered in some countries when certain sales levels are reached in a given time period. The revenue attributable to the prospective discount performance obligation is for the option to purchase additional product at a discounted amount. Certain benefits within status programs, loyalty points, prospective discounts and certain other sales incentives constitute a material right and, therefore, a distinct performance obligation in the contract with the Representative. Transaction price is allocated to the material right (performance obligation) based on estimated SSP and is deferred on the balance sheet until the associated performance obligations are satisfied. The cost of incentives is presented in inventories in our Consolidated Balance Sheets. We recognize revenue allocated to the material right in net sales in our Consolidated Statements of Operations at the point in time that the Representative receives the benefits of the material right or obtains control of the products, which occurs upon delivery to the Representative or upon expiration of the material right. For sales incentives that are delivered with the associated products order (such as gift with purchase), no deferral is required. SSP represents the estimated market value, or the estimated amount that could be charged for that material right when the entity sells it separately in similar circumstances to similar customers. Judgment is required to determine the SSP for each distinct performance obligation. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, including for certain sales incentives, we determine the SSP using information that may include market prices and other observable inputs. ii) Representative fees, primarily for the sale of brochures to Representatives and fulfillment activities related to the contract ("Representative fees") The purchase order in the contract with the Representative explicitly identifies activities that we will perform. This includes fees that we charge Representatives, primarily for the sale of brochures to Representatives and fulfillment activities, and also includes late payment fees (discussed above). Brochures represent promotional materials that are given directly by the Representatives to their customers as a marketing activity. Under ASC 606, brochures that are sold by Avon to Representatives through purchase orders represent separate performance obligations in the contract as these are promises made between Avon and the Representative. Although the brochures are used similar to marketing materials, the Representative generally orders and pays for the brochures, and we allocate consideration for purposes of revenue recognition. The revenue associated with brochures that are sold to Representatives is recognized in other revenue and the related cost is recognized in cost of sales in our Consolidated Statements of Operations. We recognize revenue when the Representative obtains control of the brochures, which occurs upon delivery to the Representative. When brochures are given away for free to Representatives as promotional items, the cost is recognized in selling, general and administrative expenses in our Consolidated Statements of Operations. We often charge the Representative for shipping and handling (including order processing) and payment processing activities on the invoice, and such activities are considered to be fulfillment costs. The consideration received represents part of the transaction price in the contract that is allocated to the performance obligations in the contract. We recognize revenue for fulfillment activities in other revenue in our Consolidated Statements of Operations when such services are provided to the Representative. The cost of these activities is recognized in SG&A expenses in our Consolidated Statements of Operations.
Other Revenue	Other revenue We also recognize revenue from the sale of products to New Avon, as part of a manufacturing and supply agreement, since the separation of the Company's North America business into New Avon on March 1, 2016, and royalties from the licensing of our name and products, in other revenue in our Consolidated Statements of Operations. Contract costs Incremental costs to obtain contracts, such as bonuses or commissions, are recognized as an asset if the entity expects to recover them. However, ASC 340-40, Other Assets and Deferred Costs , offers a practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the entity otherwise would have recognized is one year or less. We elected the practical expedient and expense costs to obtain contracts when incurred because our amortization period is one year or less. Costs to fulfill contracts with Representatives are comprised of shipping and handling (including order processing) and payment processing services, which are expensed as incurred. The fees for these services are included in the transaction price.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash equivalents are stated at cost plus accrued interest, which approximates fair value. Cash equivalents are generally high-quality, short-term money market instruments with an original maturity of three months or less and consist of time deposits with a number of U.S. and non-U.S. commercial banks and money market fund investments.
Inventories	InventoriesInventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. We classify inventory into various categories based upon its stage in the product life cycle, future marketing sales plans and the disposition process. We assign a degree of obsolescence risk to products based on this classification to estimate the level of obsolescence provision.
Brochure Costs	Brochure Costs Brochures represent promotional materials that are given directly by the Representatives to their customers as a marketing activity. Brochures that are sold by Avon to Representatives through purchase orders represent separate performance obligations in the contract as these are promises made between Avon and the Representative. Although the brochures are used similar to marketing materials, the Representative generally orders and pays for the brochures, and Avon allocates consideration for purposes of revenue recognition. The revenue associated with brochures that are sold to Representatives is recognized in other revenue and the related cost is recognized in cost of sales in our Consolidated Statements of Operations. We recognize revenue when the Representative obtains control of the brochures, which occurs upon delivery to the Representative. When brochures are given away for free to Representatives as promotional items, the cost is recognized in SG&A expenses in our Consolidated Statements of Operations.
Property, Plant and Equipment and Capitalized Software	Property, Plant and Equipment and Capitalized Software Property, plant and equipment are stated at cost and are depreciated using a straight-line method over the estimated useful lives of the assets. The estimated useful lives generally are as follows: buildings, 45 years; land improvements, 20 years; machinery and equipment, 15 years; and office equipment, five Certain systems development costs related to the purchase, development and installation of computer software, and implementation costs incurred in a hosting arrangement that is a service contract, are capitalized and amortized over the estimated useful life of the related project. Costs incurred prior to the development stage, as well as maintenance, training costs, and general and administrative expenses are expensed as incurred. The other assets balance included unamortized capitalized software costs of $74.9 at December 31, 2021 and $76.0 at December 31, 2020. The amortization expense associated with capitalized software was $22.4, $24.5 and $24.7 for the years ended December 31, 2021, 2020 and 2019, respectively.
Leases	Leases We determine if an arrangement is a lease at the lease commencement date. In addition to our lease agreements, we review all material new vendor arrangements for potential embedded lease obligations. The asset balance related to operating and finance leases is presented within right-of-use (ROU) asset and property, plant and equipment, respectively, on our Consolidated Balance Sheet. The short-term liability balance related to operating and finance leases is presented within other accrued liabilities on our Consolidated Balance Sheets. The long-term liability balance is presented within long-term operating lease liability and long-term debt on our Consolidated Balance Sheets for operating and finance leases, respectively. The lease liability is recognized based on the present value of the remaining fixed or in-substance fixed lease payments discounted using our incremental borrowing rates. We use a specific incremental borrowing rate for our material leases, which is determined based on the geography, nature of the asset and term of the lease. These rates are determined based on inputs provided by external banks and updated periodically. The lease liability includes the exercise of a purchase option only if we are reasonably certain to exercise as of the commencement date of the lease. The residual value guarantee amount is only included in the lease liability calculation to the extent payment is probable to the lessor as of the commencement of the lease. The ROU asset is calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date (i.e. prepaid rent) and initial direct costs incurred by Avon and excluding any lease incentives received from the Lessor. Variable lease payments are payments to the lessor not included in the lease liability calculation. We define variable lease payments as payments made by Avon to the lessor for the right to use a leased asset that vary because of changes in facts or circumstances (such as changes in an index rate, volume, usage, etc.) occurring after the lease commencement date, other than predetermined contractual changes due to the passage of time (for example, predetermined rent increase amounts that are set out in the contract). Variable lease payments or charges are accounted for as incurred. The lease term for purposes of lease accounting may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option as of the commencement date of the lease. For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the Company amortizes the ROU asset on a straight-line basis and records interest expense on the lease liability created at lease commencement over the lease term. We account for our lease and non-lease components as a single component for most of our asset classes, and therefore both are included in the calculation of lease liability recognized on the Consolidated Balance Sheets. However, for certain lease asset classes related to identified embedded leases we account for the lease and non-lease components separately, and therefore, the non-lease component is not included in the lease liability.
Assets and Liabilities Held for Sale	Assets and Liabilities Held for Sale A long-lived asset (or disposal group) is classified as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable within a year. A long-lived asset (or disposal group) classified as held for sale is initially measured at the lower of its carrying amount or fair value less cost to sell. An impairment loss is recognized for any initial or subsequent write-down of the long-lived asset (or disposal group) to fair value less costs to sell. A gain or loss not previously recognized by the date of the sale of the long-lived asset (or disposal group) is recognized at the date of derecognition. Long-lived assets (including those that are part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Long-lived assets classified as held for sale and the assets of a disposal group classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet.
Goodwill	Goodwill Goodwill is not amortized and is assessed for impairment annually during the fourth quarter or on the occurrence of an event that indicates impairment may have occurred, at the reporting unit level. A reporting unit is the operating segment, or a component, which is one level below that operating segment. Components are aggregated as a single reporting unit if they have similar economic characteristics. When testing goodwill for impairment, we perform either a qualitative or quantitative assessment for each of our reporting units. Factors considered in the qualitative analysis include macroeconomic conditions, industry and market considerations, cost factors and overall financial performance specific to the reporting unit. If the qualitative analysis results in a more likely than not probability of impairment, the quantitative test, as described below, is required. We perform the quantitative test to evaluate goodwill for impairment by comparing the fair value of a reporting unit with its carrying amount. If the carrying amount exceeds the reporting unit’s fair value, that difference represents an impairment; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. five
Financial Instruments	Financial Instruments We use derivative financial instruments, including forward foreign currency contracts, to manage foreign currency exposures. If applicable, derivatives are recognized in our Consolidated Balance Sheets at their fair values. When we become a party to a derivative instrument and intend to apply hedge accounting, we designate the instrument, for financial reporting purposes, as a fair value hedge, a cash flow hedge, or a net investment hedge. The accounting for changes in fair value (gains or losses) of a derivative instrument depends on whether we had designated it and it qualified as part of a hedging relationship and further, on the type of hedging relationship. We apply the following: • Changes in the fair value of a derivative that is designated as a fair value hedge, along with the loss or gain on the hedged asset or liability that is attributable to the hedged risk are recorded in earnings. • Changes in the fair value of a derivative that is designated as a cash flow hedge are recorded in AOCI and reclassified into earnings in the same period or periods during which the transaction hedged by that derivative also affects earnings. • Changes in the fair value of a derivative that is designated as a hedge of a net investment in a foreign operation are recorded in foreign currency translation adjustments within AOCI. • Changes in the fair value of a derivative that is not designated as a hedging instrument are recognized in earnings in other expense, net in our Consolidated Statements of Operations. We present the earnings effect of the hedging instrument in our Consolidated Statements of Operations in the same income statement line item in which the earnings effect of the hedged item is reported. We classify derivative cash flows as operating, investing or financing consistent with the nature of the underlying hedged item. For derivatives designated as cash flow hedges, if we conclude that the hedging relationship is perfectly effective at inception, a detailed effectiveness assessment in each period is not required as long as (i) the critical terms of the hedging instrument completely match the related terms of the hedged item (ii) it is considered probable that the counterparties to the hedging instrument and the hedged item will not default, and (iii) the hedged cash flows remain probable.
Deferred Income Taxes	Deferred Income Taxes Deferred income taxes have been provided on items recognized for financial reporting purposes in different periods than for income tax purposes using tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce our deferred tax assets to an amount that is "more likely than not" to be realized. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible or before our net operating loss and tax credit carryforwards expire. See Note 9, Income Taxes for more information. In accordance with guidance issued by the Financial Accounting Standards Board ("FASB"), we are choosing to treat the U.S. income tax consequences of Global Intangible Low-Taxed Income ("GILTI") as a period cost. As a result, at December 31, 2021, no deferred income taxes have been provided.
Uncertain Tax Positions	Uncertain Tax Positions We recognize the benefit of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. We record interest expense and penalties payable to relevant tax authorities in income taxes in our Consolidated Statements of Operations.
SG&A Expenses	SG&A Expenses SG&A expenses include costs associated with selling; marketing; distribution, including shipping and handling costs; advertising; net brochure costs; research and development; information technology; and other administrative costs, including finance, legal and human resource functions.
Shipping and Handling	Shipping and HandlingShipping and handling costs are expensed as incurred
Advertising	AdvertisingAdvertising costs, excluding brochure preparation costs, are expensed as incurred
Research and Development	Research and Development Research and development costs are expensed as incurred and amounted to $39.3 in 2021, $36.5 in 2020 and $40.6 in 2019. Research and development costs include all costs related to the design and development of new products such as salaries and benefits, supplies and materials and facilities costs.
Share-based Compensation	Share-based Compensation Where applicable, share-based payments to employees are recognized in the financial statements based on their fair value at the date of grant. If applicable, we use a Monte-Carlo simulation to calculate the fair value of performance restricted stock units with market conditions and the fair value of premium-priced stock options. We account for forfeitures on share-based payments as they occur. When the terms of an equity-settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original vesting terms of the award are met. An additional expense, measured as at the date of modification, is recognized for any modification that increases the total fair value of the share-based payment. Where an award is cancelled, any unamortized compensation cost is expensed immediately. Subsequent to the Transaction with Natura &Co, our employees are considered employees of the parent company for purposes of applying ASC 718 Compensation—Stock Compensation. S hare-based payments made by Natura &Co to our employees are recognized in the financial statements based on their fair value at the date of grant.
Restructuring Expense	Restructuring Expense We record the estimated expense for our restructuring initiatives, such as our Transformation Plan, Open Up & Grow and Avon Integration, when such costs are deemed probable and estimable, when approved by the appropriate corporate authority and by accumulating detailed estimates of costs for such plans. These expenses include the estimated costs of employee severance and related benefits, inventory write-offs, impairment or accelerated depreciation of property, plant and equipment and capitalized software, and any other qualifying exit costs. Such costs represent our best estimate, but require assumptions about the programs that may change over time, including attrition rates. Estimates are evaluated periodically to determine whether an adjustment is required.
Pension and Postretirement Expense	Pension and Postretirement ExpensePension and postretirement expense is determined based on a number of actuarial assumptions, which are generally reviewed and determined on an annual basis. These assumptions include the discount rate applied to plan obligations, the expected rate of return on plan assets, the rate of compensation increase of plan participants, price inflation, cost-of-living adjustments, mortality rates and certain other demographic assumptions, and other factors. Actual results that differ from assumptions are accumulated and amortized to expense over future periods and, therefore, generally affect recognized expense in future periods. We recognize the funded status of pension and other postretirement benefit plans in our Consolidated Balance Sheets. Each overfunded plan is recognized as an asset and each underfunded plan is recognized as a liability. The recognition of prior service costs or credits and net actuarial gains or losses, as well as subsequent changes in the funded status, are recognized as components of AOCI, net of tax, in shareholders’ equity, until they are amortized as a component of net periodic benefit cost. We recognize prior service costs or credits and actuarial gains and losses beyond a 10% corridor to earnings based on the estimated future service period of the participants. The determination of the 10% corridor utilizes a calculated value of plan assets for our more significant plans, whereby gains and losses are smoothed over three
Contingencies	Contingencies We determine whether to disclose and/or accrue for loss contingencies based on an assessment of whether the risk of loss is remote, reasonably possible or probable. We record loss contingencies when it is probable that a liability has been incurred and the amount of loss is reasonably estimable.
New Accounting Standards Implemented	New Accounting Standards Implemented Except for the changes below, we have consistently applied the accounting policies to all periods presented in these consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2020, using a modified retrospective transition approach. The adoption did not have a material impact on our condensed consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The adoption resulted in a cumulative effect decrease to retained earnings of approximately $2 to reflect a change in the allowance for doubtful accounts. ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General. ASU 2018-14 modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. Early adoption is permitted. The amendments in this Update are effective for fiscal years ending after December 15, 2020, therefore we adopted this standard effective December 31, 2020. The adoption did not have a material impact on our Consolidated Financial Statements. ASU 2017-04, Intangibles - Goodwill and other (Topic 350) In January 2017, the FASB issued Accounting Standards Update ("ASU") 2017-04 Intangibles - Goodwill and other , which simplifies the test for goodwill impairment. This Update eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of the assets acquired and liabilities assumed in a business combination. Instead an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, however the loss recognized should not exceed the total amount of goodwill allocated to the reporting unit. The guidance requires prospective adoption. We adopted the guidance for the goodwill impairment test that we have conducted since 2020, and adoption of the guidance did not have a significant impact on our financial statements. ASU 2019-12, Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Income Taxes , which is intended to simplify the accounting standard and improve the usefulness of information provided in the financial statements. We adopted this new accounting guidance as of January 1, 2021. The adoption did not have a material impact on our Consolidated Financial Statements. ASU 2020-04, Reference Rate Reform (Topic 848) In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The ASU provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. In January 2021, the FASB issued ASU 2021-01 which clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company has implemented a transition plan to identify and modify its loans and other financial instruments with attributes that are either directly or indirectly influenced by LIBOR and, as a result, has elected to apply the optional expedient included in ASU 2020-04 to account for modifications of contracts within the scope of Topics 310, Receivables, and 470, Debt, to be accounted for by prospectively adjusting the effective interest rate. Accounting Standards to be Implemented ASU 2021-08, Business Combinations (Topic 805) In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. ASU 2021-08 is effective for our fiscal year beginning after December 15, 2022. The adoption is not expected to have a material impact on our Consolidated Financial Statements.

Discontinued Operations and A_2

Discontinued Operations and Assets and Liabilities Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	The major classes of financial statement components comprising the loss on discontinued operations, net of tax for New Avon are shown below: Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 21, 2019 Selling, general and administrative expenses $ (18.5) $ (27.9) $ (36.6) Operating loss $ (18.5) $ (27.9) $ (36.6) Loss from discontinued operations, net of tax $ (18.5) $ (27.9) $ (36.6) The major classes of assets and liabilities comprising held for sale assets and held for sale liabilities on the Consolidated Balance Sheet at December 31, 2021 and December 31, 2020 are shown in the following table. Year ended December 31, 2021 2020 Current held for sale assets Inventories $ — $ 2.6 Property, Plant & Equipment (net) 2.8 9.2 Cash and cash equivalents — .7 Other assets — 1.4 $ 2.8 $ 13.9 Current held for sale liabilities Accounts payable $ — $ .5 Other liabilities — 1.8 $ — $ 2.3

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	Year Ended December 31, Year Ended December 31, 2021 2020 Statement of Operations Data Revenue from affiliates of Natura &Co (2)(3) $ 25.2 $ 6.7 Cost of sales from affiliaties of Natura &Co (2)(3) $ (22.4) $ (5.9) Gross profit from affiliates of Natura &Co (2)(3) $ 2.8 $ .8 Interest income from Instituto Avon (1) $ — $ .1 Interest expense on Loan from affiliates of Natura &Co (5) $ (50.6) $ (7.5) Interest income on Loan to affiliates of Natura &Co (5) $ 1.6 $ — December 31, 2021 December 31, 2020 Balance Sheet Data Receivables due from Instituto Avon (1) $ — $ .8 Trade Receivables due from affiliates of Natura &Co (2) $ 32.7 $ 6.1 Other receivables due from affiliates of Natura &Co (7) $ 1.4 $ — Loans to affiliates of Natura &Co maturing within one year (7) $ 46.6 $ — Loans to affiliates of Natura &Co maturing after one year (7) $ 46.7 $ — Trade Payables due to affiliates of Natura &Co (7) $ (24.5) $ — Other payables due to affiliates of Natura &Co (4) $ (4.9) $ — Loans from affiliates of Natura &Co maturing within one year (5) $ (371.7) $ (1,008.6) Loans from affiliates of Natura &Co maturing after one year (5) $ (736.3) $ — Investments in affiliates of Natura &Co (6) $ .1 $ — (1) During the second quarter of 2018, the Company entered into an agreement to loan the Instituto Avon, an independent non-government charitable organization in Brazil, R$12 million (Brazilian real) for an unsecured 5-year term at a fixed interest rate of 7% per annum, to be paid back in five equal annual installments. The Instituto Avon was created by an Avon subsidiary in Brazil, with the board and executive team comprised of Avon Brazil management. The purpose of the loan was to provide the Instituto Avon with the means to donate funds to Fundação Pio XII (a leading cancer prevention and treatment organization in Brazil and owner of the Hospital do Câncer de Barretos), in order to invest in equipment with the objective of expanding breast cancer prevention and treatment. During the fourth quarter of 2021, the loan was repaid in full. (2) During the second quarter of 2020, the Company entered into manufacturing agreements with affiliates of Natura &Co Holding. The Company recorded revenue from related party of $25.2 and $6.7 associated with these agreements during the years ended December 31, 2021 and 2020, respectively. The Company recorded gross profit from related party of $2.8 and $.8 associated with these agreements during the years ended December 31, 2021 and 2020, respectively. Trade receivables due from affiliates of Natura &Co primarily relate to these manufacturing agreements. (3) The Company is party to a license agreement with Avon Mexico, whereby Avon Mexico pays the Company a variable royalty. The Company recorded revenue from related party of $1 associated with these agreements during the year ended December 31, 2021. The Company recorded gross profit from related party of $1 associated with these agreements during the year ended December 31, 2021. (4) T he payable to Natura &Co relates to the vesting and settlement of share based compensation awards denominated in Natura &Co American Depository Receipts including the 2018 long-term employee incentive program which vested and were automatically exercised in March 2021. (5) Loans from affiliates of Natura &Co Holding at December 31, 2021 of $1,108.0 include $736.3 outstanding under a Promissory Note between Avon Beauty Limited and a subsidiary of Natura &Co Holding, and $207.3 outstanding under a Promissory Note with a subsidiary of Natura &Co Holding and an affiliate of the Company. In addition loans from affiliates of Natura &Co Holding at December 31, 2021 include $164.4 of intercompany loans between Avon Luxembourg and Avon Products, Inc. affiliates that, following the sale of Avon Luxembourg to a subsidiary of Natura &Co Holding on July 1, 2021, were redesignated as loans from affiliates of Natura & Co Holding. Loans from affiliates of Natura &Co Holding at December 31, 2020 of $1,008.6 include $965 outstanding under a Promissory Note between Avon International Operations Inc. and a subsidiary of Natura &Co Holding. Loans from affiliates of Natura &Co Holding at December 31, 2020 also include $41.6 outstanding under the Revolving Credit Facility between Avon Luxembourg and Natura &Co International S.à r.l.. See Note 15, Debt and Other Financing, for further information relating to these loans. (6) During the second quarter of 2021, Avon Cosméticos LTDA., made an investment of R$.5 in Natura &Co Pay Holding Financeira S.A., representing a 10% holding in the company. This is presented in other assets in our Consolidated Balance Sheets. (7) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, transactions and balances between Avon International and Avon Luxembourg are no longer eliminated on consolidation and instead are treated as transactions and balances with Related Parties.

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue by Product and Service	In the following tables, revenue is disaggregated by product or service type. All revenue is recognized at a point in time, when control of a product is transferred to a customer: Twelve Months Ended December 31, 2021 Reportable segments Avon International Avon LATAM Total reportable segments Affiliates of Natura Total Beauty: Skincare $ 577.6 $ 465.8 $ 1,043.4 $ — $ 1,043.4 Fragrance 514.2 375.8 890.0 — 890.0 Color 238.0 181.9 419.9 — 419.9 Total Beauty 1,329.8 1,023.5 2,353.3 — 2,353.3 Fashion & Home: Fashion 258.3 159.8 418.1 — 418.1 Home 69.6 340.4 410.0 — 410.0 Total Fashion & Home 327.9 500.2 828.1 — 828.1 Certain Brazil taxes* — 21.5 21.5 — 21.5 Product sales 1,657.7 1,545.2 3,202.9 — 3,202.9 Representative fees 66.4 107.8 174.2 — 174.2 Other .5 1.7 2.2 25.2 27.4 Other revenue 66.9 109.5 176.4 25.2 201.6 Total revenue $ 1,724.6 $ 1,654.7 $ 3,379.3 $ 25.2 $ 3,404.5 Twelve Months Ended December 31, 2020 Reportable segments Avon International Avon LATAM Total reportable segments Affiliates of Natura Total Beauty: Skincare $ 594.7 $ 515.9 $ 1,110.6 $ — $ 1,110.6 Fragrance 516.0 456.4 972.4 — 972.4 Color 265.8 197.5 463.3 — 463.3 Total Beauty 1,376.5 1,169.8 2,546.3 — 2,546.3 Fashion & Home: Fashion 267.4 192.5 459.9 — 459.9 Home 55.6 369.4 425.0 — 425.0 Total Fashion & Home 323.0 561.9 884.9 — 884.9 Product sales 1,699.5 1,731.7 3,431.2 — 3,431.2 Representative fees 66.7 108.4 175.1 — 175.1 Other 6.4 5.8 12.2 6.7 18.9 Other revenue 73.1 114.2 187.3 6.7 194.0 Total revenue $ 1,772.6 $ 1,845.9 $ 3,618.5 $ 6.7 $ 3,625.2 Twelve Months Ended December 31, 2019 Reportable segments Avon International Avon LATAM Total Beauty: Skincare $ 671.5 $ 699.9 $ 1,371.4 Fragrance 639.9 604.7 1,244.6 Color 381.6 340.0 721.6 Total Beauty 1,693.0 1,644.6 3,337.6 Fashion & Home: Fashion 383.8 235.0 618.8 Home 61.7 408.3 470.0 Total Fashion & Home 445.5 643.3 1,088.8 Certain Brazil taxes** — 67.7 67.7 Product sales 2,138.5 2,355.6 4,494.1 Representative fees 91.5 152.7 244.2 Other 4.3 20.6 24.9 Other revenue 95.8 173.3 269.1 Total revenue $ 2,234.3 $ 2,528.9 $ 4,763.2 * 2021 includes approximately $22, to reflect the impact of certain Brazil indirect taxes which were recorded in product sales, in our Consolidated Income Statements. See Note 20 Supplemental Balance Sheet Information. ** 2019 includes the impact of certain Brazil indirect taxes which was recorded in product sales of approximately $68, in our Consolidated Income Statements. See Note 20 Supplemental Balance Sheet Information.
Summary of Receivables and Contract Liabilities	The following table provides information about receivables and contract liabilities from contracts with customers at December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Accounts receivable, net of allowances of $37.1 and $51.1 $ 198.7 $ 259.1 Contract liabilities $ 37.1 $ 52.1

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory, Net [Abstract]
Components of Inventories	Inventories at December 31 consisted of the following: 2021 2020 Raw materials $ 103.4 $ 131.3 Finished goods 280.7 327.8 Total $ 384.1 $ 459.1

Debt and Other Financing (Table

Debt and Other Financing (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Debt	Debt at December 31 consisted of the following: 2021 2020 Debt maturing within one year: Short term debt $ 32.6 $ 28.0 Loans from affiliates of Natura &Co 371.7 1,008.6 Total $ 404.3 $ 1,036.6 Long-term debt: Finance lease liabilities 1.3 1.5 5.00% Notes, due March 2023 460.8 460.1 6.95% Notes, due March 2043 213.9 213.8 Loans from affiliates of Natura &Co, due 2028 736.3 — Total 1,412.3 675.4
Schedule of Carrying Values of Debt Instrument	At December 31, 2021 and 2020, the carrying values of our unsecured notes were comprised of the following: 2021 2020 Remaining Principal Unamortized Discounts Unamortized Debt Issuance Costs Total Remaining Principal Unamortized Discounts Unamortized Debt Issuance Costs Total 5.00% Notes, due March 2023 461.9 (.5) (.6) 460.8 461.9 (1.0) (.8) 460.1 6.95% Notes, due March 2043 216.1 (1.7) (.5) 213.9 216.1 (.5) (1.8) 213.8
Schedule of Maturities of Long-term Debt	Annual maturities of long-term debt, which includes our notes, loans from affiliates of Natura &Co and capital leases outstanding at December 31, 2021, are as follows: 2022 2023 2024 2025 2026 2027 and Beyond Total Maturities $ — $ 462.7 $ .3 $ .2 $ .1 $ 952.4 $ 1,415.7

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The tables below present the changes in AOCI by component and the reclassifications out of AOCI during 2021 and 2020: Foreign Currency Translation Adjustments Net Investment Hedges Pension and Postretirement Benefits Total Balance at December 31, 2020 $ (1,038.2) $ (4.3) $ (91.3) $ (1,133.8) Other comprehensive income (loss) other than reclassifications (24.1) — 67.3 43.2 Sale of Avon Luxembourg .1 (.1) — Reclassifications into earnings: Amortization of net actuarial loss and prior service cost, net of tax of $.8 (1) — — 5.1 5.1 Total reclassifications into earnings — — 5.1 5.1 Balance at December 31, 2021 $ (1,062.2) $ (4.3) $ (19.0) $ (1,085.5) Foreign Currency Translation Adjustments Cash Flow Hedges Net Investment Hedges Pension and Postretirement Benefits Total Balance at December 31, 2019 $ (942.7) $ (.6) $ (4.3) $ (92.4) $ (1,040.0) Other comprehensive loss other than reclassifications (95.5) — — (7.1) (102.6) Reclassifications into earnings: Derivative gains on cash flow hedges, net of tax of $0 — .6 — — .6 Amortization of net actuarial loss and prior service cost, net of tax of $.8 (1) — — — 8.2 8.2 Total reclassifications into earnings — .6 — 8.2 8.8 Balance at December 31, 2020 $ (1,038.2) $ — $ (4.3) $ (91.3) $ (1,133.8) (1) Gross amount reclassified to other expense, net, and related taxes reclassified to income taxes.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income from Continuing Operations before Taxes	Income from continuing operations, before taxes for the years ended December 31 was as follows: 2021 2020 2019 United States $ 19.3 $ (89.6) $ (108.3) Foreign (178.1) (214.0) 246.7 Total $ (158.8) $ (303.6) $ 138.4
Schedule of Provision for Income Taxes	The provision for income taxes for the years ended December 31 was as follows: 2021 2020 2019 Federal: Current $ .2 $ (9.5) $ (9.0) Deferred — 8.9 8.5 Total Federal .2 (.6) (0.5) Foreign: Current 35.5 31.4 79.0 Deferred (20.0) 2.6 28.9 Total Foreign 15.5 34.0 107.9 State and Local: Current .5 .6 (4.3) Deferred — — — Total State and other .5 .6 (4.3) Total $ 16.2 $ 34.0 $ 103.1
Schedule of Effective Tax Rate	The continuing operations effective tax rate for the years ended December 31 was as follows: 2021 2020 2019 Statutory federal rate 21.0 % 21.0 % 21.0 % State and local taxes, net of federal tax benefit (.3) (.2) (2.7) Tax on foreign income 67.1 (1.8) 62.1 Tax on uncertain tax positions 3.7 1.1 16.6 Reorganizations — (10.0) 185.6 Net change in valuation allowances (103.1) (21.4) (208.0) Other 1.4 .1 (.1) Effective tax rate (10.2) % (11.2) % 74.5 %
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets (liabilities) at December 31 consisted of the following: 2021 2020 Deferred tax assets: Tax loss and deduction carryforwards $ 425.0 $ 1,997.5 Intangibles 218.5 188.3 Tax credit carryforwards 119.7 119.0 Interest carryforwards 76.3 48.3 All other future deductions 199.8 199.1 Valuation allowance (815.4) (2,327.6) Total deferred tax assets 223.9 224.6 Deferred tax liabilities $ (105.0) $ (90.8) Net deferred tax assets $ 118.9 $ 133.8 Deferred tax assets (liabilities) at December 31 were classified as follows: 2021 2020 Deferred tax assets: Other assets $ 121.4 $ 135.8 Total deferred tax assets 121.4 135.8 Deferred tax liabilities: Long-term income taxes $ (2.5) $ (2.0) Total deferred tax liabilities (2.5) (2.0) Net deferred tax assets $ 118.9 $ 133.8
Reconciliation of Beginning and Ending Amount of Unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Balance at December 31, 2018 137.6 Additions based on tax positions related to the current year 13.3 Additions for tax positions of prior years 186.6 Reductions for tax positions of prior years (3.0) Reductions due to lapse of statute of limitations (.6) Reductions due to settlements with tax authorities (2.2) Balance at December 31, 2019 331.7 Additions based on tax positions related to the current year 90.6 Additions for tax positions of prior years .6 Reductions for tax positions of prior years (34.1) Reductions due to lapse of statute of limitations (16.5) Reductions due to settlements with tax authorities (.2) Balance at December 31, 2020 372.1 Additions based on tax positions related to the current year 6.8 Additions for tax positions of prior years 24.1 Reductions for tax positions of prior years (136.8) Reductions due to lapse of statute of limitations (11.2) Reductions due to settlements with tax authorities (3.3) Balance at December 31, 2021 $ 251.7
Tax Years Remaining	As of December 31, 2021, the tax years that remained subject to examination by major tax jurisdiction for our most significant subsidiaries were as follows: Jurisdiction Open Years Brazil 2016-2021 Philippines 2017-2021 Poland 2014-2021 Russia 2019-2021 United Kingdom 2019-2021 United States (Federal) 2017-2021

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value of Derivative Instruments	The following table presents the fair value of derivative instruments at December 31, 2021: Asset Liability Balance Sheet Fair Balance Sheet Fair Derivatives not designated as hedges: Foreign exchange forward contracts Prepaid expenses and other $ — Accounts payable $ 2.7 Total derivatives $ — $ 2.7 Derivatives are recognized in the Consolidated Balance Sheets at their fair values. The following table presents the fair value of derivative instruments at December 31, 2020: Asset Liability Balance Sheet Fair Balance Sheet Fair Derivatives not designated as hedges: Foreign exchange forward contracts Prepaid expenses and other $ 2.8 Accounts payable $ 6.0 Total derivatives $ 2.8 $ 6.0 The following table presents the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis at December 31, 2021: Level 1 Level 2 Total Liabilities: Foreign exchange forward contracts $ — $ 2.7 $ 2.7 Total $ — $ 2.7 $ 2.7 The following table presents the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis at December 31, 2020: Level 1 Level 2 Total Assets: Available-for-sale securities $ 4.2 $ — $ 4.2 Foreign exchange forward contracts $ — $ 2.8 $ 2.8 Total $ 4.2 $ 2.8 $ 7.0 Liabilities: Foreign exchange forward contracts $ — $ 6.0 $ 6.0 Total $ — $ 6.0 $ 6.0

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Hierarchy	The following table presents the fair value of derivative instruments at December 31, 2021: Asset Liability Balance Sheet Fair Balance Sheet Fair Derivatives not designated as hedges: Foreign exchange forward contracts Prepaid expenses and other $ — Accounts payable $ 2.7 Total derivatives $ — $ 2.7 Derivatives are recognized in the Consolidated Balance Sheets at their fair values. The following table presents the fair value of derivative instruments at December 31, 2020: Asset Liability Balance Sheet Fair Balance Sheet Fair Derivatives not designated as hedges: Foreign exchange forward contracts Prepaid expenses and other $ 2.8 Accounts payable $ 6.0 Total derivatives $ 2.8 $ 6.0 The following table presents the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis at December 31, 2021: Level 1 Level 2 Total Liabilities: Foreign exchange forward contracts $ — $ 2.7 $ 2.7 Total $ — $ 2.7 $ 2.7 The following table presents the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis at December 31, 2020: Level 1 Level 2 Total Assets: Available-for-sale securities $ 4.2 $ — $ 4.2 Foreign exchange forward contracts $ — $ 2.8 $ 2.8 Total $ 4.2 $ 2.8 $ 7.0 Liabilities: Foreign exchange forward contracts $ — $ 6.0 $ 6.0 Total $ — $ 6.0 $ 6.0
Fair Value of Financial Instruments	The net asset (liability) amounts recorded in the balance sheet (carrying amount) and the estimated fair values of our remaining financial instruments at December 31 consisted of the following: 2021 2020 Carrying Fair Value Carrying Fair Value Available-for-sale securities $ — $ — $ 4.2 $ 4.2 Loans to affiliates of Natura &Co maturing within one year 46.6 46.6 — — Loans to affiliates of Natura &Co maturing after one year 46.7 46.7 — — Debt maturing within one year (32.6) (32.6) (28.0) (28.0) Loans from affiliates of Natura &Co maturing within one year (371.7) (371.7) (1,008.6) (1,008.6) Long-term debt (1) (676.0) (754.2) (675.4) (782.4) Loans from affiliates of Natura &Co maturing after one year (736.3) (736.3) — — Foreign exchange forward contracts (2.7) (2.7) (3.2) (3.2) (1) The carrying value of long-term debt is presented net of debt issuance costs and includes any related discount or premium, as applicable.

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Allocation of Share-based Compensation Costs	For the years ended December 31: 2021 2020 2019 Compensation cost for stock-based compensation $ 13.4 $ 24.9 $ 15.6 Total income tax (cost)/ benefit recognized for share-based arrangements (.2) 1.9 1.3
Schedule of Valuation Assumptions	When estimating the fair value of each option, we used the following weighted-average assumptions for options granted during the year ended December 31, 2019: 2019 Risk-free rate (1) 2.4% Expected term (2) 7 years Expected Avon volatility (3) 45% Expected dividends —% (1) The risk-free rate was based upon the rate on a zero coupon U.S. Treasury bill, for periods within the contractual life of the option, in effect at the time of grant. (2) The expected term of the option was based on the vesting terms of the respective option and a contractual life of 10 years. (3) Expected Avon volatility was based on the daily historical volatility of our stock price, over a period similar to the expected life of the option.
Schedule of Share-based Payment Award, Performance Restricted Stock Units, Valuation Assumptions	When estimating the fair value of the PRSUs, we used the following weighted-average assumptions: 2019 PRSUs Risk-free rate (1) 2.4% Expected Avon volatility (2) 54.8% Expected average volatility (3) 29.9% Expected dividends —% (1) The risk-free rate was based upon the rate on a zero coupon U.S. Treasury bill, for periods within the three year performance period, in effect at the time of grant. (2) Expected Avon volatility was based on the weekly historical volatility of our stock price, over a period similar to the three year performance period of the 2019 PRSUs. (3) Expected average volatility was based on the weekly historical volatility of the stock prices of each member of companies included in the S&P 400 index as of the date of the grant, over a period similar to the three year performance period of the 2019 PRSUs.
Schedule of Options Activity During Period	A summary of nominal cost options at December 31, 2021 and changes during 2021, is as follows: Nominal cost options Weighted-Average January 1, 2021 1,547 $ 11.51 Granted 1,661 9.72 Exercised (600) (12.12) Forfeited (282) (12.10) Outstanding at December 31, 2021 2,326 $ 10.00
Schedule of Share-Based Compensation Performance Restricted Stock Units Activity	A summary of performance share units at December 31, 2021 and changes during 2021, is as follows: Performance Share Units Weighted-Average January 1, 2021 1,543 $ 20.91 Granted 628 17.32 Exercised — — Forfeited (317) (20.45) Outstanding at December 31, 2021 1,854 $ 19.78

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits, Description [Abstract]
Summary of Defined Benefit Pension and Postretirement Plans	The following table summarizes changes in the benefit obligation, plan assets and the funded status of our significant defined benefit pension and postretirement plans. We use a December 31 measurement date for all of our employee benefit plans. Pension Plans U.S. Plans Non-U.S. Plans Postretirement Benefits 2021 2020 2021 2020 2021 2020 Change in Benefit Obligation: Beginning balance $ (67.9) $ (71.7) $ (767.5) $ (685.9) $ (7.7) $ (26.8) Service cost (.9) (1.2) (4.3) (4.3) — — Interest cost (1.0) (1.4) (8.7) (11.7) (.3) (.7) Actuarial gain (loss) 1.8 (6.2) 54.6 (61.8) .4 (1.5) Benefits paid 7.7 12.6 25.7 27.8 .6 5.4 Actual expenses and taxes — — .4 .5 — — Plan amendments — — — — — 4.1 Curtailments — — .2 — — — Settlements — — 1.8 1.1 — — Special termination benefits — — — — (3.0) 5.8 Transfers — — — — — 4.9 Foreign currency changes and other — — 13.5 (33.2) .3 1.1 Sale of Avon Luxembourg — — 13.1 — — — Ending balance $ (60.3) $ (67.9) $ (671.2) $ (767.5) $ (9.7) $ (7.7) Change in Plan Assets: Beginning balance $ 59.7 $ 63.3 $ 762.0 $ 695.4 $ — $ — Actual return on plan assets 1.6 8.0 29.3 62.0 — — Company contributions .7 1.0 10.1 3.3 .6 10.2 Benefits paid (7.7) (12.6) (25.7) (27.8) (.6) (5.3) Actual expenses and taxes — — (.4) — — — Settlements — — (1.8) (1.1) — — Transfers — — — — — (4.9) Foreign currency changes and other — — (9.1) 30.2 — — Ending balance $ 54.3 $ 59.7 $ 764.4 $ 762.0 $ — $ — Funded Status: Funded status at end of year $ (6.0) $ (8.2) $ 93.2 $ (5.5) $ (9.7) $ (7.7) Amount Recognized in Balance Sheet: Other assets $ — $ — $ 162.4 $ 103.1 $ — $ — Accrued compensation (.7) (.9) (1.2) (2.1) (6.3) (3.6) Employee benefit plans liability (5.3) (7.4) (68.0) (106.5) (3.4) (4.1) Net amount recognized $ (6.0) $ (8.3) $ 93.2 $ (5.5) $ (9.7) $ (7.7) Pretax Amounts Recognized in Accumulated Other Comprehensive Loss: Net actuarial loss $ 14.7 $ 19.6 $ 122.8 $ 204.7 .8 $ 1.9 Prior service (credit) cost — (.1) 2.0 1.5 (.8) (5.3) Total pretax amount recognized $ 14.7 $ 19.5 $ 124.8 $ 206.2 $ — $ (3.4) Supplemental Information: Accumulated benefit obligation $ 59.5 $ 66.8 $ 159.4 $ 200.6 N/A N/A Plans with Projected Benefit Obligation in Excess of Plan Assets: Projected benefit obligation $ 60.3 $ 67.9 $ 170.0 $ 220.1 N/A N/A Fair value plan assets 54.3 59.7 100.8 111.5 N/A N/A Plans with Accumulated Benefit Obligation in Excess of Plan Assets: Accumulated benefit obligation 59.5 7.3 153.6 190.1 N/A N/A Fair value plan assets 54.3 — 91.7 98.3 N/A N/A
Schedule of Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Income	Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Loss Pension Benefits U.S. Plans Non-U.S. Plans Postretirement Benefits 2021 2020 2019 2021 2020 2019 2021 2020 2019 Net Periodic Benefit Cost: Service cost $ .9 $ 1.2 $ 1.7 $ 4.3 $ 4.3 $ 4.0 $ — $ — $ .1 Interest cost 1.0 1.4 2.3 8.7 11.7 15.3 .3 .7 1.2 Expected return on plan assets (2.0) (2.6) (3.4) (16.0) (16.0) (31.0) — — — Amortization of prior service credit — — — — (.1) — (4.5) (.2) (.2) Amortization of net actuarial losses 2.4 2.9 2.8 7.5 6.3 4.9 .7 — — Amortization of transition obligation — — — — — — — — — Settlements/curtailments 1.0 2.6 3.0 .1 .1 (.6) — — — Special termination benefits — — — — — — 3.0 (4.2) — Other — — — — — — — — — Net periodic benefit cost $ 3.3 $ 5.5 $ 6.4 $ 4.6 $ 6.3 $ (7.4) $ (.5) $ (3.7) $ 1.1 Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive (Loss) Income: Actuarial losses (gains) $ (1.4) $ .8 $ (3.0) $ (68.1) $ 15.9 $ 13.1 $ (.4) $ 1.5 $ 2.5 Prior service cost (credit) — — — — — — 4.5 (4.1) (1.3) Amortization of prior service credit — — — — — — — .2 .2 Amortization of net actuarial losses (3.4) (5.5) (5.7) (7.6) (6.4) (4.6) (.7) (1.6) — Foreign currency changes — — — (5.9) 11.6 1.7 — — — Total recognized in other comprehensive loss* $ (4.8) $ (4.7) $ (8.7) $ (81.6) $ 21.1 $ 10.2 $ 3.4 $ (4.0) $ 1.4 Total recognized in net periodic benefit cost and other comprehensive loss $ (1.5) $ .8 $ (2.3) $ (77.0) $ 27.4 $ 2.8 $ 2.9 $ (7.7) $ 2.5 * Amounts represent the pre-tax effect classified within other comprehensive loss. The net of tax amounts are classified within our Consolidated Statements of Comprehensive Loss.
Weighted-Average Assumptions Used to Determine Benefit Obligations	Weighted-average assumptions used to determine benefit obligations recorded in our Consolidated Balance Sheets as of December 31 were as follows: Pension Benefits Postretirement U.S. Plans Non-U.S. Plans Benefits 2021 2020 2021 2020 2021 2020 Discount rate 2.81 % 2.43 % 2.09 % 1.45 % 3.61 % 3.95 % Rate of compensation increase 4.00 % 4.00 % 2.56 % 2.51 % N/A N/A Interest crediting rate 1.78 % 1.62 % 2.75 % 2.68 % N/A N/A
Weighted-Average Assumptions Used to Determine Net Benefit Cost	Weighted-average assumptions used to determine net benefit cost recorded in our Consolidated Statements of Operations for the years ended December 31 were as follows: Pension Benefits U.S. Plans Non-U.S. Plans Postretirement Benefits 2021 2020 2019 2021 2020 2019 2021 2020 2019 Discount rate 2.42 % 3.16 % 4.24 % 1.45 % 2.05 % 2.92 % 3.95 % 3.66 % 5.17 % Rate of compensation increase 4.00 % 4.00 % 4.00 % 2.51 % 2.54 % 2.69 % N/A N/A N/A Rate of return on assets 4.15 % 4.90 % 5.50 % 2.32 % 2.55 % 5.27 % N/A N/A N/A Interest crediting rate 1.49 % 2.49 % 3.36 % 2.74 % 2.69 % 2.69 % N/A N/A N/A
Pension and Postretirement Plans Target and Weighted-Average Asset Allocations	Our U.S. and non-U.S. funded defined benefit pension plans target and weighted-average asset allocations at December 31, 2021 and 2020, by asset category were as follows: U.S. Pension Plan Non-U.S. Pension Plans % of Plan Assets % of Plan Assets Target at Year-End Target at Year-End Asset Category 2022 2021 2020 2022 2021 2020 Equity securities 30 % 30 % 31 % 23 % 23 % 21 % Debt securities 70 70 69 72 72 74 Other — — — 5 5 5 Total 100 % 100 % 100 % 100 % 100 % 100 %
Schedule Of Fair Value Hierarchy For Pension And Postretirement Assets	The following tables present the fair value hierarchy for pension assets measured at fair value on a recurring basis at December 31, 2021 : U.S. Pension Plan Asset Category Level 1 Level 2 Total Equity Securities: Domestic equity $ — $ 8.3 $ 8.3 International equity — 6.6 6.6 Emerging markets — 1.6 1.6 — 16.5 16.5 Fixed Income Securities: Corporate bonds — 21.6 21.6 Government securities — 8.8 8.8 Other — 7.3 7.3 — 37.7 37.7 Other Cash — .1 .1 — .1 .1 Total $ — $ 54.3 $ 54.3 Non-U.S. Pension Plans Asset Category Level 1 Level 2 Level 3 Total Equity Securities: Domestic equity $ — $ 29.4 $ — $ 29.4 International equity — 145.2 — 145.2 — 174.6 — 174.6 Fixed Income Securities: Corporate bonds — 257.6 — 257.6 Government securities — 256.9 — 256.9 Other — 36.5 — 36.5 — 551.0 — 551.0 Other Cash 34.3 — — 34.3 Derivatives — 2.2 — 2.2 Real estate — — 2.3 2.3 34.3 2.2 2.3 38.8 Total $ 34.3 $ 727.8 $ 2.3 $ 764.4 The following tables present the fair value hierarchy for pension assets measured at fair value on a recurring basis at December 31, 2020: U.S. Pension Plan Asset Category Level 1 Level 2 Total Equity Securities: Domestic equity $ — $ 9.3 $ 9.3 International equity — 7.5 7.5 Emerging markets — 1.9 1.9 — 18.7 18.7 Fixed Income Securities: Corporate bonds — 23.7 23.7 Government securities — 9.4 9.4 Other — 7.8 7.8 — 40.9 40.9 Total $ — $ 59.7 $ 59.7 Non-U.S. Pension Plans Asset Category Level 1 Level 2 Level 3 Total Equity Securities: Domestic equity $ — $ 26.0 $ — $ 26.0 International equity — 132.0 — 132.0 — 158.0 — 158.0 Fixed Income Securities: Corporate bonds — 32.4 — 32.4 Government securities — 497.4 — 497.4 Other — 37.3 — 37.3 — 567.1 — 567.1 Other: Cash 33.3 — — 33.3 Derivatives — 2.0 — 2.0 Real estate — — 1.6 1.6 33.3 2.0 1.6 36.9 Total $ 33.3 $ 727.1 $ 1.6 $ 762.0
Reconciliation of Beginning and Ending Balance For Our Level 3 Investments	A reconciliation of the beginning and ending balances for our Level 3 investments is provided in the table below: Amount Balance at January 1, 2020 $ 1.6 Balance at December 31, 2020 1.6 Actual return on plan assets held .7 Balance at December 31, 2021 2.3
Schedule of Expected Benefit Payments	Total benefit payments expected to be paid from the plans are as follows: Pension Benefits U.S. Plans Non-U.S. Plans Total Postretirement 2022 $ 5.7 $ 26.2 $ 31.9 $ 6.3 2023 4.8 26.8 31.6 .3 2024 5.0 27.9 32.9 .3 2025 4.1 28.0 32.1 .3 2026 3.9 27.7 31.6 .3 2027-2031 14.7 149.6 164.3 1.4
Schedule of Assets Held in Trust	The assets held in the trust are included in other assets and at December 31 consisted of the following: 2021 2020 Corporate-owned life insurance policies $ 24.6 $ 28.5 Cash and cash equivalents 5.8 5.2 Total $ 30.4 $ 33.7

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting, Measurement Disclosures [Abstract]
Schedule of Total Revenue	Total Revenue 2021 2020 2019 Avon International $ 1,724.6 $ 1,772.6 $ 2,234.3 Avon Latin America (1) 1,654.7 1,845.9 2,528.9 Total revenue from reportable segments (2) 3,379.3 3,618.5 4,763.2 Revenue from affiliates to Natura &Co 25.2 6.7 — Total revenue $ 3,404.5 $ 3,625.2 $ 4,763.2
Schedule of Operating Profit	Operating (Loss) Profit 2021 2020 2019 Segment Profit Avon International $ 49.9 $ 27.4 $ 170.9 Avon Latin America (1) (10.9) (39.1) 194.1 Total (loss) profit from reportable segments (3) 39.0 (11.7) 365.0 Unallocated global expenses (4) (27.0) (11.6) (35.8) Certain Brazil Indirect taxes (5) (1.7) 10.6 — CTI restructuring initiatives (68.7) (23.7) (139.3) Costs related to the Transaction (6) — (85.8) (64.3) Operating (loss) profit $ (58.4) $ (122.2) $ 125.6 (1) 2021 includes the impact of certain Brazil indirect taxes, which was recorded in product sales in the amount of approximately $21 in our Consolidated Income Statements. 2019 includes the impact of certain Brazil indirect taxes, which was recorded in product sales in the amount of approximately $68 in our Consolidated Income Statements. See Note 20 Supplemental Balance Sheet Information. (2) Total revenue from reportable segments also includes revenue from other business activities of $4.7, $14.5 and $18.1 for the years ended December 31, 2021, 2020 and 2019, respectively, allocated to Avon International and Avon Latin America segments. Other business activities include revenue from the sale of products to New Avon since the separation of the Company’s North America business into New Avon on March 1, 2016 and ongoing royalties from the licensing of our name and products. Previously reported amounts have been allocated to Avon International and Avon Latin America segments to conform to the current year presentation. (3) Total profit from reportable segments also includes profit from other business activities and central expenses allocated to Avon International and Avon Latin America segments. Other business activities of $1.5, $7.3, and $2.4 for the years ended December 31, 2021, 2020 and 2019, respectively, include profit from the sale of products to New Avon since the separation of the Company’s North America business into New Avon on March 1, 2016 and ongoing royalties from the licensing of our name and products. Central expenses of $206.7, $197.6, and $214.7 for the years ended December 31, 2021, 2020 and 2019, respectively, include corporate general and administrative expenses allocated to Avon International and Avon Latin America to the extent they support the operating activity of the segment. Previously reported amounts have been allocated to segments to conform to the current year presentation. (4) For the years ended December 31, 2021, 2020 and 2019, unallocated global expenses primarily include stewardship and other expenses not directly attributable to reportable segments. (5) The year ended December 31, 2021 includes the impact of certain Brazil taxes, which were recorded in selling, general and administrative expenses, net in the amounts of approximately $2 . The year ended December 31, 2020 includes the impact of certain Brazil indirect taxes, which were recorded in selling, general and administrative expenses, net in the amounts of approximately $11 . (6) For the year ended December 31, 2020, costs related to the Transaction primarily include professional fees of approximately $46, severance payments of approximately $25 and acceleration of share based compensation of approximately $10 relating to these terminations triggered by change in control provisions. For the year ended 31 December 2019, costs related to the Transaction primarily include professional fees and impairment losses on assets. Refer to Note 21, Merger with Natura Cosméticos S.A. for more information relating to the Natura transaction. (7) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, from the same date, the results of Avon Luxembourg are no longer included within Avon's consolidated results. The year ended December 31, 2021 includes the results of Avon Luxembourg for the period from January 1 to June 30, 2021. The years ended December 31, 2020 and 2019 include the results of Avon Luxembourg.
Schedule of Total Assets	Total Assets 2021 2020 2019 Avon International (1) $ 1,362.0 $ 1,364.4 $ 1,712.4 Avon Latin America (2) 945.8 1,199.9 1,373.9 Total assets $ 2,307.8 $ 2,564.3 $ 3,086.3 (1) Avon International includes assets of $420.7 at December 31, 2019, that were not previously allocated to our reportable segments. (2) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, balances at December 31, 2021 do not include the assets of Avon Luxembourg. Balances at December 31, 2020 and 2019 include the assets of Avon Luxembourg. Capital Expenditures 2021 2020 2019 Avon International (1) $ 53.3 $ 36.0 $ 39.6 Avon Latin America (2) 15.0 8.6 18.9 Total capital expenditures $ 68.3 $ 44.6 $ 58.5 (1) Avon International includes capital expenditures of $13.8 for the year ended December 31, 2019, that were not previously allocated to our reportable segments.
Schedule of Depreciation and Amortization	Depreciation and Amortization 2021 2020 2019 Avon International (1) $ 48.1 $ 49.5 $ 51.6 Avon Latin America (2) 24.7 32.3 41.3 Total depreciation and amortization $ 72.8 $ 81.8 $ 92.9 (1) Avon International includes depreciation and amortization of $19.9 for the year ended December 31, 2019 that was not previously allocated to our reportable segments. (2) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, from the same date, the results of Avon Luxembourg are no longer included within Avon's consolidated results. The year ended December 31, 2021 includes the results of Avon Luxembourg for the period from January 1 to June 30, 2021. The years ended December 31, 2020 and 2019 include the results of Avon Luxembourg.
Schedule of Total Revenue by Major Country	A major country is defined as one with total revenues greater than 10% of consolidated total revenues. 2021 2020 2019 Brazil $ 627.0 $ 729.9 $ 1,034.4 Mexico (1) 249.2 420.2 509.4 All other 2,528.3 2,475.1 3,219.4 Total $ 3,404.5 $ 3,625.2 $ 4,763.2 (1) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, from the same date, the results of Avon Luxembourg are no longer included within Avon's consolidated results. The year ended December 31, 2021 includes the results of Avon Luxembourg for the period from January 1 to June 30, 2021. The years ended December 31, 2020 and 2019 include the results of Avon Luxembourg.
Schedule of Long-Lived Assets by Major Country	Long-lived assets in Brazil, Poland and Mexico consist primarily of property, plant and equipment related to manufacturing and distribution facilities, long-lived assets in the U.S. consist primarily of property, plant and equipment, including our global research and development facility and right-of-use assets related to equipment. 2021 2020 2019 U.S. $ 122.7 $ 135.3 $ 149.4 Brazil 75.4 86.4 116.1 Poland 95.0 96.8 99.3 Mexico (1)(2) — 55.2 67.8 All other 183.9 220.8 137.6 Total $ 477.0 $ 594.5 $ 570.2 (1) Mexico's long-lived assets are greater than 10% of total long-lived assets in 2019 only (2) On July 1, 2021, the Company sold Avon Luxembourg, including our Mexican business, to a subsidiary of Natura &Co Holding. As a result, balances at December 31, 2021 do not include the assets of Avon Luxembourg. Balances at December 31, 2020 and 2019 include the assets of Avon Luxembourg. In the above table, long lived assets have been calculated by including property, plant and equipment, net and right-of-use assets which are difficult to move and are relatively illiquid. In 2019, our definition of long lived assets also included certain intangible assets and other long term receivables and excluded right-of use assets which resulted in the following disclosure in previous filings. 2019 Brazil $ 203.3 U.S. 120.8 Poland 86.3 All other 335.6 Total 746.0

Leases and Commitments (Tables)

Leases and Commitments (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Assets and Liabilities, Lessee	Classification 2021 2020 Assets Operating right-of-use assets Right-of-use asset $ 111.1 $ 153.1 Finance right-of-use assets Property, Plant and Equipment 2.2 2.4 Total right-of-use assets 113.3 155.5 Liabilities Current Operating lease liabilities Other accrued liabilities $ 37.1 $ 46.2 Finance lease liabilities Other accrued liabilities 1.2 1.1 Total current lease liabilities 38.3 47.3 Noncurrent Operating lease liabilities Long-term operating lease liability $ 87.5 $ 120.9 Finance lease liabilities Long-term debt 1.3 1.5 Total noncurrent lease liabilities $ 88.8 $ 122.4 Total lease liability $ 127.1 $ 169.7
Lease Cost	The table below shows the lease income and expenses recorded in the Consolidated Statement of Operations incurred during the years ended December 31: Lease Costs Classification 2021 2020 Operating lease cost (1) Selling, general and administrative expenses $ 51.7 $ 63.6 Finance lease cost Amortization of right-of-use assets Selling, general and administrative expenses 1.3 1.2 Interest on lease liabilities Interest Expense .2 .3 Short-term leases costs Selling, general and administrative expenses 11.0 2.3 Sublease income (2) Selling, general and administrative expenses (14.5) (15.3) Net lease cost $ 49.7 $ 52.1 (1) Includes variable lease costs which are immaterial. These are presented in selling, general and administrative expenses in our Consolidated Statements of Operations.
Operating Lease Maturity Analysis	The maturity analysis of the finance and operating lease liabilities is reflected below. This table also reflects the reconciliation of the undiscounted cash flows to the discounted finance and operating lease liabilities as recognized in the December 31, 2021 Consolidated Balance Sheet: Maturity of Lease Liabilities Operating Leases Finance Leases Total 2022 45.7 1.3 47.0 2023 36.3 .8 37.1 2024 26.7 .3 27.0 2025 22.0 .2 22.2 2026 12.2 .1 12.3 Thereafter 5.1 — 5.1 Total lease payments $ 148.0 $ 2.7 $ 150.7 Less: Interest 23.4 .2 23.6 Present value of lease liabilities $ 124.6 $ 2.5 $ 127.1
Finance Lease Maturity Analysis	The maturity analysis of the finance and operating lease liabilities is reflected below. This table also reflects the reconciliation of the undiscounted cash flows to the discounted finance and operating lease liabilities as recognized in the December 31, 2021 Consolidated Balance Sheet: Maturity of Lease Liabilities Operating Leases Finance Leases Total 2022 45.7 1.3 47.0 2023 36.3 .8 37.1 2024 26.7 .3 27.0 2025 22.0 .2 22.2 2026 12.2 .1 12.3 Thereafter 5.1 — 5.1 Total lease payments $ 148.0 $ 2.7 $ 150.7 Less: Interest 23.4 .2 23.6 Present value of lease liabilities $ 124.6 $ 2.5 $ 127.1
Lease Terms	As noted in our lease accounting policy (See Note 1, Description of the Business and Summary of Significant Accounting Policies), the Company uses the incremental borrowing rate as the lease discount rate. Lease Term and Discount Rate 2021 2020 Weighted-average remaining lease term (years) Operating leases 4.0 4.2 Finance leases 2.7 2.5 Weighted-average discount rate Operating leases 8.3 % 8.5 % Finance leases 9.6 % 10.5 %
Cash Flow Classification	The table below sets out the classification of lease payments in the Consolidated Statement of Cash Flows. The ROU assets obtained in exchange for new finance and operating lease liabilities represent the new operating and finance leases entered into during the years ended December 31. Other Information 2021 2020 Operating Cash Flows From Operating Leases $ 54.0 $ 63.7 Operating Cash Flows From Finance Leases .2 .3 Financing Cash Flows From Finance Leases 1.3 1.3 Cash Paid For Amounts Included In Measurement of Liabilities $ 55.5 $ 65.3 Right-of-use Assets Obtained In Exchange For New Finance Liabilities $ 1.4 $ .9 Right-of-use Assets Obtained In Exchange For New Operating Liabilities $ 8.8 $ 24.9
Purchase Obligations	Purchase obligations include commitments to purchase paper, inventory and other services. At December 31, 2021, our purchase obligations by due date were as follows: Year Purchase Obligations 2022 $ 159.2 2023 51.8 2024 21.9 2025 1.7 2026 1.7 Later years 1.9 Total $ 238.2

Restructuring Initiatives (Tabl

Restructuring Initiatives (Tables)	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The costs during the twelve months ended December 31, 2021, 2020 and 2019 consisted of the following: Year ended December 31, 2021 2020 2019 CTI recorded in operating profit - COGS Manufacturing asset write-offs $ — $ — $ 11.1 Inventory write-off — (1.8) 1.4 — (1.8) 12.5 CTI recorded in operating profit - SG&A Net charges for employee-related costs, including severance benefits 36.7 5.2 56.4 Implementation costs, primarily related to professional service fees 17.5 10.3 44.9 Dual running costs 1.1 3.1 9.1 Contract termination and other net costs 10.5 3.9 7.9 Impairment of other assets 1.0 .8 5.3 Accelerated depreciation .3 .4 1.3 Variable lease charges 1.6 1.8 1.9 Foreign Currency Translation Adjustment Write-offs — — .7 68.7 25.5 127.5 CTI recorded in operating profit 68.7 23.7 140.0 CTI recorded in other (income) expense Gain on sale of business / assets (9.9) (1.5) (23.3) Total CTI $ 58.8 $ 22.2 $ 116.7 Avon Integration $ 15.4 $ 16.1 $ — Open Up & Grow $ 44.0 $ 10.9 $ 106.6 Transformation Plan & Other $ (.6) $ (4.8) $ 9.4
Schedule of Restructuring Reserve	The liability balance included in other accrued liabilities in our Consolidated Balance Sheet for the restructuring actions associated with Open Up & Grow at December 31, 2021 is as follows: Employee-Related Costs Inventory/ Asset Write-offs Contract Terminations/Other Total Balance at December 31, 2019 $ 17.8 $ — $ 6.4 $ 24.2 2020 charges 2.7 .7 3.8 7.2 Adjustments (3.0) (1.8) — (4.8) Cash payments (7.8) — (7.4) (15.2) Non-cash write-offs — 1.1 — 1.1 Foreign exchange (.7) — — (.7) Balance at December 31, 2020 $ 9.0 $ — $ 2.8 $ 11.8 2021 charges 33.8 1.0 3.4 38.2 Adjustments (1.3) — — (1.3) Cash payments (26.8) — (5.0) (31.8) Non-cash write-offs — (1.0) — (1.0) Foreign exchange (.7) — — (.7) Balance at December 31, 2021 $ 14.0 $ — $ 1.2 $ 15.2
Schedule of Restructuring Charges Reportable	The following table presents the restructuring charges incurred to date, under the Avon Integration , Open Up & Grow and the Transformation Plan, along with the estimated charges expected to be incurred on approved initiatives under the plans: Employee- Related Costs Inventory/ Asset Write-offs Contract Foreign Currency Translation Adjustment Write-offs Total Avon Integration Charges incurred to-date $ 12.4 $ .2 $ 12.6 Estimated charges to be incurred on approved initiatives — — — — — Total expected charges on approved initiatives $ 12.4 $ — $ .2 $ — $ 12.6 Open Up & Grow Charges incurred to-date $ 115.8 $ 107.4 $ 15.9 $ (10.9) $ 228.2 Estimated charges to be incurred on approved initiatives $ .3 — — — $ .3 Total expected charges on approved initiatives $ 116.1 $ 107.4 $ 15.9 $ (10.9) $ 228.5 Transformation Plan Charges incurred to-date $ 122.7 $ 2.5 $ 40.9 $ 3.4 $ 169.5 Estimated charges to be incurred on approved initiatives — — — — — Total expected charges on approved initiatives $ 122.7 $ 2.5 $ 40.9 $ 3.4 $ 169.5 The charges, net of adjustments, of initiatives under the Open Up & Grow and the Transformation Plan, along with the estimated charges expected to be incurred on approved initiatives under the plans, by reportable segment are as follows: Avon International Avon LATAM Total Avon Integration 2020 6.2 4.6 $ 10.8 2021 (1.2) 3.0 $ 1.8 Charges incurred to-date 5.0 7.6 12.6 Estimated charges to be incurred on approved initiatives — — — Total expected charges on approved initiatives $ 5.0 $ 7.6 $ 12.6 Open Up & Grow 2018 52.8 64.3 $ 117.1 2019 34.7 36.9 71.6 2020 3.2 (.8) 2.4 2021 36.9 .2 37.1 Charges incurred to-date 127.6 100.6 228.2 Estimated charges to be incurred on approved initiatives .3 — .3 Total expected charges on approved initiatives $ 127.9 $ 100.6 $ 228.5

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill Avon International Avon LATAM Total Gross balance at December 31, 2020 $ 109.3 $ 63.2 $ 172.5 Accumulated impairments (89.3) — (89.3) Net balance at December 31, 2020 $ 20.0 $ 63.2 $ 83.2 Changes during the period ended December 31, 2021: Foreign exchange (2.4) (8.7) (11.1) Gross balance at December 31, 2021 $ 106.9 $ 54.5 $ 161.4 Accumulated impairments (89.3) — (89.3) Net balance at December 31, 2021 $ 17.6 $ 54.5 $ 72.1

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Components of Prepaid Expenses and Other	At December 31, 2021 and 2020, prepaid expenses and other included the following: Components of Prepaid expenses and other 2021 2020 Prepaid taxes and tax refunds receivable $ 84.0 $ 117.6 Receivables other than trade 27.8 34.9 Prepaid brochure costs, paper and other literature 8.3 12.0 Other 45.5 39.7 Prepaid expenses and other $ 165.6 $ 204.2
Components of Other Assets	At December 31, 2021 and 2020, other assets included the following: Components of Other assets 2021 2020 Capitalized software (Note 1) 74.9 76.0 Judicial deposits 47.2 50.9 Net overfunded pension plans (Note 13) 162.5 103.0 Long-term receivables including taxes 180.2 157.0 Trust assets associated with supplemental benefit plans (Note 13) 30.4 33.7 Other 14.2 17.9 Other assets $ 509.4 $ 438.5

Description of the Business a_3

Description of the Business and Summary of Significant Accounting Policies (Narrative) (Details) $ / shares in Units, $ in Millions

Jul. 01, 2021USD ($)

Jan. 31, 2020USD ($)$ / shares

Dec. 31, 2019$ / shares

Dec. 31, 2015USD ($)

Aug. 31, 2019USD ($)

Dec. 31, 2021USD ($)businessChannelsegmentregion

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Mar. 31, 2021USD ($)

May 31, 2020USD ($)

Apr. 30, 2019

Mar. 01, 2016

Mar. 31, 2013

Property, Plant and Equipment [Line Items]

Number of business channels | businessChannel

1

Number of regions where company has geographic operations | region

2

Dividend paid (in USD per share) | $ / shares

$ 0.016

Dividends declared (in USD per share) | $ / shares

$ 0.016

Payments of dividends

$ 9

$ 0

$ 8.6

$ 0

Net proceeds from sale of business / assets

$ 23.4

16.9

11.3

99.9

Gain on sale of business

$ 148

148.4

Foreign exchange (gains) losses

$ (5.2)

(5.1)

(51.5)

Number of reportable segments | segment

2

Prepaid expenses and other

$ 165.6

204.2

Brochure costs

93.9

Brochure income

49.3

66.8

96.9

Capitalized software

74.9

76

Amortization of capitalized software

22.4

24.5

24.7

Shipping and handling costs

2,001.4

2,152.9

2,627.5

Advertising costs

67.8

59.9

72.9

Research and development costs

$ 39.3

36.5

40.6

Amortization period for gains and losses, period 1

3 years

Amortization period for gains and losses, period 2

5 years

Minimum

Property, Plant and Equipment [Line Items]

Prepaid brochures, campaign period

21 days

Number of years used in calculating the estimated fair value of reporting units

5 years

Maximum

Property, Plant and Equipment [Line Items]

Prepaid brochures, campaign period

28 days

Number of years used in calculating the estimated fair value of reporting units

10 years

5.00% Notes, due March 2023

Property, Plant and Equipment [Line Items]

Notes

$ 461

Interest rate, stated percentage

5.00%

Natura Revolving Facility

Property, Plant and Equipment [Line Items]

Amount repaid

150

Maximum borrowing capacity

$ 250

$ 100

Revision of Prior Period, Reclassification, Adjustment

Property, Plant and Equipment [Line Items]

Foreign exchange (gains) losses

37.4

Settlement of derivative operations

37.4

New Avon

Property, Plant and Equipment [Line Items]

Ownership

19.90%

19.90%

Deferred Brochure Costs

Property, Plant and Equipment [Line Items]

Prepaid expenses and other

4

6.7

Cost of Sales

Property, Plant and Equipment [Line Items]

Brochure costs

54.8

75.8

101.1

Selling, General and Administrative Expenses

Property, Plant and Equipment [Line Items]

Brochure costs

72.6

77.1

Shipping and Handling

Property, Plant and Equipment [Line Items]

Shipping and handling costs

$ 339.4

373.1

$ 432.1

Buildings

Property, Plant and Equipment [Line Items]

Estimated useful lives

45 years

Land Improvements

Property, Plant and Equipment [Line Items]

Estimated useful lives

20 years

Machinery and Equipment

Property, Plant and Equipment [Line Items]

Estimated useful lives

15 years

Office Equipment | Minimum

Property, Plant and Equipment [Line Items]

Estimated useful lives

5 years

Office Equipment | Maximum

Property, Plant and Equipment [Line Items]

Estimated useful lives

10 years

Deferred Brochure Costs

Property, Plant and Equipment [Line Items]

Inventory

$ 4.1

$ 7.6

North America Segment | Discontinued Operations

Property, Plant and Equipment [Line Items]

Cash contribution into privately-held company

$ 100

Percentage of ownership after transaction

20.00%

Avon Luxembourg Holdings

Property, Plant and Equipment [Line Items]

Net proceeds from sale of business / assets

$ 150

Affiliated Entity

Property, Plant and Equipment [Line Items]

Sale of convertible preferred stock

$ 435

New Accounting Standards (Narra

New Accounting Standards (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2021	[1]	Dec. 31, 2020	[1]	Dec. 31, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Shareholders' deficit	$ 854.7		$ 867.2		$ 983.8	$ 896.8
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Shareholders' deficit	$ 404.2		$ 360.5		(2,138.9)	$ (2,234.3)
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Shareholders' deficit					2
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Shareholders' deficit					2
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings | Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Shareholders' deficit					$ 2
[1]	The number of shares of Common Stock (par value $0.01 per share) outstanding at December 31, 2021 and 2020 was 101.34.

Discontinued Operations and A_3

Discontinued Operations and Assets and Liabilities Held for Sale (Narrative) (Details)

Dec. 23, 2021USD ($)

Nov. 17, 2021USD ($)

Jul. 01, 2021USD ($)

Jun. 26, 2019USD ($)

May 09, 2019USD ($)

Feb. 15, 2019USD ($)

Sep. 30, 2021USD ($)

Jun. 30, 2021USD ($)

Aug. 31, 2020USD ($)

Jun. 30, 2020USD ($)

Apr. 30, 2020USD ($)

Mar. 31, 2020USD ($)

Aug. 31, 2019USD ($)

Dec. 31, 2021USD ($)property

Sep. 30, 2021USD ($)

Jun. 30, 2021USD ($)

Sep. 30, 2020USD ($)

Jun. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Jun. 30, 2019USD ($)

Mar. 31, 2019USD ($)

Aug. 31, 2019USD ($)

Jun. 30, 2020USD ($)

Dec. 31, 2021USD ($)property

Dec. 31, 2020USD ($)businessproperty

Dec. 31, 2019USD ($)

Mar. 31, 2021USD ($)

May 31, 2020USD ($)

Aug. 14, 2019USD ($)

Apr. 30, 2019

Mar. 01, 2016

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 26,800,000

$ 9,900,000

$ 1,500,000

$ 50,100,000

Net proceeds from sale of business / assets

$ 23,400,000

16,900,000

11,300,000

99,900,000

Gain on sale of business

$ 148,000,000

148,400,000

Restricted cash

$ 0

0

7,800,000

2,900,000

AOCI, Gain on sale of business/asset

$ 3,400,000

$ 0

$ 0

(3,400,000)

Natura Revolving Facility

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Amount repaid

150,000,000

Maximum borrowing capacity

$ 250,000,000

$ 100,000,000

Avon International

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Number of properties held for sale | property

1

Number of businesses held for sale | business

1

Avon LATAM

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Number of properties held for sale | property

1

1

1

Avon Beauty Arabia

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Write-off of loan balance

$ 3,900,000

Gain on sale of business

$ 1,100,000

Cosmetics Manufacturing Operations In India

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 1,100,000

Net proceeds from sale of business / assets

$ 2,900,000

Avon Luxembourg Holdings

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Net proceeds from sale of business / assets

$ 150,000,000

Spanish Distribution Center

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 8,300,000

Net proceeds from sale of business / assets

$ 14,700,000

Gain on sale

$ 6,200,000

Italy Branch

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 1,400,000

Net proceeds from sale of business / assets

$ 1,700,000

Avon Shanghai

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 1,400,000

Net proceeds from sale of business / assets

2,900,000

Hungary Distribution Center in Gödöllő

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 100,000

Net proceeds from sale of business / assets

$ 3,100,000

$ 3,400,000

Deposit

$ 300,000

China Wellness Plant

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 1,400,000

Net proceeds from sale of business / assets

$ 6,600,000

$ 6,600,000

Restricted cash

$ 3,300,000

$ 3,300,000

$ 3,300,000

$ 3,300,000

Rye Office

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 9,900,000

Net proceeds from sale of business / assets

$ 22,400,000

Selling price

23,200,000

Disposal costs

$ 800,000

Malaysia Maximin

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

3,300,000

Net proceeds from sale of business / assets

$ 7,600,000

Gain on sale

$ 3,000,000

Consideration transferred

$ 7,800,000

New Avon

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Ownership

19.90%

19.90%

Consideration transferred

$ 24,500,000

Transaction costs

$ 1,100,000

Investment in New Avon

0

$ 0

Avon Beauty Arabia

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Ownership

51.00%

Avon Manufacturing (Guangzhou), Ltd.

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain on sale of business

$ 10,300,000

Net proceeds from sale of business / assets

$ 46,400,000

Gain on sale

$ 8,200,000

Restricted cash

$ 7,600,000

Avon Manufacturing (Guangzhou), Ltd. | TheFaceShop Co., LTd.

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Net proceeds from sale of business / assets

71,000,000

Disposal costs

1,100,000

Cash payment for outstanding loans

$ 23,500,000

Discontinued Operations and A_4

Discontinued Operations and Assets and Liabilities Held for Sale (Financial Components of Discontinued Operations) (Details) - Discontinued Operations - North America Segment - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Selling, general and administrative expenses	$ (18.5)	$ (27.9)	$ (36.6)
Operating loss	(18.5)	(27.9)	(36.6)
Loss from discontinued operations, net of tax	$ (18.5)	$ (27.9)	$ (36.6)

Discontinued Operations and A_5

Discontinued Operations and Assets and Liabilities Held for Sale (Assets and Liabilities Held For Sale) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Held for sale cash and cash equivalents	$ 0	$ 0.7	$ 0
Held-for-sale
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Inventories	0	2.6
Property, Plant & Equipment (net)	2.8	9.2
Held for sale cash and cash equivalents	0	0.7
Other assets	0	1.4
Held for sale assets	2.8	13.9
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Accounts payable	0	0.5
Other liabilities	0	1.8
Held for sale liabilities	$ 0	$ 2.3

Related Party Transactions (Det

Related Party Transactions (Details) R$ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2018BRL (R$)installment	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2021USD ($)
Related Party Transaction [Line Items]
Revenue from affiliates of Natura &Co		$ 25,200,000	$ 6,700,000	$ 0
Cost of sales from affiliates of Natura &Co		(22,400,000)	(5,900,000)	0
Interest expense on Loan from affiliates of Natura &Co		(50,600,000)	(7,500,000)	0
Loans to affiliates of Natura &Co maturing within one year		46,600,000	0
Loans to affiliates of Natura &Co maturing after one year		46,700,000	0
Other payables due to affiliates of Natura &Co		(4,900,000)	0
Loans from affiliates of Natura &Co maturing within one year		(1,108,000,000)
Loans from affiliates of Natura &Co maturing after one year		(736,300,000)	0
Debt outstanding				$ 0
Loans from affiliates of Natura &Co		371,700,000	1,008,600,000
Natura &Co Pay Holding Financeira S.A. | Avon Cosmeticos LTDA
Related Party Transaction [Line Items]
Ownership					10.00%
Natura Promissory Note
Related Party Transaction [Line Items]
Debt outstanding		736,300,000	965,000,000
Natura And Affiliate Promissory Note
Related Party Transaction [Line Items]
Debt outstanding		207,300,000
Natura Revolving Facility
Related Party Transaction [Line Items]
Debt outstanding			41,600,000
Licensing Agreements
Related Party Transaction [Line Items]
Gross profit from affiliates of Natura &Co		1,000,000
Natura & Co
Related Party Transaction [Line Items]
Interest income from related parties		1,600,000	0
Interest expense on Loan from affiliates of Natura &Co		(50,600,000)	(7,500,000)
Receivables due from related parties		32,700,000	6,100,000
Other receivables due from affiliates of Natura &Co		1,400,000	0
Loans to affiliates of Natura &Co maturing within one year		46,600,000	0
Trade Payables due to affiliates of Natura &Co		(24,500,000)	0
Loans from affiliates of Natura &Co maturing within one year		(371,700,000)	(1,008,600,000)
Loans from affiliates of Natura &Co maturing after one year		(736,300,000)	0
Investments in affiliates of Natura &Co		100,000	0		$ 500,000
Loans from affiliates of Natura &Co		164,400,000
Natura & Co | Manufacturing and Supply Agreement
Related Party Transaction [Line Items]
Revenue from affiliates of Natura &Co		25,200,000	6,700,000
Cost of sales from affiliates of Natura &Co		(22,400,000)	(5,900,000)
Gross profit from affiliates of Natura &Co		2,800,000	800,000
Natura & Co | Licensing Agreements
Related Party Transaction [Line Items]
Revenue from affiliates of Natura &Co		1,000,000
Instituto Avon
Related Party Transaction [Line Items]
Interest income from related parties		0	100,000
Receivables due from related parties		$ 0	$ 800,000
Affiliated Entity | Loan To Related Party | Instituto Avon
Related Party Transaction [Line Items]
Loan amount | R$	R$ 12
Loan term	5 years
Loan interest rate	7.00%
Loan annual installments | installment	5

Revenue (Disaggregation of Reve

Revenue (Disaggregation of Revenue) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 3,202.9	$ 3,431.2	$ 4,494.1
Other	27.4	18.9	24.9
Total Revenues	3,404.5	3,625.2	4,763.2
Revenue from affiliates of Natura &Co	25.2	6.7	0
Total Beauty
Disaggregation of Revenue [Line Items]
Net sales	2,353.3	2,546.3	3,337.6
Skincare
Disaggregation of Revenue [Line Items]
Net sales	1,043.4	1,110.6	1,371.4
Fragrance
Disaggregation of Revenue [Line Items]
Net sales	890	972.4	1,244.6
Color
Disaggregation of Revenue [Line Items]
Net sales	419.9	463.3	721.6
Total Fashion & Home
Disaggregation of Revenue [Line Items]
Net sales	828.1	884.9	1,088.8
Fashion
Disaggregation of Revenue [Line Items]
Net sales	418.1	459.9	618.8
Home
Disaggregation of Revenue [Line Items]
Net sales	410	425	470
Certain Brazil taxes
Disaggregation of Revenue [Line Items]
Net sales	21.5		67.7
Total Revenues	21		68
Net sales
Disaggregation of Revenue [Line Items]
Net sales	3,202.9	3,431.2	4,494.1
Representative fees
Disaggregation of Revenue [Line Items]
Representative fees	174.2	175.1	244.2
Other revenue
Disaggregation of Revenue [Line Items]
Other revenue	201.6	194	269.1
Operating Segments
Disaggregation of Revenue [Line Items]
Other	2.2	12.2
Total Revenues	3,379.3	3,618.5	4,763.2
Operating Segments | Total Beauty
Disaggregation of Revenue [Line Items]
Net sales	2,353.3	2,546.3
Operating Segments | Skincare
Disaggregation of Revenue [Line Items]
Net sales	1,043.4	1,110.6
Operating Segments | Fragrance
Disaggregation of Revenue [Line Items]
Net sales	890	972.4
Operating Segments | Color
Disaggregation of Revenue [Line Items]
Net sales	419.9	463.3
Operating Segments | Total Fashion & Home
Disaggregation of Revenue [Line Items]
Net sales	828.1	884.9
Operating Segments | Fashion
Disaggregation of Revenue [Line Items]
Net sales	418.1	459.9
Operating Segments | Home
Disaggregation of Revenue [Line Items]
Net sales	410	425
Operating Segments | Certain Brazil taxes
Disaggregation of Revenue [Line Items]
Net sales	21.5
Operating Segments | Net sales
Disaggregation of Revenue [Line Items]
Net sales	3,202.9	3,431.2
Operating Segments | Representative fees
Disaggregation of Revenue [Line Items]
Representative fees	174.2	175.1
Operating Segments | Other revenue
Disaggregation of Revenue [Line Items]
Other revenue	176.4	187.3
Other reconciling items
Disaggregation of Revenue [Line Items]
Other	25.2	6.7
Total Revenues	25.2	6.7	0
Revenue from affiliates of Natura &Co	25.2	6.7
Other reconciling items | Other revenue
Disaggregation of Revenue [Line Items]
Other revenue	25.2	6.7
Avon International | Operating Segments
Disaggregation of Revenue [Line Items]
Other	0.5	6.4	4.3
Total Revenues	1,724.6	1,772.6	2,234.3
Avon International | Operating Segments | Total Beauty
Disaggregation of Revenue [Line Items]
Net sales	1,329.8	1,376.5	1,693
Avon International | Operating Segments | Skincare
Disaggregation of Revenue [Line Items]
Net sales	577.6	594.7	671.5
Avon International | Operating Segments | Fragrance
Disaggregation of Revenue [Line Items]
Net sales	514.2	516	639.9
Avon International | Operating Segments | Color
Disaggregation of Revenue [Line Items]
Net sales	238	265.8	381.6
Avon International | Operating Segments | Total Fashion & Home
Disaggregation of Revenue [Line Items]
Net sales	327.9	323	445.5
Avon International | Operating Segments | Fashion
Disaggregation of Revenue [Line Items]
Net sales	258.3	267.4	383.8
Avon International | Operating Segments | Home
Disaggregation of Revenue [Line Items]
Net sales	69.6	55.6	61.7
Avon International | Operating Segments | Certain Brazil taxes
Disaggregation of Revenue [Line Items]
Net sales	0		0
Avon International | Operating Segments | Net sales
Disaggregation of Revenue [Line Items]
Net sales	1,657.7	1,699.5	2,138.5
Avon International | Operating Segments | Representative fees
Disaggregation of Revenue [Line Items]
Representative fees	66.4	66.7	91.5
Avon International | Operating Segments | Other revenue
Disaggregation of Revenue [Line Items]
Other revenue	66.9	73.1	95.8
Avon LATAM | Operating Segments
Disaggregation of Revenue [Line Items]
Other	1.7	5.8	20.6
Total Revenues	1,654.7	1,845.9	2,528.9
Avon LATAM | Operating Segments | Total Beauty
Disaggregation of Revenue [Line Items]
Net sales	1,023.5	1,169.8	1,644.6
Avon LATAM | Operating Segments | Skincare
Disaggregation of Revenue [Line Items]
Net sales	465.8	515.9	699.9
Avon LATAM | Operating Segments | Fragrance
Disaggregation of Revenue [Line Items]
Net sales	375.8	456.4	604.7
Avon LATAM | Operating Segments | Color
Disaggregation of Revenue [Line Items]
Net sales	181.9	197.5	340
Avon LATAM | Operating Segments | Total Fashion & Home
Disaggregation of Revenue [Line Items]
Net sales	500.2	561.9	643.3
Avon LATAM | Operating Segments | Fashion
Disaggregation of Revenue [Line Items]
Net sales	159.8	192.5	235
Avon LATAM | Operating Segments | Home
Disaggregation of Revenue [Line Items]
Net sales	340.4	369.4	408.3
Avon LATAM | Operating Segments | Certain Brazil taxes
Disaggregation of Revenue [Line Items]
Net sales	21.5		67.7
Avon LATAM | Operating Segments | Net sales
Disaggregation of Revenue [Line Items]
Net sales	1,545.2	1,731.7	2,355.6
Avon LATAM | Operating Segments | Representative fees
Disaggregation of Revenue [Line Items]
Representative fees	107.8	108.4	152.7
Avon LATAM | Operating Segments | Other revenue
Disaggregation of Revenue [Line Items]
Other revenue	$ 109.5	$ 114.2	$ 173.3

Revenue (Summary of Receivables

Revenue (Summary of Receivables and Contract Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Accounts receivable, net of allowances of $37.1 and $51.1	$ 198.7	$ 259.1
Contract liabilities	37.1	52.1
Allowances	$ 37.1	$ 51.1

Revenue (Details)

Revenue (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Revenue recognized related to contract liability	$ 39.5
Deferred revenue related to contract liability	$ 29.9

Inventories (Components of Inve

Inventories (Components of Inventories) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Inventory, Net [Abstract]
Raw materials	$ 103.4	$ 131.3
Finished goods	280.7	327.8
Total	$ 384.1	$ 459.1

Debt and Other Financing (Debt)

Debt and Other Financing (Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Jul. 31, 2019	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2013
Debt maturing within one year:
Short term debt	$ 32.6	$ 28
Loans from affiliates of Natura &Co	371.7	1,008.6
Total	404.3	1,036.6
Long-term debt:
Finance lease liabilities	1.3	1.5
Loans from affiliates of Natura &Co, due 2028	736.3	0
Total	1,412.3	675.4
5.00% Notes, due March 2023
Long-term debt:
Notes	$ 460.8	460.1
Interest rate, stated percentage	5.00%				5.00%	5.00%	5.00%	5.00%
6.95% Notes, due March 2043
Long-term debt:
Notes	$ 213.9	$ 213.8
Interest rate, stated percentage	6.95%		6.95%	6.95%		6.95%		6.95%

Debt and Other Financing (Narra

Debt and Other Financing (Narrative) (Details) - USD ($)	1 Months Ended						3 Months Ended						12 Months Ended
	Nov. 30, 2020	Sep. 30, 2020	Dec. 31, 2019	Jul. 31, 2019	Jun. 30, 2018	Aug. 31, 2016	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2013	Mar. 31, 2008
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt							$ (25,600,000)						$ 0	$ (37,700,000)	$ (11,600,000)
Write off of debt issuance cost							7,900,000
Loss on debt extinguishment							17,700,000
Senior notes							0						0	0
Loans from affiliates of Natura &Co maturing within one year							1,008,600,000						371,700,000	1,008,600,000
Loans from affiliates of Natura &Co maturing after one year							0						736,300,000	0
Loans Payable
Debt Instrument [Line Items]
Short-term debt, interest rate	7.70%
Natura & Co
Debt Instrument [Line Items]
Loans from affiliates of Natura &Co maturing within one year													164,400,000
Loans from affiliates of Natura &Co maturing after one year							0						$ 736,300,000	0
Fourth Quarter 2018 Repurchase
Debt Instrument [Line Items]
Payments for debt extinguishment accrued interest											$ 700,000
Gain (loss) on extinguishment of debt											2,100,000
Write off of debt issuance cost											300,000
Debt repurchase discount received											2,400,000
4.60% Notes, due March 2020
Debt Instrument [Line Items]
Principal amount of debt				$ 274,800,000														$ 500,000,000
Interest rate, stated percentage			4.60%	4.60%					4.60%						4.60%	4.60%	4.60%	4.60%
Repayments of debt						$ 50,100,000
Repurchase amount				$ 274,800,000							23,000,000					$ 40,000,000
Repayments of long-term debt			$ 112,200,000
Payments for debt extinguishment accrued interest			1,700,000
Gain (loss) on extinguishment of debt									$ (1,500,000)	$ (8,100,000)
Debt repurchase discount received				600,000
Debt repurchase, premium paid				8,200,000
Accrued interest paid on extinguishment of debt				$ 5,400,000
Make whole premium			$ 1,400,000						$ 1,400,000						$ 1,400,000
5.00% Notes, due March 2023
Debt Instrument [Line Items]
Principal amount of debt																		$ 500,000,000
Interest rate, stated percentage				5.00%									5.00%			5.00%	5.00%	5.00%
Repurchase amount											$ 27,000,000					$ 11,100,000
6.95% Notes, due March 2043
Debt Instrument [Line Items]
Principal amount of debt																		$ 250,000,000
Interest rate, stated percentage		6.95%						6.95%		6.95%			6.95%			6.95%		6.95%
Repurchase amount		$ 27,800,000						$ 27,800,000								$ 6,200,000
Gain (loss) on extinguishment of debt								(4,100,000)
Write off of debt issuance cost		300,000
Make whole premium		3,800,000						$ 3,800,000
Accrued interest		$ 1,200,000
6.50% Notes, due March 2019
Debt Instrument [Line Items]
Principal amount of debt																			$ 350,000,000
Interest rate, stated percentage				6.50%	6.50%							6.50%				6.50%			6.50%
Repayments of debt						68,100,000
Repurchase amount																$ 44,000,000
Repayments of long-term debt					$ 237,800,000
Payment for debt extinguishment or debt prepayment cost					6,200,000							$ 6,200,000
Payments for debt extinguishment accrued interest					$ 4,600,000
Gain (loss) on extinguishment of debt												(2,900,000)
Write off of debt issuance cost												300,000
2013 Notes
Debt Instrument [Line Items]
Increase in interest rate for every one-notch downgrade of long-term credit ratings below investment grade													0.25%
Maximum aggregate increase in interest rate related to downgrade of long-term credit ratings below investment grade													2.00%
7.875% Senior Secured Notes Due August 2022
Debt Instrument [Line Items]
Principal amount of debt						$ 500,000,000
Interest rate, stated percentage						7.875%
Repayment of principal	$ 500,000,000
Payment of premium	9,800,000
Payment of accrued interest	8,400,000
6.50% Senior Secured Notes, Due August 2022
Debt Instrument [Line Items]
Principal amount of debt				$ 400,000,000
Repayment of principal	400,000,000
Payment of premium	7,900,000
Payment of accrued interest	$ 5,600,000
Unsecured Notes
Debt Instrument [Line Items]
Accrued interest							$ 15,200,000						$ 14,700,000	$ 15,200,000
Interest Rate Swap | 6.50% Notes, due March 2019
Debt Instrument [Line Items]
Deferred gain on termination of contract												$ 3,600,000

Debt and Other Financing (Sched

Debt and Other Financing (Schedule of Public Notes) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
5.00% Notes, due March 2023
Debt Instrument [Line Items]
Remaining Principal	$ 461.9	$ 461.9
Unamortized Discounts	(0.5)	(1)
Unamortized Debt Issuance Costs	(0.6)	(0.8)
Total	460.8	460.1
6.95% Notes, due March 2043
Debt Instrument [Line Items]
Remaining Principal	216.1	216.1
Unamortized Discounts	(1.7)	(0.5)
Unamortized Debt Issuance Costs	(0.5)	(1.8)
Total	$ 213.9	$ 213.8

Debt and Other Financing (Matur

Debt and Other Financing (Maturities of Long-Term Debt) (Details) $ in Millions	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 0
2023	462.7
2024	0.3
2025	0.2
2026	0.1
2027 and Beyond	952.4
Total	$ 1,415.7

Debt and Other Financing (Other

Debt and Other Financing (Other Financing) (Details)	Jan. 03, 2020USD ($)	Feb. 28, 2019EUR (€)	Jun. 30, 2015USD ($)	Dec. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Nov. 30, 2020USD ($)	May 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Loans from affiliates of Natura &Co maturing within one year				$ 1,008,600,000		$ 371,700,000
Loans from affiliates of Natura &Co				0		736,300,000
Short term debt				28,000,000		32,600,000
Write off of debt issuance cost				7,900,000
Amount outstanding under the revolving credit facility										$ 0
Letters of credit outstanding				16,900,000		11,300,000
Natura Revolving Facility Due May 2022
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 250,000,000		$ 100,000,000
Amount outstanding under the revolving credit facility				$ 41,600,000
3.13% related party loan
Debt Instrument [Line Items]
Loans from affiliates of Natura &Co maturing within one year						207,000,000		$ 960,000,000
Interest rate, stated percentage								3.13%
Loans from affiliates of Natura &Co						$ 736,000,000
2015 Facility
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 400,000,000
Debt instrument term			5 years
Write off of debt issuance cost	$ 7,800,000				$ 2,000,000
2019 Facility
Debt Instrument [Line Items]
Maximum borrowing capacity | €		€ 200,000,000
Debt instrument term		3 years
4.60% Notes, due February 2022
Debt Instrument [Line Items]
Debt issuance costs					$ 11,000,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Components of Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income, beginning balance		$ (871.5)
Other comprehensive income (loss) other than reclassifications		43.2	$ (102.6)
Sale of New Avon	$ 3.4	0	0	$ (3.4)
Derivative gains on cash flow hedges, net of tax of $0			0.6
Amortization of net actuarial loss and prior service cost, net of tax		5.1	8.2
Total reclassifications into earnings		5.1	8.8
Accumulated other comprehensive income, ending balance		(858.5)	(871.5)
Derivative gains on cash flow hedges, tax			0
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income, beginning balance		(1,133.8)	(1,040)
Accumulated other comprehensive income, ending balance		(1,085.5)	(1,133.8)	(1,040)
Foreign Currency Translation Adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income, beginning balance		(1,038.2)	(942.7)
Other comprehensive income (loss) other than reclassifications		(24.1)	(95.5)
Sale of New Avon		0.1
Derivative gains on cash flow hedges, net of tax of $0			0
Amortization of net actuarial loss and prior service cost, net of tax		0	0
Total reclassifications into earnings		0	0
Accumulated other comprehensive income, ending balance		(1,062.2)	(1,038.2)	(942.7)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income, beginning balance		0	(0.6)
Other comprehensive income (loss) other than reclassifications			0
Derivative gains on cash flow hedges, net of tax of $0			0.6
Amortization of net actuarial loss and prior service cost, net of tax			0
Total reclassifications into earnings			0.6
Accumulated other comprehensive income, ending balance			0	(0.6)
Net Investment Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income, beginning balance		(4.3)	(4.3)
Other comprehensive income (loss) other than reclassifications		0	0
Sale of New Avon
Derivative gains on cash flow hedges, net of tax of $0			0
Amortization of net actuarial loss and prior service cost, net of tax		0	0
Total reclassifications into earnings		0	0
Accumulated other comprehensive income, ending balance		(4.3)	(4.3)	(4.3)
Pension and Postretirement Benefits
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income, beginning balance		(91.3)	(92.4)
Other comprehensive income (loss) other than reclassifications		67.3	(7.1)
Sale of New Avon		(0.1)
Derivative gains on cash flow hedges, net of tax of $0			0
Amortization of net actuarial loss and prior service cost, net of tax		5.1	8.2
Total reclassifications into earnings		5.1	8.2
Accumulated other comprehensive income, ending balance		(19)	(91.3)	$ (92.4)
Amortization of net actuarial loss and prior service cost, tax		$ 0.8	$ 0.8

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Loss) (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign exchange gains (losses)	$ (5.3)	$ 8.8	$ 0.8

Income Taxes (Income from Conti

Income Taxes (Income from Continuing Operations before Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
United States	$ 19.3	$ (89.6)	$ (108.3)
Foreign	(178.1)	(214)	246.7
(Loss) Income from continuing operations, before taxes	$ (158.8)	$ (303.6)	$ 138.4

Income Taxes (Provision For Inc

Income Taxes (Provision For Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Federal:
Current	$ 0.2	$ (9.5)	$ (9)
Deferred	0	8.9	8.5
Total Federal	0.2	(0.6)	(0.5)
Foreign:
Current	35.5	31.4	79
Deferred	(20)	2.6	28.9
Total Foreign	15.5	34	107.9
State and Local:
Current	0.5	0.6	(4.3)
Deferred	0	0	0
Total State and other	0.5	0.6	(4.3)
Total	$ 16.2	$ 34	$ 103.1

Income Taxes (Effective Tax Rat

Income Taxes (Effective Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Statutory federal rate	21.00%	21.00%	21.00%
State and local taxes, net of federal tax benefit	(0.30%)	(0.20%)	(2.70%)
Tax on foreign income	67.10%	(1.80%)	62.10%
Tax on uncertain tax positions	3.70%	1.10%	16.60%
Reorganizations	0.00%	(10.00%)	185.60%
Net change in valuation allowances	(103.10%)	(21.40%)	(208.00%)
Other	1.40%	0.10%	(0.10%)
Effective tax rate	(10.20%)	(11.20%)	74.50%

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Tax Credit Carryforward [Line Items]
Change in estimate related to restructuring transactions		$ 30.5
One-time tax reserves			$ 256.9
Deferred tax assets with full valuation allowance	$ 1,638	635
Deferred tax asset, potential valuation allowance	67
Valuation allowance recorded against deferred tax assets	8
Deferred tax asset, valuation allowance, excluding de-valued deferred tax assets	126	2.6
Deferred tax assets, tax credit carryforwards, excluding adoption of ASU 2013-11	119.7
Tax credit carryforward, valuation allowance	119.7
Foreign tax credit carryforwards	87.6
Tax credit carryforwards, research	23.7
Tax credit carryforward	8.4
Deferred tax assets, net operating loss	393.7
Operating loss carryforwards, valuation allowance	322.4
Operating loss carryforwards subject to offset in accordance with ASU 2013--11	22.4
Tax loss and deduction carryforwards	425	1,997.5
Valuation allowance	815.4	2,327.6
Undistributed earnings of foreign subsidiaries	1,200
Decrease in deferred tax liability associated with undistributed earnings of foreign subsidiaries	7.9
Total gross unrecognized tax benefits	251.7	372.1	331.7	$ 137.6
Unrecognized tax benefits that would impact effective tax rate	95.8
Expense (reversal of expense) for interest and penalties	0.5	1	(1)
Accrued interest and penalties	7.1	6.8
Minimum
Tax Credit Carryforward [Line Items]
Increase in unrecognized tax benefits is reasonably possible	5
Maximum
Tax Credit Carryforward [Line Items]
Increase in unrecognized tax benefits is reasonably possible	10
United Kingdom Tax Authority
Tax Credit Carryforward [Line Items]
Foreign income tax benefit	89	21
Foreign
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	2,599
Deferred tax asset, not subject to expiration	1,059.2
Deferred tax assets, operating loss carryforwards, subject to expiration	1,539.8
Domestic
Tax Credit Carryforward [Line Items]
Tax loss and deduction carryforwards	31.4
Deferred tax asset, not subject to expiration	149.3
Deferred Tax Assets That Cannot Be Benefitted
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance	164	65.1
Deferred Tax Assets Generated In Current Year
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance	71	69.9
Deferred Tax Asset, Tax On Foreign Income
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance	89	21
Deferred Tax Assets, Change In Judgment
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance	4	4.7
Deferred Tax Assets, True-up Adjustment
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance		(30.5)
Deferred Tax Assets Utilization Of Foreign Tax Credits
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance			(232.5)
Deferred Tax Assets Tax Rate Change And Write Off
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance			$ (66.5)
Deferred Tax Asset Associated With Merger
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance		(81.8)
Deferred tax assets with full valuation allowance		465
Deferred Tax Asset Realization Remote
Tax Credit Carryforward [Line Items]
Deferred tax assets with full valuation allowance		170
Deferred Tax Asset Realization Remote | Foreign
Tax Credit Carryforward [Line Items]
Deferred tax assets with full valuation allowance		70
Deferred Tax Asset Realization Remote | State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Deferred tax assets with full valuation allowance		100
Deferred Tax Asset, Currency Translation And Other
Tax Credit Carryforward [Line Items]
Net increase (decrease) in valuation allowance		$ 19.4
Valuation Allowance, Federal Loss Carryforwards | Domestic
Tax Credit Carryforward [Line Items]
Valuation allowance	$ 31.4

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets (Liabilities) Resulting From Temporary Differences) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Tax loss and deduction carryforwards	$ 425	$ 1,997.5
Intangibles	218.5	188.3
Tax credit carryforwards	119.7	119
Interest carryforwards	76.3	48.3
All other future deductions	199.8	199.1
Valuation allowance	(815.4)	(2,327.6)
Total deferred tax assets	223.9	224.6
Deferred tax liabilities:
Total deferred tax liabilities	(105)	(90.8)
Net deferred tax assets	$ 118.9	$ 133.8

Income Taxes (Deferred Tax As_2

Income Taxes (Deferred Tax Assets (Liabilities) Classification) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Deferred tax asset	$ 121.4	$ 135.8
Deferred tax liabilities:
Long-term income taxes	(2.5)	(2)
Net deferred tax assets	118.9	133.8
Other Assets
Deferred tax assets:
Deferred tax asset	121.4	135.8
Long Term Income Taxes
Deferred tax liabilities:
Long-term income taxes	$ (2.5)	$ (2)

Income Taxes (Reconciliation Of

Income Taxes (Reconciliation Of Beginning And Ending Amount Of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 372.1	$ 331.7	$ 137.6
Additions based on tax positions related to the current year	6.8	90.6	13.3
Additions for tax positions of prior years	24.1	0.6	186.6
Reductions for tax positions of prior years	(136.8)	(34.1)	(3)
Reductions due to lapse of statute of limitations	(11.2)	(16.5)	(0.6)
Reductions due to settlements with tax authorities	(3.3)	(0.2)	(2.2)
Unrecognized tax benefits, ending balance	$ 251.7	$ 372.1	$ 331.7

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Derivative [Line Items]
Asset	$ 0	$ 2.8
Liability	2.7	6
Prepaid expenses and other | Derivatives not designated as hedges: | Foreign exchange forward contracts
Derivative [Line Items]
Asset	0	2.8
Accounts payable | Derivatives not designated as hedges: | Foreign exchange forward contracts
Derivative [Line Items]
Liability	$ 2.7	$ 6

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative [Line Items]
Total exposure to floating rate interest rates	5.00%	4.00%
Foreign Exchange Contract
Derivative [Line Items]
Notional amounts of derivative contracts	$ 171
Losses in other expense from undesignated foreign currency exchange contracts	$ 0.3	$ 5.7

Fair Value Assets and Liabiliti

Fair Value Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets:
Foreign exchange forward contracts	$ 0	$ 2.8
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange forward contracts	2.7	6
Fair Value
Assets:
Available-for-sale securities		4.2
Foreign exchange forward contracts		2.8
Total		7
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange forward contracts	2.7	6
Total	2.7	6
Fair Value | Level 1
Assets:
Available-for-sale securities		4.2
Foreign exchange forward contracts		0
Total		4.2
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange forward contracts	0	0
Total	0	0
Fair Value | Level 2
Assets:
Available-for-sale securities		0
Foreign exchange forward contracts		2.8
Total		2.8
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange forward contracts	2.7	6
Total	$ 2.7	$ 6

Fair Value (Fair Value of Finan

Fair Value (Fair Value of Financial Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans to affiliates of Natura &Co maturing within one year	$ 46.6	$ 0
Loans to affiliates of Natura &Co maturing after one year	46.7	0
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	4.2
Loans to affiliates of Natura &Co maturing within one year	46.6	0
Loans to affiliates of Natura &Co maturing after one year	46.7	0
Debt maturing within one year	(32.6)	(28)
Loans from affiliates of Natura &Co maturing within one year	(371.7)	(1,008.6)
Long-term debt	(676)	(675.4)
Loans from affiliates of Natura &Co maturing after one year	(736.3)	0
Carrying Amount | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts	(2.7)	(3.2)
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	4.2
Loans to affiliates of Natura &Co maturing within one year	46.6	0
Loans to affiliates of Natura &Co maturing after one year	46.7	0
Debt maturing within one year	(32.6)	(28)
Loans from affiliates of Natura &Co maturing within one year	(371.7)	(1,008.6)
Long-term debt	(754.2)	(782.4)
Loans from affiliates of Natura &Co maturing after one year	(736.3)	0
Fair Value | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts	$ (2.7)	$ (3.2)

Share-Based Compensation Plan_2

Share-Based Compensation Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions

Mar. 27, 2020

Jan. 03, 2020

Jan. 31, 2020

Dec. 31, 2019

May 31, 2019

Mar. 31, 2019

Mar. 31, 2018

Feb. 28, 2018

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-average grant-date fair value per share (in dollars per share)

$ 1.13

Outstanding stock options (in shares)

14,900,000

0

0

Cash settlement of options, recorded to equity

$ 20.5

Cash settlement of options, recorded to SG&A expenses

$ 3.5

Share modification and incremental fair value expense

$ 1.5

Accelerated costs

1.7

Compensation cost for share-based payments

0.5

$ 13.4

$ 24.9

$ 15.6

Merger Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exchange ratio

30.00%

Share modification and incremental fair value expense

$ 3.4

Accelerated costs

$ 10

$ 10

Transaction costs

$ 44

$ 44

Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Contractual term

10 years

10 years

Stock Options | 2019 Award Date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Options, grant date premium on exercise price

25.00%

Performance Restricted Stock Units (PRSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

3 years

Granted (in dollars per share)

$ 2.98

$ 2.79

Outstanding shares (in shares)

3,000,000

400,000

0

0

400,000

Granted (in shares)

200,000

200,000

Shares exchanged (in shares)

3,276,774

Vested (in shares)

0

Nonvested, ending balance (in shares)

3,000,000

400,000

0

0

400,000

Performance Restricted Stock Units (PRSUs) | 2019 Award Date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Granted (in dollars per share)

$ 2.63

Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Outstanding shares (in shares)

4,400,000

0

0

Shares exchanged (in shares)

2,083,872

Nonvested, ending balance (in shares)

4,400,000

0

0

Restricted Stock Units (RSUs) | Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

1 year

Performance Share Units (PSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Granted (in dollars per share)

$ 17.32

Outstanding shares (in shares)

1,854,000

1,543,000

Granted (in shares)

628,000

Unrecognized compensation cost

$ 27.5

Unrecognized compensation costs, recognized over a weighted average period

1 year 7 months 6 days

Nonvested, ending balance (in shares)

1,854,000

1,543,000

Restricted Stock Units - Treasury Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Granted (in dollars per share)

$ 2.25

Outstanding shares (in shares)

600,000

600,000

Granted (in shares)

600,000

Nonvested, ending balance (in shares)

600,000

600,000

Compensation cost for share-based payments

$ 0.4

Restricted Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Shares exchanged (in shares)

4,808,534

Shares cancelled to satisfy withholding tax obligations (in shares)

1,400,010

Restricted Stock | Merger Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Outstanding awards converted (in shares)

3,408,524

Nominal Cost Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Outstanding stock options (in shares)

2,326,000

1,547,000

Fair value

$ 10.5

Unrecognized compensation cost

$ 11.4

Unrecognized compensation costs, recognized over a weighted average period

3 years

2016 Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Maximum award (in shares)

20,451,976

Additional shares (in shares)

5,000,000

Unused shares (in shares)

15,451,976

Multiplier for grant award

135.00%

Natura & Co Long Term Incentive Plan | Performance Share Units (PSUs) | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in dollars per share)

$ 17.32

$ 20.91

Granted (in shares)

627,983

1,543,244

Employment period

3 years

Natura & Co Long Term Incentive Plan | Performance Share Units (PSUs) | Share-based Payment Arrangement, Tranche One | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

50.00%

Natura & Co Long Term Incentive Plan | Performance Share Units (PSUs) | Share-based Payment Arrangement, Tranche Two | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

50.00%

Natura & Co Long Term Incentive Plan | Nominal Cost Options | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in dollars per share)

$ 9.72

Granted (in shares)

1,660,941

Natura & Co Long Term Incentive Plan | Nominal Cost Options | Share-based Payment Arrangement, Tranche One | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

50.00%

Natura & Co Long Term Incentive Plan | Nominal Cost Options | Share-based Payment Arrangement, Tranche Two | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

50.00%

Natura & Co Long Term Incentive Plan | Nominal Cost Options | Share-based Payment Arrangement, Tranche Three | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

50.00%

Natura & Co Long Term Incentive Plan | Nominal Cost Options | Share-Based Payment Arrangement, Tranche Four | Natura & Co

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

50.00%

Share-Based Compensation Plan_3

Share-Based Compensation Plans (Schedule of Compensation Cost and Income Tax Benefit) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Compensation cost for stock-based compensation	$ 0.5	$ 13.4	$ 24.9	$ 15.6
Total income tax (cost)/ benefit recognized for share-based arrangements		$ (0.2)	$ 1.9	$ 1.3

Share-Based Compensation Plan_4

Share-Based Compensation Plans (Schedule of Weighted-Average Assumptions for Stock Options) (Details) - Stock Options	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate		2.40%
Expected term		7 years
Expected Avon volatility		45.00%
Expected dividends		0.00%
Contractual term	10 years	10 years

Share-Based Compensation Plan_5

Share-Based Compensation Plans (Schedule of Weighted Average Assumptions (PRSUs)) (Details) - Performance Restricted Stock Units (PRSUs)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years	3 years
2019 Award Date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate		2.40%
Expected Avon volatility		54.80%
Expected average volatility		29.90%
Expected dividends		0.00%
Vesting period		3 years

Share-Based Compensation Plan_6

Share-Based Compensation Plans (Schedule of Nominal Cost Option) (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Nominal Cost Options
Outstanding, beginning balance (in shares)	0
Outstanding, ending balance (in shares)	0
Nominal Cost Options
Nominal Cost Options
Outstanding, beginning balance (in shares)	1,547,000
Granted (in shares)	1,661,000
Exercised (in shares)	(600,000)
Forfeited (in shares)	(282,000)
Outstanding, ending balance (in shares)	2,326,000
Weighted-Average Modification-Date Fair Value
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 11.51
Exercised (in dollars per share) | $ / shares	9.72
Exercised (in dollars per share) | $ / shares	(12.12)
Forfeited (in dollars per share) | $ / shares	(12.10)
Outstanding, ending balance (in dollars per share) | $ / shares	$ 10

Share-Based Compensation Plan_7

Share-Based Compensation Plans (Schedule of Summary of Performance Restricted Stock Units) (Details) - Performance Share Units (PSUs) shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Performance Restricted Stock Units
Nonvested, beginning balance (in shares) | shares	1,543
Granted (in shares) | shares	628
Exercised (in shares) | shares	0
Forfeited (in shares) | shares	(317)
Nonvested, ending balance (in shares) | shares	1,854
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, beginning balance (in dollars per share) | $ / shares	$ 20.91
Granted (in dollars per share) | $ / shares	17.32
Exercised (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	(20.45)
Nonvested, ending balance (in dollars per share) | $ / shares	$ 19.78

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Amortization period for gains and losses, period 1	3 years
Amortization period for gains and losses, period 2	5 years
Postemployment benefits liability	$ 6.5	$ 9.1
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Weighted average discount rate	2.15%	1.53%
Rate of return on assets	2.45%
Supplemental Employee Retirement Plan
Defined Benefit Plan Disclosure [Line Items]
Qualified pension plans, benefit obligations	$ 6.7	$ 7.6
Minimum | U.S. Pension and Postretirement Plans
Defined Benefit Plan Disclosure [Line Items]
Expected contributions related to continuing operations	10
Maximum | U.S. Pension and Postretirement Plans
Defined Benefit Plan Disclosure [Line Items]
Expected contributions related to continuing operations	15
Non-U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Qualified pension plans, benefit obligations	671.2	767.5	$ 685.9
Qualified pension plans, plan assets	$ 764.4	$ 762	$ 695.4
Weighted average discount rate	2.09%	1.45%
Rate of return on assets	2.32%	2.55%	5.27%
UK Defined Contribution Plan
Defined Benefit Plan Disclosure [Line Items]
Employer match toward contributions, doubled	5.00%
Maximum contribution percent of eligible compensation	10.00%
Employer contribution	$ 8.1	$ 7.6	$ 7.5
Personal Savings Account Plan
Defined Benefit Plan Disclosure [Line Items]
Employer contribution	$ 0.9	1	$ 1.3
Maximum employee contribution to plan	25.00%
Maximum contribution for eligible participants	3.00%
Employer match toward contributions, fifty cents for dollar, minimum	4.00%
Employer match toward contributions, fifty cents for dollar, maximum	6.00%
Retirement Savings Account Plan
Defined Benefit Plan Disclosure [Line Items]
Employer match toward contributions, fifty cents for dollar, minimum	3.00%
Employer match toward contributions, fifty cents for dollar, maximum	6.00%
Vesting period	3 years
U.S. Qualified Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Qualified pension plans, benefit obligations	$ 53.6	60.4
Qualified pension plans, plan assets	54.3	59.7
UK Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Qualified pension plans, benefit obligations	492	545.5
Qualified pension plans, plan assets	$ 653.6	$ 648.4
Rate of return on assets	2.10%
UK Pension Plan | Liability Driven Investments
Defined Benefit Plan Disclosure [Line Items]
Liability driven investments allocation	76.00%
UK Pension Plan | Equity Securities, Emerging Market Debt and High Yield Securities
Defined Benefit Plan Disclosure [Line Items]
Equity securities allocation	24.00%

Employee Benefit Plans (Reconci

Employee Benefit Plans (Reconciliation of Benefit Obligations, Plan Assets and Funded Status) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Amount Recognized in Balance Sheet:
Other assets	$ 509.4	$ 438.5
Accrued compensation	(81.5)	(89.4)
Other Postretirement Benefits Plan
Change in Benefit Obligation:
Beginning balance	(7.7)	(26.8)
Service cost	0	0	$ (0.1)
Interest cost	(0.3)	(0.7)	(1.2)
Actuarial gain (loss)	0.4	(1.5)
Benefits paid	0.6	5.4
Actual expenses and taxes	0	0
Plan amendments	0	4.1
Curtailments	0	0
Settlements	0	0
Special termination benefits	(3)	5.8
Transfers	0	4.9
Foreign currency changes and other	0.3	1.1
Sale of Avon Luxembourg	0	0
Ending balance	(9.7)	(7.7)	(26.8)
Change in Plan Assets:
Beginning balance	0	0
Actual return on plan assets	0	0
Company contributions	0.6	10.2
Benefits paid	(0.6)	(5.3)
Actual expenses and taxes	0	0
Settlements	0	0
Transfers	0	(4.9)
Foreign currency changes and other	0	0
Ending balance	0	0	0
Funded Status:
Funded status at end of year	(9.7)	(7.7)
Amount Recognized in Balance Sheet:
Other assets	0	0
Accrued compensation	(6.3)	(3.6)
Employee benefit plans liability	(3.4)	(4.1)
Net amount recognized	(9.7)	(7.7)
Pretax Amounts Recognized in Accumulated Other Comprehensive Loss:
Net actuarial loss	0.8	1.9
Prior service (credit) cost	(0.8)	(5.3)
Total pretax amount recognized	0	(3.4)
U.S. | Pension Plan
Change in Benefit Obligation:
Beginning balance	(67.9)	(71.7)
Service cost	(0.9)	(1.2)	(1.7)
Interest cost	(1)	(1.4)	(2.3)
Actuarial gain (loss)	1.8	(6.2)
Benefits paid	7.7	12.6
Actual expenses and taxes	0	0
Plan amendments	0	0
Curtailments	0	0
Settlements	0	0
Special termination benefits	0	0
Transfers	0	0
Foreign currency changes and other	0	0
Sale of Avon Luxembourg	0	0
Ending balance	(60.3)	(67.9)	(71.7)
Change in Plan Assets:
Beginning balance	59.7	63.3
Actual return on plan assets	1.6	8
Company contributions	0.7	1
Benefits paid	(7.7)	(12.6)
Actual expenses and taxes	0	0
Settlements	0	0
Transfers	0	0
Foreign currency changes and other	0	0
Ending balance	54.3	59.7	63.3
Funded Status:
Funded status at end of year	(6)	(8.2)
Amount Recognized in Balance Sheet:
Other assets	0	0
Accrued compensation	(0.7)	(0.9)
Employee benefit plans liability	(5.3)	(7.4)
Net amount recognized	(6)	(8.3)
Pretax Amounts Recognized in Accumulated Other Comprehensive Loss:
Net actuarial loss	14.7	19.6
Prior service (credit) cost	0	(0.1)
Total pretax amount recognized	14.7	19.5
Supplemental Information:
Accumulated benefit obligation	59.5	66.8
Plans with Projected Benefit Obligation in Excess of Plan Assets:
Projected benefit obligation	60.3	67.9
Fair value plan assets	54.3	59.7
Plans with Accumulated Benefit Obligation in Excess of Plan Assets:
Accumulated benefit obligation	59.5	7.3
Fair value plan assets	54.3	0
Non-U.S. Plans | Pension Plan
Change in Benefit Obligation:
Beginning balance	(767.5)	(685.9)
Service cost	(4.3)	(4.3)	(4)
Interest cost	(8.7)	(11.7)	(15.3)
Actuarial gain (loss)	54.6	(61.8)
Benefits paid	25.7	27.8
Actual expenses and taxes	0.4	0.5
Plan amendments	0	0
Curtailments	0.2	0
Settlements	1.8	1.1
Special termination benefits	0	0
Transfers	0	0
Foreign currency changes and other	13.5	(33.2)
Sale of Avon Luxembourg	13.1	0
Ending balance	(671.2)	(767.5)	(685.9)
Change in Plan Assets:
Beginning balance	762	695.4
Actual return on plan assets	29.3	62
Company contributions	10.1	3.3
Benefits paid	(25.7)	(27.8)
Actual expenses and taxes	(0.4)	0
Settlements	(1.8)	(1.1)
Transfers	0	0
Foreign currency changes and other	(9.1)	30.2
Ending balance	764.4	762	$ 695.4
Funded Status:
Funded status at end of year	93.2	(5.5)
Amount Recognized in Balance Sheet:
Other assets	162.4	103.1
Accrued compensation	(1.2)	(2.1)
Employee benefit plans liability	(68)	(106.5)
Net amount recognized	93.2	(5.5)
Pretax Amounts Recognized in Accumulated Other Comprehensive Loss:
Net actuarial loss	122.8	204.7
Prior service (credit) cost	2	1.5
Total pretax amount recognized	124.8	206.2
Supplemental Information:
Accumulated benefit obligation	159.4	200.6
Plans with Projected Benefit Obligation in Excess of Plan Assets:
Projected benefit obligation	170	220.1
Fair value plan assets	100.8	111.5
Plans with Accumulated Benefit Obligation in Excess of Plan Assets:
Accumulated benefit obligation	153.6	190.1
Fair value plan assets	$ 91.7	$ 98.3

Employee Benefit Plans (Compone

Employee Benefit Plans (Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Pension Plan | U.S.
Net Periodic Benefit Cost:
Service cost	$ 0.9	$ 1.2	$ 1.7
Interest cost	1	1.4	2.3
Expected return on plan assets	(2)	(2.6)	(3.4)
Amortization of prior service credit	0	0	0
Amortization of net actuarial losses	2.4	2.9	2.8
Amortization of transition obligation	0	0	0
Settlements/curtailments	1	2.6	3
Special termination benefits	0	0	0
Other	0	0	0
Net periodic benefit cost	3.3	5.5	6.4
Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive (Loss) Income:
Actuarial losses (gains)	(1.4)	0.8	(3)
Prior service cost (credit)	0	0	0
Amortization of prior service credit	0	0	0
Amortization of net actuarial losses	(3.4)	(5.5)	(5.7)
Foreign currency changes	0	0	0
Total recognized in other comprehensive loss	(4.8)	(4.7)	(8.7)
Total recognized in net periodic benefit cost and other comprehensive loss	(1.5)	0.8	(2.3)
Pension Plan | Non-U.S. Plans
Net Periodic Benefit Cost:
Service cost	4.3	4.3	4
Interest cost	8.7	11.7	15.3
Expected return on plan assets	(16)	(16)	(31)
Amortization of prior service credit	0	(0.1)	0
Amortization of net actuarial losses	7.5	6.3	4.9
Amortization of transition obligation	0	0	0
Settlements/curtailments	0.1	0.1	(0.6)
Special termination benefits	0	0	0
Other	0	0	0
Net periodic benefit cost	4.6	6.3	(7.4)
Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive (Loss) Income:
Actuarial losses (gains)	(68.1)	15.9	13.1
Prior service cost (credit)	0	0	0
Amortization of prior service credit	0	0	0
Amortization of net actuarial losses	(7.6)	(6.4)	(4.6)
Foreign currency changes	(5.9)	11.6	1.7
Total recognized in other comprehensive loss	(81.6)	21.1	10.2
Total recognized in net periodic benefit cost and other comprehensive loss	(77)	27.4	2.8
Other Postretirement Benefits Plan
Net Periodic Benefit Cost:
Service cost	0	0	0.1
Interest cost	0.3	0.7	1.2
Expected return on plan assets	0	0	0
Amortization of prior service credit	(4.5)	(0.2)	(0.2)
Amortization of net actuarial losses	0.7	0	0
Amortization of transition obligation	0	0	0
Settlements/curtailments	0	0	0
Special termination benefits	3	(4.2)	0
Other	0	0	0
Net periodic benefit cost	(0.5)	(3.7)	1.1
Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive (Loss) Income:
Actuarial losses (gains)	(0.4)	1.5	2.5
Prior service cost (credit)	4.5	(4.1)	(1.3)
Amortization of prior service credit	0	0.2	0.2
Amortization of net actuarial losses	(0.7)	(1.6)	0
Foreign currency changes	0	0	0
Total recognized in other comprehensive loss	3.4	(4)	1.4
Total recognized in net periodic benefit cost and other comprehensive loss	$ 2.9	$ (7.7)	$ 2.5

Employee Benefit Plans (Weighte

Employee Benefit Plans (Weighted-Average Assumptions Used to Determine Benefit Obligations) (Details)	Dec. 31, 2021	Dec. 31, 2020
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.15%	1.53%
Pension Plan | U.S.
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.81%	2.43%
Rate of compensation increase	4.00%	4.00%
Interest crediting rate	1.78%	1.62%
Pension Plan | Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.09%	1.45%
Rate of compensation increase	2.56%	2.51%
Interest crediting rate	2.75%	2.68%
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.61%	3.95%

Employee Benefit Plans (Weigh_2

Employee Benefit Plans (Weighted-Average Assumptions used to Determine Net Benefit Cost) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Rate of return on assets	2.45%
Pension Plan | U.S.
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.42%	3.16%	4.24%
Rate of compensation increase	4.00%	4.00%	4.00%
Rate of return on assets	4.15%	4.90%	5.50%
Interest crediting rate	1.49%	2.49%	3.36%
Pension Plan | Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	1.45%	2.05%	2.92%
Rate of compensation increase	2.51%	2.54%	2.69%
Rate of return on assets	2.32%	2.55%	5.27%
Interest crediting rate	2.74%	2.69%	2.69%
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.95%	3.66%	5.17%

Employee Benefit Plans (Pension

Employee Benefit Plans (Pension and Postretirement Plans Target and Weighted-Average Asset Allocations) (Details) - Pension Plan	Dec. 31, 2021	Dec. 31, 2020
U.S.
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	100.00%
Defined benefit plan, actual plan asset allocation	100.00%	100.00%
U.S. | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	30.00%
Defined benefit plan, actual plan asset allocation	30.00%	31.00%
U.S. | Debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	70.00%
Defined benefit plan, actual plan asset allocation	70.00%	69.00%
U.S. | Other
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	0.00%
Defined benefit plan, actual plan asset allocation	0.00%	0.00%
Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	100.00%
Defined benefit plan, actual plan asset allocation	100.00%	100.00%
Non-U.S. Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	23.00%
Defined benefit plan, actual plan asset allocation	23.00%	21.00%
Non-U.S. Plans | Debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	72.00%
Defined benefit plan, actual plan asset allocation	72.00%	74.00%
Non-U.S. Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, target plan asset allocations	5.00%
Defined benefit plan, actual plan asset allocation	5.00%	5.00%

Employee Benefit Plans (Fair Va

Employee Benefit Plans (Fair Value Hierarchy for Pension and Postretirement Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2.3	$ 1.6	$ 1.6
U.S. | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	54.3	59.7	63.3
U.S. | Pension Plan | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16.5	18.7
U.S. | Pension Plan | Domestic equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8.3	9.3
U.S. | Pension Plan | International equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6.6	7.5
U.S. | Pension Plan | Emerging markets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1.6	1.9
U.S. | Pension Plan | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	37.7	40.9
U.S. | Pension Plan | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	21.6	23.7
U.S. | Pension Plan | Government securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8.8	9.4
U.S. | Pension Plan | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7.3	7.8
U.S. | Pension Plan | Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.1
U.S. | Pension Plan | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.1
U.S. | Pension Plan | Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Domestic equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | International equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Emerging markets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Government securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. | Pension Plan | Level 1 | Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
U.S. | Pension Plan | Level 1 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
U.S. | Pension Plan | Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	54.3	59.7
U.S. | Pension Plan | Level 2 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16.5	18.7
U.S. | Pension Plan | Level 2 | Domestic equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8.3	9.3
U.S. | Pension Plan | Level 2 | International equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6.6	7.5
U.S. | Pension Plan | Level 2 | Emerging markets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1.6	1.9
U.S. | Pension Plan | Level 2 | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	37.7	40.9
U.S. | Pension Plan | Level 2 | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	21.6	23.7
U.S. | Pension Plan | Level 2 | Government securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8.8	9.4
U.S. | Pension Plan | Level 2 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7.3	7.8
U.S. | Pension Plan | Level 2 | Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.1
U.S. | Pension Plan | Level 2 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.1
Non-U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	764.4	762	$ 695.4
Non-U.S. Plans | Pension Plan | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	174.6	158
Non-U.S. Plans | Pension Plan | Domestic equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29.4	26
Non-U.S. Plans | Pension Plan | International equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	145.2	132
Non-U.S. Plans | Pension Plan | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	551	567.1
Non-U.S. Plans | Pension Plan | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	257.6	32.4
Non-U.S. Plans | Pension Plan | Government securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	256.9	497.4
Non-U.S. Plans | Pension Plan | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	36.5	37.3
Non-U.S. Plans | Pension Plan | Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	38.8	36.9
Non-U.S. Plans | Pension Plan | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	34.3	33.3
Non-U.S. Plans | Pension Plan | Derivatives
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2.2	2
Non-U.S. Plans | Pension Plan | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2.3	1.6
Non-U.S. Plans | Pension Plan | Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	34.3	33.3
Non-U.S. Plans | Pension Plan | Level 1 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | Domestic equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | International equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | Government securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	34.3	33.3
Non-U.S. Plans | Pension Plan | Level 1 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	34.3	33.3
Non-U.S. Plans | Pension Plan | Level 1 | Derivatives
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 1 | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	727.8	727.1
Non-U.S. Plans | Pension Plan | Level 2 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	174.6	158
Non-U.S. Plans | Pension Plan | Level 2 | Domestic equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29.4	26
Non-U.S. Plans | Pension Plan | Level 2 | International equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	145.2	132
Non-U.S. Plans | Pension Plan | Level 2 | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	551	567.1
Non-U.S. Plans | Pension Plan | Level 2 | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	257.6	32.4
Non-U.S. Plans | Pension Plan | Level 2 | Government securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	256.9	497.4
Non-U.S. Plans | Pension Plan | Level 2 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	36.5	37.3
Non-U.S. Plans | Pension Plan | Level 2 | Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2.2	2
Non-U.S. Plans | Pension Plan | Level 2 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 2 | Derivatives
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2.2	2
Non-U.S. Plans | Pension Plan | Level 2 | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2.3	1.6
Non-U.S. Plans | Pension Plan | Level 3 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Domestic equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | International equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Government securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2.3	1.6
Non-U.S. Plans | Pension Plan | Level 3 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Derivatives
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Pension Plan | Level 3 | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2.3	$ 1.6

Employee Benefit Plans (Recon_2

Employee Benefit Plans (Reconciliation of the Beginning and Ending Balances for Investments) (Details) - Level 3 - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Change in Plan Assets:
Beginning balance	$ 1.6	$ 1.6
Actual return on plan assets held	0.7
Ending balance	$ 2.3	$ 1.6

Employee Benefit Plans (Total B

Employee Benefit Plans (Total Benefit Payments) (Details) $ in Millions	Dec. 31, 2021USD ($)
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
2022	$ 31.9
2023	31.6
2024	32.9
2025	32.1
2026	31.6
2027-2031	164.3
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
2022	6.3
2023	0.3
2024	0.3
2025	0.3
2026	0.3
2027-2031	1.4
U.S. | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
2022	5.7
2023	4.8
2024	5
2025	4.1
2026	3.9
2027-2031	14.7
Non-U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
2022	26.2
2023	26.8
2024	27.9
2025	28
2026	27.7
2027-2031	$ 149.6

Employee Benefit Plans (Supplem

Employee Benefit Plans (Supplemental Retirement Programs) (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)investment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Deferred Compensation Plan
Defined Benefit Plan Disclosure [Line Items]
Maximum deferral of base salary	50.00%
Maximum deferral of incentive compensation bonuses	100.00%
Number of permitted investment alternatives | investment	3
Expenses associated with deferred compensation plan	$ 0	$ 0.1	$ 0.8
Deferred compensation liability	0.7	0.8
Supplemental Employee Retirement Plan
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost SERP Restoration	1	1.2	$ 1.3
Benefit obligation SERP Restoration	$ 6.7	$ 7.6

Employee Benefit Plans (Assets

Employee Benefit Plans (Assets Held In Trust) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Assets held-in-trust	$ 30.4	$ 33.7
Corporate-owned life insurance policies
Defined Benefit Plan Disclosure [Line Items]
Assets held-in-trust	24.6	28.5
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Assets held-in-trust	$ 5.8	$ 5.2

Segment Information (Total Reve

Segment Information (Total Revenue) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 3,404.5	$ 3,625.2	$ 4,763.2
Operating Segments
Segment Reporting Information [Line Items]
Revenues	3,379.3	3,618.5	4,763.2
Operating Segments | Avon International
Segment Reporting Information [Line Items]
Revenues	1,724.6	1,772.6	2,234.3
Operating Segments | Avon LATAM
Segment Reporting Information [Line Items]
Revenues	1,654.7	1,845.9	2,528.9
Other reconciling items
Segment Reporting Information [Line Items]
Revenues	$ 25.2	$ 6.7	$ 0

Segment Information (Operating

Segment Information (Operating Profit) (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Operating (loss) profit			$ (58.4)	$ (122.2)	$ 125.6
Certain Brazil indirect taxes			0	0	(118.3)
CTI restructuring initiatives			(68.7)	(23.7)	(139.3)
Costs related to the Transaction			0	(85.8)	(64.3)
Revenues			3,404.5	3,625.2	4,763.2
Central expenses			206.7	197.6	214.7
Accelerated costs		$ 1.7
Merger Agreement
Segment Reporting Information [Line Items]
Acquisition related expense				46	44
Severance costs	$ 25			25
Accelerated costs	$ 10			10
Brazil IPI tax release
Segment Reporting Information [Line Items]
Revenues			21		68
Operating Segments
Segment Reporting Information [Line Items]
Operating (loss) profit			39	(11.7)	365
Revenues			3,379.3	3,618.5	4,763.2
Operating Segments | Avon International
Segment Reporting Information [Line Items]
Operating (loss) profit			49.9	27.4	170.9
Revenues			1,724.6	1,772.6	2,234.3
Operating Segments | Avon LATAM
Segment Reporting Information [Line Items]
Operating (loss) profit			(10.9)	(39.1)	194.1
Revenues			1,654.7	1,845.9	2,528.9
Other reconciling items
Segment Reporting Information [Line Items]
Revenues			25.2	6.7	0
Corporate, non-segment
Segment Reporting Information [Line Items]
Operating (loss) profit			1.5	7.3	2.4
Unallocated global expenses			(27)	(11.6)	(35.8)
Certain Brazil indirect taxes			1.7	(10.6)	0
Revenues			$ 4.7	$ 14.5	$ 18.1

Segment Information (Total Asse

Segment Information (Total Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Assets	$ 2,307.8	$ 2,564.3	$ 3,086.3
Avon International
Segment Reporting Information [Line Items]
Assets not previously allocated to segments			420.7
Operating Segments | Avon International
Segment Reporting Information [Line Items]
Assets	1,362	1,364.4	1,712.4
Operating Segments | Avon LATAM
Segment Reporting Information [Line Items]
Assets	$ 945.8	$ 1,199.9	$ 1,373.9

Segment Information (Capital Ex

Segment Information (Capital Expenditures) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Total capital expenditures	$ 68.3	$ 44.6	$ 58.5
Operating Segments | Avon International
Segment Reporting Information [Line Items]
Total capital expenditures	53.3	36	39.6
Capital expenditures not previously allocated to segments			13.8
Operating Segments | Avon LATAM
Segment Reporting Information [Line Items]
Total capital expenditures	$ 15	$ 8.6	$ 18.9

Segment Information (Depreciati

Segment Information (Depreciation and Amortization) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 72.8	$ 81.8	$ 92.9
Avon International | Operating Segments
Segment Reporting Information [Line Items]
Depreciation and amortization	48.1	49.5	51.6
Depreciation and amortization not previously allocated to segments			19.9
Avon LATAM | Operating Segments
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 24.7	$ 32.3	$ 41.3

Segment Information (Total Re_2

Segment Information (Total Revenue by Major Country) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 3,202.9	$ 3,431.2	$ 4,494.1
Revenues	3,404.5	3,625.2	4,763.2
Brazil
Disaggregation of Revenue [Line Items]
Revenues	627	729.9	1,034.4
Mexico
Disaggregation of Revenue [Line Items]
Revenues	249.2	420.2	509.4
All other
Disaggregation of Revenue [Line Items]
Revenues	$ 2,528.3	$ 2,475.1	$ 3,219.4

Segment Information (Long-Lived

Segment Information (Long-Lived Assets by Major Country) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 477	$ 594.5	$ 570.2
U.S.
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	122.7	135.3	149.4
Brazil
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	75.4	86.4	116.1
Poland
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	95	96.8	99.3
Mexico
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	0	55.2	67.8
All other
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 183.9	$ 220.8	$ 137.6

Segment Information (Long-Liv_2

Segment Information (Long-Lived Assets, Net of Right-of-Use Assets) (Details) $ in Millions	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Long lived asset, including property, plant and equipment, net, certain intangible and other long-term receivables	$ 746
Brazil
Segment Reporting Information [Line Items]
Long lived asset, including property, plant and equipment, net, certain intangible and other long-term receivables	203.3
U.S.
Segment Reporting Information [Line Items]
Long lived asset, including property, plant and equipment, net, certain intangible and other long-term receivables	120.8
Poland
Segment Reporting Information [Line Items]
Long lived asset, including property, plant and equipment, net, certain intangible and other long-term receivables	86.3
All other
Segment Reporting Information [Line Items]
Long lived asset, including property, plant and equipment, net, certain intangible and other long-term receivables	$ 335.6

Leases and Commitments - Balanc

Leases and Commitments - Balance Sheet Implication (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets
Right-of-use assets	$ 111.1	$ 153.1
Finance right-of-use assets	$ 2.2	$ 2.4
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization
Total right-of-use assets	$ 113.3	$ 155.5
Liabilities
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Other accrued liabilities	Other accrued liabilities
Operating lease liabilities	$ 37.1	$ 46.2
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other accrued liabilities	Other accrued liabilities
Finance lease liabilities	$ 1.2	$ 1.1
Total current lease liabilities	38.3	47.3
Noncurrent
Operating lease liabilities	$ 87.5	$ 120.9
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt	Long-term debt
Finance lease liabilities	$ 1.3	$ 1.5
Total noncurrent lease liabilities	88.8	122.4
Total lease liability	$ 127.1	$ 169.7

Leases and Commitments - Income

Leases and Commitments - Income and Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 51.7	$ 63.6
Amortization of right-of-use assets	1.3	1.2
Interest on lease liabilities	0.2	0.3
Short-term leases costs	11	2.3
Sublease Income	(14.5)	(15.3)
Net lease cost	$ 49.7	$ 52.1

Leases and Commitments - Maturi

Leases and Commitments - Maturity of Lease Liability (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 45.7
2023	36.3
2024	26.7
2025	22
2026	12.2
Thereafter	5.1
Total lease payments	148
Less: Interest	23.4
Present value of lease liabilities	124.6
Finance Lease, Liability, Payment, Due [Abstract]
2022	1.3
2023	0.8
2024	0.3
2025	0.2
2026	0.1
Thereafter	0
Total lease payments	2.7
Less: Interest	0.2
Present value of lease liabilities	2.5
Lease Liabilities, Payments Due [Abstract]
2022	47
2023	37.1
2024	27
2025	22.2
2026	12.3
Thereafter	5.1
Total lease payments	150.7
Less: Interest	23.6
Present value of lease liabilities	$ 127.1	$ 169.7

Leases and Commitments - Lease

Leases and Commitments - Lease Term and Discount Rate (Details)	Dec. 31, 2021	Dec. 31, 2020
Weighted-average remaining lease term
Operating leases	4 years	4 years 2 months 12 days
Finance leases	2 years 8 months 12 days	2 years 6 months
Weighted-average discount rate
Operating leases	8.30%	8.50%
Finance leases	9.60%	10.50%

Leases and Commitments - Other

Leases and Commitments - Other Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating Cash Flows From Operating Leases	$ 54	$ 63.7
Operating Cash Flows From Finance Leases	0.2	0.3
Financing Cash Flows From Finance Leases	1.3	1.3
Cash Paid For Amounts Included In Measurement of Liabilities	55.5	65.3
Right-of-use Assets Obtained In Exchange For New Finance Liabilities	1.4	0.9
Right-of-use Assets Obtained In Exchange For New Operating Liabilities	$ 8.8	$ 24.9

Leases and Commitments - Schedu

Leases and Commitments - Schedule of Purchase Obligations (Details) $ in Millions	Dec. 31, 2021USD ($)
Leases [Abstract]
2022	$ 159.2
2023	51.8
2024	21.9
2025	1.7
2026	1.7
Later years	1.9
Total	$ 238.2

Restructuring Initiatives - Nar

Restructuring Initiatives - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	$ 58.8	$ 22.2	$ 116.7
Avon Integration
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	15.4	16.1	0
Employee-related liabilities	1.6	0.7
Open Up & Grow
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	44	10.9	106.6
Transformation Plan & Other
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	(0.6)	(4.8)	$ 9.4
Employee-related liabilities	$ 1.5	$ 3.5

Restructuring Initiatives - Sum

Restructuring Initiatives - Summary (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	$ 58.8	$ 22.2	$ 116.7
Avon Integration
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	15.4	16.1	0
Open Up & Grow
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	44	10.9	106.6
Transformation Plan & Other
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	(0.6)	(4.8)	9.4
Cost of Sales
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	0	(1.8)	12.5
Cost of Sales | Manufacturing asset write-offs
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	0	0	11.1
Cost of Sales | Inventory write-off
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	0	(1.8)	1.4
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	68.7	25.5	127.5
Selling, General and Administrative Expenses | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	36.7	5.2	56.4
Selling, General and Administrative Expenses | Implementation costs, primarily related to professional service fees
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	17.5	10.3	44.9
Selling, General and Administrative Expenses | Dual running costs
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	1.1	3.1	9.1
Selling, General and Administrative Expenses | Contract termination and other net costs
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	10.5	3.9	7.9
Selling, General and Administrative Expenses | Impairment of other assets
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	1	0.8	5.3
Selling, General and Administrative Expenses | Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	0.3	0.4	1.3
Selling, General and Administrative Expenses | Variable lease charges
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	1.6	1.8	1.9
Selling, General and Administrative Expenses | Foreign Currency Translation Adjustment Write-offs
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	0	0	0.7
Operating Profit
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	68.7	23.7	140
Other Expense
Restructuring Cost and Reserve [Line Items]
CTI restructuring initiative	$ (9.9)	$ (1.5)	$ (23.3)

Restructuring Initiatives - Ope

Restructuring Initiatives - Open Up Avon (Details) - Open Up & Grow - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 11.8	$ 24.2
Charges	38.2	7.2
Adjustments	(1.3)	(4.8)
Cash payments	(31.8)	(15.2)
Non-cash write-offs	1	1.1
Foreign exchange	(0.7)	(0.7)
Ending Balance	15.2	11.8
Employee-Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	9	17.8
Charges	33.8	2.7
Adjustments	(1.3)	(3)
Cash payments	(26.8)	(7.8)
Non-cash write-offs	0	0
Foreign exchange	(0.7)	(0.7)
Ending Balance	14	9
Inventory write-off
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0
Charges	1	0.7
Adjustments	0	(1.8)
Cash payments	0	0
Non-cash write-offs	1	1.1
Foreign exchange	0	0
Ending Balance	0	0
Contract termination and other net costs
Restructuring Reserve [Roll Forward]
Beginning Balance	2.8	6.4
Charges	3.4	3.8
Adjustments	0	0
Cash payments	(5)	(7.4)
Non-cash write-offs	0	0
Foreign exchange	0	0
Ending Balance	$ 1.2	$ 2.8

Restructuring Initiatives - Res

Restructuring Initiatives - Restructuring Initiatives by Charge Type (Details) $ in Millions	Dec. 31, 2021USD ($)
Avon Integration
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	$ 12.6
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	12.6
Avon Integration | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	12.4
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	12.4
Avon Integration | Inventory write-off
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	0
Avon Integration | Contract termination and other net costs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	0.2
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	0.2
Avon Integration | Foreign Currency Translation Adjustment Write-offs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	0
Open Up & Grow
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	228.2
Estimated charges to be incurred on approved initiatives	0.3
Total expected charges on approved initiatives	228.5
Open Up & Grow | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	115.8
Estimated charges to be incurred on approved initiatives	0.3
Total expected charges on approved initiatives	116.1
Open Up & Grow | Inventory write-off
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	107.4
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	107.4
Open Up & Grow | Contract termination and other net costs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	15.9
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	15.9
Open Up & Grow | Foreign Currency Translation Adjustment Write-offs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	(10.9)
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	(10.9)
Transformation Plan & Other
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	169.5
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	169.5
Transformation Plan & Other | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	122.7
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	122.7
Transformation Plan & Other | Inventory write-off
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	2.5
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	2.5
Transformation Plan & Other | Contract termination and other net costs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	40.9
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	40.9
Transformation Plan & Other | Foreign Currency Translation Adjustment Write-offs
Restructuring Cost and Reserve [Line Items]
Charges incurred to-date	3.4
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	$ 3.4

Restructuring Initiatives - Cha

Restructuring Initiatives - Charges Reportable by Business Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Avon Integration
Restructuring Cost and Reserve [Line Items]
Charges incurred	$ 1.8	$ 10.8
Charges incurred to-date	12.6
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	12.6
Avon Integration | Avon International
Restructuring Cost and Reserve [Line Items]
Charges incurred	(1.2)	6.2
Charges incurred to-date	5
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	5
Avon Integration | Avon LATAM
Restructuring Cost and Reserve [Line Items]
Charges incurred	3	4.6
Charges incurred to-date	7.6
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	7.6
Open Up & Grow
Restructuring Cost and Reserve [Line Items]
Charges incurred	37.1	2.4	$ 71.6	$ 117.1
Charges incurred to-date	228.2
Estimated charges to be incurred on approved initiatives	0.3
Total expected charges on approved initiatives	228.5
Open Up & Grow | Avon International
Restructuring Cost and Reserve [Line Items]
Charges incurred	36.9	3.2	34.7	52.8
Charges incurred to-date	127.6
Estimated charges to be incurred on approved initiatives	0.3
Total expected charges on approved initiatives	127.9
Open Up & Grow | Avon LATAM
Restructuring Cost and Reserve [Line Items]
Charges incurred	0.2	$ (0.8)	$ 36.9	$ 64.3
Charges incurred to-date	100.6
Estimated charges to be incurred on approved initiatives	0
Total expected charges on approved initiatives	$ 100.6

Series C Convertible Preferre_2

Series C Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 03, 2020	Dec. 30, 2019	Mar. 01, 2016	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jan. 31, 2020
Class of Stock [Line Items]
Dividend accrual, percentage			1.25%
Payables to affiliates of Natura &Co					$ 29.4	$ 0
Increase in carrying value of preferred stock				$ 60.9
Conversion of stock (in shares)		435,000
Common stock, par value (in dollars per share)		$ 0.25		$ 0.25	$ 0.01	$ 0.01	$ 0.01
Dividends paid				$ 8.7
Natura & Co
Class of Stock [Line Items]
Dividends paid	$ 91.5
Private Placement
Class of Stock [Line Items]
Discount on shares			$ 8.7
Series C Preferred Stock
Class of Stock [Line Items]
Shares issued (in shares)			435,000
Stock issued during period			$ 435
Payables to affiliates of Natura &Co				$ 91.3
Conversion of stock (in shares)		435,000

Contingencies (Narrative) (Deta

Contingencies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)lawsuit	Dec. 31, 2020USD ($)
Loss Contingencies [Line Items]
Number of litigation suits | lawsuit	151
Number of litigation suits, new | lawsuit	19
Number of litigation suits, dismissed | lawsuit	20
IPI Tax On Manufactured Products - Minimum Pricing Rules
Loss Contingencies [Line Items]
Loss contingency, estimate of possible loss	$ 360	$ 378
IPI Tax On Manufactured Products - Decree Equated Certain Commercial Companies
Loss Contingencies [Line Items]
Loss contingency, estimate of possible loss	243	231
Brazilian Financial Indemnities
Loss Contingencies [Line Items]
Loss contingency, estimate of possible loss	157	185
Brazil labor-related
Loss Contingencies [Line Items]
Estimated litigation liability	11	8
Shareholder Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party		$ 14.5
Payments for legal settlements	$ 2

Goodwill (Schedule of Goodwill)

Goodwill (Schedule of Goodwill) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Goodwill [Roll Forward]
Gross balance at period start	$ 172.5
Accumulated impairments	(89.3)
Net balance at period start	83.2
Foreign exchange	(11.1)
Gross balance at period end	161.4
Accumulated impairments at period end	(89.3)
Net balance at period end	72.1
Avon International
Goodwill [Roll Forward]
Gross balance at period start	109.3
Accumulated impairments	(89.3)
Net balance at period start	20
Foreign exchange	(2.4)
Gross balance at period end	106.9
Accumulated impairments at period end	(89.3)
Net balance at period end	17.6
Avon LATAM
Goodwill [Roll Forward]
Gross balance at period start	63.2
Accumulated impairments	0
Net balance at period start	63.2
Foreign exchange	(8.7)
Gross balance at period end	54.5
Accumulated impairments at period end	0
Net balance at period end	$ 54.5

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Components of Prepaid Expenses and Other) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Prepaid taxes and tax refunds receivable	$ 84	$ 117.6
Receivables other than trade	27.8	34.9
Prepaid brochure costs, paper and other literature	8.3	12
Other	45.5	39.7
Prepaid expenses and other	$ 165.6	$ 204.2

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information (Components of Other Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Capitalized software	$ 74.9	$ 76
Judicial deposits	47.2	50.9
Net overfunded pension plans	162.5	103
Long-term receivables including taxes	180.2	157
Trust assets associated with supplemental benefit plans	30.4	33.7
Other	14.2	17.9
Other assets	$ 509.4	$ 438.5

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information, Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Brazil indirect taxes receivables	$ 128	$ 112
Brazil indirect taxes, additional receivable	$ 24

Merger with Natura Cosm_ticos_2

Merger with Natura Cosméticos S.A. - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	May 22, 2019	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 03, 2020	Dec. 30, 2019
Business Combination, Separately Recognized Transactions [Line Items]
Shares authorized (in shares)			1,525,000,000				1,525,000,000
Common stock, shares authorized (in shares)		1,000	1,500,000,000	1,000	1,000	1,000	1,500,000,000
Common stock, par value (in dollars per share)		$ 0.01	$ 0.25	$ 0.01	$ 0.01	$ 0.01	$ 0.25		$ 0.25
Preferred stock, shares authorized (in shares)			25,000,000				25,000,000
Preferred stock, par value (in USD per share)		$ 0.01	$ 1				$ 1
Shares canceled (in shares)		550,890,788
Common stock shares outstanding (in shares)		101.34		101.34	101.34	101.34
Accelerated costs			$ 1.7
Settlement of stock options					$ 0	$ 25.8	$ 0
Write off of debt issuance cost				$ 7.9
Minimum
Business Combination, Separately Recognized Transactions [Line Items]
Tax attributes lost due to Transaction		$ 546
Maximum
Business Combination, Separately Recognized Transactions [Line Items]
Tax attributes lost due to Transaction		616
Merger Agreement
Business Combination, Separately Recognized Transactions [Line Items]
Share conversion ratio	60.00%
Acquisition related expense						46	$ 44
Severance costs		25				25
Accelerated costs		10				$ 10
Settlement of stock options		26
Deferred compensation payment		12
Write off of debt issuance cost		$ 7.8
Merger Agreement | Natura & Co
Business Combination, Separately Recognized Transactions [Line Items]
Common stock composing one American depository shares (in shares)								2
American Depositary Shares | Merger Agreement
Business Combination, Separately Recognized Transactions [Line Items]
Share conversion ratio	30.00%

VALUATION AND QUALIFYING ACCO_2

VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at End of Period	$ 37.1
Allowance for doubtful accounts receivable
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	51.1	$ 66.6	$ 93
Charged to Costs and Expenses	62.4	78.3	115.4
Charged to Revenue	0	0	0
Deductions	(76.4)	(93.8)	(141.8)
Balance at End of Period		51.1	66.6
Refund liability
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	9.1
Charged to Costs and Expenses	0
Charged to Revenue	75.9
Deductions	(80.7)
Balance at End of Period	4.3	9.1
Refund liability
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	9.1	10.7	12.3
Charged to Costs and Expenses		0	0
Charged to Revenue		101.4	132.6
Deductions		(103)	(134.2)
Balance at End of Period		9.1	10.7
Allowance for inventory obsolescence
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	70.4	82	146.1
Charged to Costs and Expenses	26.8	37.9	37.1
Charged to Revenue	0	0	0
Deductions	(42.4)	(49.5)	(101.2)
Balance at End of Period	54.8	70.4	82
Deferred tax asset valuation allowance
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	2,327.6	2,960	3,257.5
Charged to Costs and Expenses	125.7	(632.4)	(297.5)
Charged to Revenue	0	0	0
Deductions	(1,637.9)	0	0
Balance at End of Period	$ 815.4	$ 2,327.6	$ 2,960